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ABSTRACT 
The advancement of cancer treatment depends on understanding the 
biological processes that contribute to disease progression.  The spread of tumor 
cells from the primary site to distant organs is the biggest obstacle to efficacious 
treatment. The insulin receptor substrate (IRS) proteins IRS1 and IRS2 are 
cytoplasmic adaptor proteins that organize signaling events downstream of the 
Insulin receptor (IR) and the Insulin-like growth factor receptor 1 (IGF1R).  Both of 
these receptors have been implicated in cancer progression.  The IRS proteins 
share a significant level of homology and are both capable of recruiting and 
activating phosphatidylinositol-3 kinase (PI3K). Despite these similarities, 
signaling through IRS1 and IRS2 leads to distinct tumor cell outcomes in vitro and 
in vivo.  In vitro, IRS1 regulates cell proliferation and growth and IRS2 regulates 
metabolism, survival and invasion. In vivo, Irs2 is a positive regulator of tumor 
metastasis, whereas Irs1 does not promote metastasis.  The major objective of 
this thesis work was to further the understanding of the mechanism by which IRS2 
signaling regulates tumor progression.  
 
To investigate how IRS-1 and IRS-2 regulate distinct tumor cell outcomes, 
I examined the involvement of the microtubule cytoskeleton in IRS-dependent 
signaling.  I determined that IRS2-mediated AKT activation is dependent upon an 
vii 
 
intact microtubule cytoskeleton, whereas IRS1-mediated AKT signaling occurs 
independently of microtubules.  As a result, drugs that disrupt microtubules 
promote apoptosis in cells that signal through IRS2, but cells that signal through 
IRS1 are resistant to the effects of microtubule disruption.  However, AKT inhibition 
sensitizes IRS1-dependent cells to apoptotic cell death upon microtubule 
disruption. From a clinical perspective, my studies identify IRS2 as a potential 
biomarker for the response of breast cancer patients to anti-microtubule drug 
therapy.   To investigate further the mechanism of IRS2 contributions to tumor 
progression, I employed a mutagenesis approach to identify structural 
requirements of IRS2 for its function.  I established that the ability of IRS2 to 
activate PI3K is necessary for its regulation of both invasion and tumor initiating 
cell (TIC) self-renewal. I also identified two independent regions within the IRS2 C-
terminus that are required for invasion and self-renewal, respectively. 
Characterization of the invasion-promoting region identified BMP2-induced protein 
kinase (BMP2K) as an interacting protein. Suppression of BMP2K expression in 
mammary tumor cells disrupts IRS2-mediated tumor cell invasion.  Taken together, 
my work advances the understanding of how IRS2 contributes to breast cancer 
progression and provides a molecular understanding for the development of novel 
approaches for the treatment of breast cancer and other malignancies that rely 
upon IRS2.     
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Breast Cancer Epidemiology and Implications 
 
 Breast cancer is one of the most common malignancies affecting women in 
the USA, second only to skin cancer.  Every year 250,000 new cases of invasive 
breast carcinoma are diagnosed, which accounts for 29% of the malignancies 
affecting women.  In addition, 60,000 new cases of breast carcinoma in situ 
(lobular and ductal), pre-malignant lesions that increase the risk of developing 
breast cancer later in life, are diagnosed every year [1, 2].  Current screening 
methods such as mammography have significantly improved early detection of 
breast cancer and have helped advance successful treatment at early stages of 
the disease [3]. The use of surgical approaches, chemotherapy and radiation have 
been instrumental in the effective treatment of early stage breast cancer.  Early 
detection of breast cancer is of extreme importance when it comes to effective 
treatment.   Stages I and II, representing localized disease, have a 99% five-year 
survival rate, while stages III and IV, representing metastatic breast cancer, have 
a significant decrease in five-year survival at 73% and 23% respectively [4].   
 
 Breast cancer is a heterogenous disease that can be divided into five major 
molecular subtypes. These subtypes are classified as basal-like, ErbB2-
overexpressing, luminal A and luminal B and normal breast tissue-like [5].   
Survival analysis of each subtype shows different outcomes; Basal like breast 
cancers have a poor prognosis while estrogen receptor (ER) positive luminal 
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breast cancers have variable outcomes [6].  Although originally the ErbB2 subtype 
had poor outcomes, the discovery of targeted therapies against the ErbB2 receptor 
improved disease free survival for this subtype [7].  Many basal-like breast cancers 
lack the classic three markers ER, progesterone receptor (PR) and HER2, used in 
the histopathologic classification of breast cancer, and these breast cancers are 
classified as triple-negative breast cancers (TNBCs) [8]. TNBCs are highly 
aggressive and commonly diagnosed in a younger population [9].  This type of 
breast cancer has a very high tendency to metastasize and patients have an 
increased risk of relapse in comparison to patients with other molecular subtype 
tumors [9].  
 
 For cancer patients, metastasis is the leading cause of cancer related 
mortality.  Annually, an estimated 40,000 women succumb to metastatic breast 
cancer [1, 10].  Common sites of breast cancer metastasis include regional lymph 
nodes, bone, brain, lung, liver and adrenal gland.  The spread of breast cancer to 
distant organs represents a significant limitation to treatment.  Metastatic disease 
selects for a more aggressive phenotype and is resistant to standard therapies, 
making treatment more difficult.  Current treatment modalities for metastatic breast 
cancer include cytotoxic chemotherapies, however these drugs cause many side 
effects and provide little clinical benefit to patients [3, 4].   
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 Despite a greater understanding of breast cancer in the past ten years, 
there has been no significant progress in the treatment of metastatic disease [11].  
A randomized clinical trial over a period of 30 years showed no evidence of 
increased survival in patients with metastatic breast cancer [12].   Although we 
have made strides in the treatment of local disease, we need to pay attention to 
understanding how cancer progresses in order to better treat metastatic disease. 
Better understanding of processes that contribute to tumor progression will help 
the cancer community design more effective approaches for the treatment of 
advanced stage disease.  
 
Cancer Metastasis: Overview of the Field  
 
 Despite all of the advances in clinical oncology and basic cancer research, 
metastasis continues to be a lethal trait of cancer.    Metastasis is the process 
during which cancer cells leave the primary tumor and travel to distant organ sites 
to give rise to a secondary tumor.  Metastasis is a multi-step process that consists 
of local invasion of tumor cells into adjacent stromal tissue, trans-endothelial 
migration into blood or lymphatic vessels, survival in the circulatory system, 
extravasation from the vessels and colonization at distal sites [13]. The process of 
colonization is very inefficient and is a rate limiting step for metastasis [14, 15].   
Millions of cells can escape the primary tumor site but less than 0.1% of 
disseminated cells will give rise to a secondary tumor at a distant site [14, 15].  In 
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some cases, cells that reach distal organs remain in a state of growth arrest known 
as dormancy.  However, the eventual growth of these cells will disrupt proper organ 
function.  There are many complicating factors in the research of cancer 
progression and the onset of metastasis including the heterogeneous nature of 
tumors and multiple mechanisms implicated in the metastatic cascade. 
Understanding metastasis requires the dissection of molecular mechanisms that 
contribute to each step of the process.   
 
Tumor cell invasion 
 
 Tumor cell invasion is essential for allowing cancer cells to move through 
non-permissive tissue barriers that normally restrain cells to specific locations.  The 
ability of cancer cells to invade is required at many steps in the metastatic cascade: 
invasion through the basement membrane, through the extracellular matrix that 
surrounds the tumor and through the basement membrane supporting the blood 
vessels to both intravasate and extravasate [16].   Due to the complex nature of 
this process a better understanding of molecular mechanisms and the events that 
contribute to invasion can contribute to better treatment of cancers.   
 
 Cancer cells gain the ability to invade into the surrounding tissue by 
activating pathways used during development and wound healing.  This is one of 
the reasons cancer is known as a “wound that never heals”.   One process that 
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controls the regulation of a number of pathways is referred to as the epithelial to 
mesenchymal transition (EMT).  During EMT, tumor cells downregulate epithelial 
markers like E-Cadherin resulting in the loss of cell adhesion junctions and cell-to-
cell contact [17, 18].  In addition, cancer cells upregulate a host of mesenchymal 
markers, such as Vimentin or N-Cadherin, which result in the reorganization of the 
cytoskeleton and enhancement of cell motility [17]. Many studies have implicated 
the EMT as a driving force in breast cancer progression.  In ER+ breast cancer 
cells, suppression of transforming growth factor-β (TGFβ) signaling inhibits the 
EMT, resulting in cells that are less invasive [19].  It has also been demonstrated 
that expression of TGFβ receptor I (TβIR) causes activation of EMT and induces 
migration and invasion of cancer cells [20].  In addition to the TGFβ signaling 
pathway, other developmental pathways that are dysregulated in cancer, like the 
Wnt and Notch signaling pathways, have been implicated in the induction of EMT 
and an increase in invasion [21].  In addition to its involvement in tumor cell 
invasion, EMT is also implicated in maintenance of tumor initiating cells, prevention 
of apoptosis and senescence, and resistance against chemotherapy [22, 23].  The 
involvement of EMT in so many biological processes implicated in cancer suggests 
that EMT plays a very important role in tumorigenesis and is a driver of metastasis.      
 
 While EMT has been shown to enhance a tumor’s ability to metastasize, the 
principle that EMT is required for tumor metastasis is currently being challenged.  
It has not been definitively shown that all cells that have achieved the formation of 
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secondary tumors at a distant site have undergone EMT [24].  Several transgenic 
mouse models have been developed that suggest that EMT is not a requirement 
for invasion and metastasis in vivo.  One group used the Polyoma middle T antigen 
under the mouse mammary tumor virus promoter (MMTV-PyMT) transgenic 
mouse model to irreversibly express green fluorescent protein (GFP) upon the 
induction of EMT by the activation of the Fsp1 promoter [25].  Results from this 
study showed that cells that successfully formed lung metastases were GFP 
negative, suggesting that they did not undergo EMT.  In a similar effort to 
investigate the role of EMT in metastasis, expression of the EMT transcription 
factors ZEB1 and ZEB2 was inhibited by expression of micro-RNAs in MMTV-
PyMT derived cells.   Inhibition of these transcriptions factors and the inability of 
cells to undergo the EMT failed to block metastasis upon orthotopic injection of 
cells into mice [24, 25].  These experiments provide evidence that there are 
alternative mechanisms to EMT that can aid carcinoma cells in invasion from the 
primary tumor.     
 
To further understand tumor cell invasion, we need to understand the 
mechanism of invasion.  There are two models for single cell invasion, the 
mesenchymal and the ameboid models [26]. Cells from connective tissue 
sarcomas or poorly differentiated carcinomas invade using the mesenchymal 
model.  This model is characterized by the formation of focal adhesions, actin 
cytoskeleton rearrangement, integrin clustering and protease dependent ECM 
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degradation.  In the mesenchymal model, the leading edge of invasive cells has a 
high concentration of focal adhesions [27].  These focal adhesions act as the 
recruitment sites for matrix metalloproteases and targets the degradation of ECM 
to places that will enhance invasion by the cancer cells [28].  In contrast, the 
amoeboid cell invasion model is characterized by a more diffuse cytoskeleton and 
less dependence on cell-matrix interactions [27]. This type of invasion is more 
common in low grade carcinomas.  These cells squeeze through the matrix using 
small blebs present on the cell surface [29, 30].  The blebs are characterized by a 
low concentration of β1 integrins and reduced focal adhesions [31].  Due to the low 
dependence on focal adhesions, cells can move faster than cells that rely on 
mesenchymal invasion.  Tumor xenograft studies using breast carcinoma cells 
have demonstrated that breast cancer cells predominantly invade using the 
amoeboid model, however some cancer cells can employ both models [32, 33].    
 
Tumor cells can also invade as part of a multicellular cohort [28, 34-36]. 
This collective invasion mechanism relies upon tumor heterogeneity or tumor 
stromal cells in assisting the cancer cells to escape the tumor [37-40].  Tumors are 
composed of an array of cells that form a heterogenous tissue ranging from 
epithelial to mesenchymal characteristics.  Mesenchymal cells with a higher 
invasive potential can help less invasive cancer cells overcome the limitations 
imposed by the primary tumor environment and invade the surrounding tissue [37].  
In organoids derived from mouse mammary tumors, the more invasive cells can 
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invade the surrounding matrix and pull other epithelial cells with them [35, 41].  
Additionally, stromal cells like fibroblasts can assist epithelial tumor cells to escape 
the primary tumor by degrading the extracellular matrix [38, 42]. These 
observations demonstrate that the tumor microenvironment and its cellular 
constituents can have an important role in the ability of tumor cells to invade the 
surrounding tissue and metastasize.   
 
 The tumor microenvironment is composed of both cellular and noncellular 
components and consists of ECM, fibroblasts, macrophages, neutrophils, 
lymphocytes, adipocytes and the blood and lymphatic vascular networks [43].  
There is extensive evidence that components of the tumor microenvironment play 
a role in many aspects of tumorigenesis and tumor progression.  The ECM plays 
a very important role in the ability of cancer cells to invade, mainly in its function 
as a barrier.  One of the steps for tumor cells invasion, especially in the 
mesenchymal model, is the degradation of the ECM, so cells can move into the 
surrounding tissue [44, 45].  Matrix metalloproteases, enzymes that can break 
down and degrade ECM proteins, have been viewed as a good target for inhibiting 
invasion.  However, upon inhibition of these proteases, cancer cells employing a 
mesenchymal model of invasion were able to switch to the amoeboid mode to 
overcome the protease inhibition [28, 46, 47]. Extensive phase III clinical trials of 
metalloprotease inhibitors not only failed, but in some cases worsened the disease 
[48, 49].  The use of metalloprotease inhibitors provided evidence that increased 
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tumor ECM and the stiffness of the ECM impacts invasion by allowing for the 
transition of cells from the mesenchymal to amoeboid model of invasion and 
enhanced tumor cell invasion.   
 
In addition to the non-cellular components of the tumor microenvironment, 
normal stromal cells also take part in the regulation of tumor cell invasion.  A 
stromal cell extensively implicated in the progression and metastasis of mouse 
mammary tumor cells is the macrophage [50].  Ablation of macrophage infiltration 
in mammary tumors does not impact primary tumor growth, but significantly inhibits 
tumor metastasis.  The paracrine signaling of macrophage colony stimulating 
factor-1 (CSF-1) is required for human breast tumor metastasis in vivo [51].  
Expression of the CSF-1 receptor (CSF-1R) in ovarian, endometrial and breast 
carcinomas has been associated with adverse clinicopathological outcomes [52-
54].  In vivo imaging revealed that macrophages in breast tumors facilitate invasion 
by paving the way for breast tumor cells to reach endothelial cells where tumor 
cells can intravasate [39, 55].  These data suggest that macrophages play a 
significant role in the metastatic process of breast cancers.    
 
Recent studies have implicated the importance of adipocytes and their role 
in tumorigenesis and cell invasion.  Exposure of ER+ and TNBC cells to media 
conditioned by mouse and human adipocytes or direct co-culture with adipocytes 
enhanced the proliferation, migration and invasion of the cancer cells [56-58].  The 
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major adipokine released from adipocytes, adiponectin has been shown to 
stimulate migration and invasion in MDA-MB-231 cells upon incubation of cells 
with this hormone [59].  It is important to recognize the role adipocytes can play in 
tumorigenesis due to the current obesity epidemic in the country.  Obesity is a risk 
factor for breast cancer and other malignancies and also predicts poor outcomes.  
This could play a role in tumor formation and progression, as well as affect the 
treatment of cancer.         
 
Chemical changes to the tumor microenvironment can also impact tumor 
formation and progression.  Alterations to the O2 availability in the tumor has a 
profound effect on tumor cell invasion.  As tumors grow at an accelerated pace 
they can surpass their capacity to obtain a proper blood supply, which in 
combination with excessive growth creates a hypoxic environment [60].  In human 
breast tumors in situ measurement of oxygen pressure (PO2) revealed a pressure 
of 10 mm Hg while surrounding normal breast tissues have a PO2 of 65mm Hg [61, 
62].  Prolonged hypoxia can lead to regions of cell death as seen in advanced solid 
tumors  [63].  The low oxygen level leads to gene regulatory changes mediated by 
the hypoxia-inducible factors (HIF), a protein complex composed of an O2 
regulated alpha subunit and a constitutively active HIF-1β subunit.  The alpha 
subunits are subjected to constitutive ubiquitination and degradation that is only 
inhibited under hypoxic conditions [64].  Data from immunohistochemical studies 
performed in human tumor samples linked elevated levels of HIF-1α with increased 
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risk of metastasis [65].  This implicates a decrease in tumor oxygen tension with a 
more aggressive tumor behavior.  
 
One of the main roles of HIF-1α is to enhance blood vessel formation in a 
tumor by transcription of the vascular endothelial growth factor (VEGF) gene [66].  
It has been shown that knockout of HIF-1α in the MMTV-PyMT mouse model 
impairs tumor growth, vascularization and metastasis [67, 68].  In an orthotopic 
study using the breast cancer cell line MDA-MB-231, cells expressing shRNA 
against HIF-1α and HIF-2α were injected into mammary fat pads. Both 
knockdowns demonstrated a decrease in tumor lymphatic vessel density and 
metastasis to the regional lymph nodes [69].  Other studies using the same model 
demonstrated that injection of HIF-1α knockdown MDA-MB-231 cells can diminish 
the colonization of bone metastases [70].  Additionally, orthotopic injection of MDA-
MB-231 HIF-1α knockdown cells into immunodeficient mice showed a decrease in 
spontaneous lung metastasis and decreased metastatic burden [71].  These data 
taken together suggest that the ability of cells to activate the HIF transcription 
factors under hypoxic conditions can result in increased metastasis.   
 
Studies of tumor angiogenesis inhibition have contributed to the 
understanding of the impact of hypoxia on tumor cell invasion.   In the pancreatic 
condtional β-VEGF knockout mice tumors develop regions of intense hypoxia.  
These regions of hypoxia correlate with an increase in invasion, and an increase 
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in metastasis [68, 72].  Also, in the pancreatic cancer model RIP1-Tag2 mice, 
treatment with anti-VEGFR2 antibodies or the VEGFR inhibitor sunitinib causes 
hypoxia in tumors, increases local invasion at the primary tumor site and increases 
metastasis [73].  Responses to VEGF inhibition in clinical trials have not been as 
predicted with regard to outcomes.  Inhibition of this pathway has resulted in 
decreased time to progression, followed by resistance to therapy [73].  Many of the 
patients undergoing this therapy develop metastatic disease.  The induction of 
tumor hypoxia contributes to a more invasive phenotype in these tumors and 
increases their metastatic potential.   
 
 Hypoxia can also impact tumor invasion by increasing the ECM stiffness 
by enhancing collagen hydroxylation.   Studies investigating elevated fibrillar 
collagen in primary breast tumors revealed that increases in tumor fibrillar collagen 
are associated with recurrence and increased mortality [42].  The mechanism by 
which hypoxia increases tumor fibrillar collagen was studied in MDA-MB-231 cells.  
Under hypoxic conditions MDA-MB-231 cells have increased expression of prolyl-
4-hydoxsylase enzymes, which are responsible for the generation of fibrillar 
collagen [74, 75].  Injection of MDA-MB-231 cells with prolyl-4-hydroxylase 
knockdown resulted in diminished tumor growth and a complete inhibition of lung 
metastasis [75].  These findings suggest that hypoxic environments not only 
increase the machinery for new formation of blood vessels to facilitate tumor cell 
extravasation, but also enhance tumor ECM stiffness by increasing collagen I 
14 
 
formation in tumors.  A stiff environment has been implicated in enhanced invasion 
suggesting that hypoxia plays a role in creating the ideal environment for cancer 
cells to escape the primary tumor.   
 
Tumor-initiating cells and their contribution to metastasis 
 
 In a cancer patient, millions of tumor cells escape into the circulatory 
system, but a very limited number of those cells can give rise to a tumor at a distant 
site  [76].   Based on the “seed and soil” theory by Paget, the development of 
secondary growth depends on organs with the right growth conditions, only the 
proper soil will allow the growth of the newly resident cells [14, 77].  In the case of 
breast cancer, the major sites for metastasis are the bones, the lungs, the liver, 
the adrenal grands and the brain [76].  Even if tumor cells can travel to all of the 
organs in the human body, they may encounter conditions that restrict growth 
and/or survival and the formation of a secondary tumor.  Upon arrival at a distant 
organ, many of the cells will become dormant until the proper conditions develop 
to allow growth again.   
 
A conventional model of cancer propagation argues that all cells from a 
tumor have the potential to give rise to a metastatic tumor based on their ability to 
enter the cell cycle [78].  As we are familiar with the heterogeneous nature of 
tumors, not all cells in a tumor are created equal and only a limited number of cells 
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can initiate a tumor.  The heterogeneity of tumors takes place due to the 
hierarchical nature of tumors with a population of cells known as the cancer stem 
cells (CSC), or as I will refer to them hereafter tumor-initiating cells (TICs), and 
transit amplifying cells that give rise to the bulk of the tumor [79-81].   Discoveries 
in the leukemia field first pointed to a small subset of cells as responsible for the 
propagation of the disease [82-84]. This subset of cells can be identified by cell 
surface markers, in the case of leukemia those markers are CD34+CD38- [84].  
Serial transplantation of the CD34+CD38- cells demonstrates enhanced tumor 
formation activity in comparison to other tumor cells, and the ability of these TICs 
to self-renew.  Self-renewal is the ability of these cells to maintain the TIC 
population while giving rise to differentiated cells that comprise the heterogeneous 
tumor [85].   
 
 In human breast cancer, there is a population of cells capable of giving rise 
to new tumors upon transplantation.  Breast cancer cells isolated from human 
tumors using the markers CD44+CD24-/lowLin- have an increased tumor forming 
ability in NOD/SCID mice [86]. Serial transplantation of cells derived from tumors 
formed by CD44+CD24-/lowLin- cells can form heterogeneous tumors that mimic the 
original tumor [86].    Murine models of mammary cancer have also been tested 
for the identification of tumor-initiating cells.  In the MMTV-Wnt1 model the 
THY+CD24+ cells were found to have enhanced tumor activity [87].  In the TP53-
null mammary model β1integrinhiCD24+ had the same tumor forming potential 
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[88].  Furthermore, work in vitro using the TNBC cells SUM149, MDA-MB-468 and 
MDA-MB-231 revealed a population of cells in each cell line with the markers 
CD44+CD49f+ that have tumor-initiating potential [89].  These cells not only 
possess enhanced self-renewal ability but also show increased resistance to the 
drug paclitaxel [89].  TIC populations represent a limitation to conventional 
treatment because they tend to be more resistant to therapeutic interventions and 
are responsible for the recurrence of cancers.   These TICs cells have also been 
implicated in the ability of cancer cells to effectively colonize a distant organ during 
metastasis.    
 
Direct evidence for the implication of TICs in metastasis came from patient 
derived xenograft (PDX) tumors.  The most metastatic PDX tumors have a high 
percentage of TICs present in the primary tumors, while the least metastatic 
tumors have a lower percentage of these cells [90].  In the TNBC cell line 
SUM1315, inhibition of the Wnt signaling pathway caused a decreased in the 
percentage of CD44+/CD24- cells and affected the ability of these cells to form a 
primary tumor and metastasize upon transplantation [91].  Analysis of breast 
cancer cells isolated from a bone marrow metastasis showed an increased number 
of TICs in comparison to the primary tumor [92].  In murine and human 
inflammatory breast cancer models, TICs have been correlated with more invasive, 
metastatic and aggressive disease and poor outcomes [93].  These findings 
support the idea that a small population of cells is responsible for tumor formation 
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and is also responsible for the successful colonization of distant organs during 
metastasis.    
 
 The environmental niche of TICs plays a vital role in their behavior.  As 
discussed earlier, the hypoxic environment affects metastasis and studies have 
established that TICs are key players in metastasis.  Inhibition of HIF-1α 
expression using shRNA in various TNBCs leads to inhibition of primary tumor 
growth and metastasis to the lungs supporting the importance of hypoxia in TICs 
[94].  SUM159 cells exposed to hypoxia in vitro for 48 hours caused an enrichment 
in TICs and the knockdown of HIF-1α in this cell line abrogated the hypoxia 
mediated TIC-induction [95].   Additional evidence from exposure of MCF-7 breast 
cancer cells to hypoxia shows an increase in the stem cell factors KLF4, NANOG, 
OCT4 and SOX2, which are important for maintenance of pluripotent stem cells 
and embryonic stem cells [96, 97].  The role hypoxia plays in mammary tumor 
progressions seems to be complex, not only can hypoxia influence the tumor 
microenvironment to enhance migration and invasion but it can also play a positive 
role in the maintenance of TICs, which can successfully colonize a distant site to 
form a metastatic lesion.     
 
Pathophysiological conditions can trigger tumor cells to acquire tumor-
initiating properties through the induction of EMT. Several studies have indicated 
that metastatic cells that have undergone EMT exhibit a TIC phenotype. 
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Disseminated breast cancer cells isolated from pleural effusions are enriched for 
CD44+CD24- cells [98]. Also, in pancreatic tumors, cells isolated from the invasive 
leading edge of a tumor are enriched for stem cell markers.  Studies have shown 
that forced repression of E-cadherin by Snail expression, a step in the EMT 
process, triggered an enrichment in CD44+CD24- cells [99].   A study looking at 
the stem cell marker CD44 in human tumors and its association with EMT showed 
a positive correlation between CD44 expression and the EMT markers SNAI1, 
ZEB1, TWIST and VIMENTIN in human breast tumors [100].  The same study 
showed an association between the TIC marker CD44 expression and other stem 
cell markers like ALDH1, SOX2, NANOG, KLF4, MYC and OCT4, further 
implicating EMT with TICs. Of interest, this study reported a significant correlation 
between CD44 expression in breast cancer and poor overall survival rate [100].  
Therefore, the developmentally conserved EMT program not only allows epithelial 
tumor cells to become more invasive but also contributes to the promotion of TIC 
properties in cancers.   
 
 TICs are not only a problem when it comes to cancer metastasis, these cells 
are also a big hurdle in the treatment and eradication of cancer.  The presence of 
TICs in tumors can explain breast cancer treatment resistance and recurrence of 
disease ([89, 100, 101]).  Upon treatment with paclitaxel and 5-fluorouracil, the 
breast carcinoma cell lines Sum159 and Sum149 undergo an enrichment in TICs 
and develop resistance to these therapies [102]. Although these treatments can 
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eliminate the bulk of the cancer cell population, as long as a subset of TICs remain 
they can repopulate the tumor after treatment has been withdrawn.   
 
The identification of signaling pathways that are important in TICs can help 
identify strategies to target this cell population.  In breast cancer, the Wnt/β-
catenin, sonic hedgehog, notch and PTEN signaling pathways have been 
implicated in TIC self-renewal regulation [21].  One assay used to assess cancer 
stem cell activity in vitro is the mammosphere formation assay.  This assay allows 
for cells with stem cell properties to grow in non-adherent growth conditions [103].  
Expression of the Wnt activator Pygo2 in MDA-MB-231 cells enhances 
mammosphere formation suggesting an enrichment in TICs [104].  Deletion of the 
same activator in MMTV-Wnt1 tumor cells negatively affected mammosphere 
formation and tumor-forming capacity upon transplantation [105].  Identification of 
pathways that contribute to the ability of TICs to self-renew will contribute to better 
targeting of this population of cells in tumors and better treatment for localized and 
metastatic disease.  As evidence of this, treatment of breast cancer cells with Wnt 
pathway inhibitors Salinomycin or CWP232228 induces the cell death of TICs [102, 
106, 107].  Discoveries of novel regulators of TICs can provide alternative 
approaches for the eradication of metastatic cancers.   
 
Insulin Receptor Substrate (IRS) Proteins 
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The IRS proteins are a family of cytoplasmic adaptor proteins that 
coordinate signaling downstream of cell surface receptors to regulate cellular 
outcomes.  IRS1 and IRS2 are the main isoforms ubiquitously expressed in 
mammalian cells, whereas IRS4 is limited in its expression to kidney, brain, thymus 
and liver [108, 109].  Mice, but not humans, also express IRS-3 [108].  All the IRS 
proteins share significant homology in their sequence, specifically in their N-termini 
and to a lesser extent in their C-terminal tails.  IRS1 and IRS2 are expressed in 
both normal mammary epithelial cells and breast cancer. However, the expression 
pattern of IRS1 and IRS2 in breast cancer is variable.  IRS1 is highly expressed in 
localized tumors, while IRS2 is more highly expressed in invasive tumors [110].   
Additional studies have also investigated the subcellular localization of these 
adaptor proteins in breast cancer.  Immunohistochemical analysis of IRS1 and 
IRS2 expression in human breast tumor samples shows IRS1 is cytoplasmic and 
nuclear, whereas IRS2 is cytoplasmic and at the plasma membrane [111].  The 
nuclear localization of IRS1 correlates with enhanced survival in response to 
tamoxifen treatment and IRS2 membrane localization correlates with decreased 
overall survival [111, 112].  These studies support that not only the relative 
expression of the IRS proteins in breast tumors, but also their subcellular 
localization, can impact the clinical outcome for patients. 
 
 Murine mammary tumor models have contributed tremendously to the 
understanding of IRS biology in breast cancer.  Transgenic mice overexpressing 
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IRS1 or IRS2 in the mammary glands develop mammary hyperplasia, tumors and 
metastases to the lungs [113]. Research performed by the Shaw Lab took 
advantage of the MMTV-PyMT model of murine mammary tumor metastasis and 
generated PyMT:Irs1-/- and PyMT:Irs2-/- mice to determine the role that the IRS 
proteins play in mammary tumor development and metastasis [114].  Knockout of 
Irs1 or Irs2 in this model did not impact primary tumor growth, but rather altered 
the ability of these tumors to metastasize (Figure 1.1) .  PyMT:Irs2-/- mice exhibited 
a significant decrease in mammary tumor metastasis while PyMT:Irs1-/- mice, with 
elevated levels of IRS2 expression in the tumors, exhibited an increased 
metastatic rate [114].  Cell lines derived from these PyMT:Irs-/- tumors further 
demonstrated the disparities between these two proteins in breast cancer.  Irs2-/- 
cells are more sensitive to cell death upon serum starvation, have decreased 
invasion and decreased aerobic glycolysis [115-117].  In contrast, Irs1-/- cells are 
more invasive, have greater survival upon serum starvation and maintain their 
ability to perform aerobic glycolysis.  The ability of Irs2 to regulate glycolysis, 
invasion and tumor cell survival are likely important for its promotion of tumor 
metastasis in vivo.    
 
IRS4 is emerging as a protein of interest in multiple cancers, however, there 
is limited information on IRS-4 in human breast cancer.  Although IRS-4 is not 
expressed in the normal breast epithelium, it has tumorigenic potential, as 
expression of IRS4 in the non-transformed human mammary epithelial cell line  
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Figure 1.1 Analysis of IRS involvement in PyV-MT mammary tumor 
metastasis. (A) Female FVB/PyV-MT+/- mice were analyzed for their total tumor 
burden at 80 days of age. The mean tumor volume (±SEM) was determined for 
each Irs genotype using the formula: volume = 4/3p(length/2)(width/2)(length/2). 
The number of mice analyzed for each genotype is indicated. Statistical 
significance was determined using the Student’s t-test. A p-value of ≤0.05 was 
considered statistically significant. (B) Lungs from 80-day-old female 
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FVB/PyV-MT+/- mice were sectioned and screened microscopically for the 
presence of metastatic lesions. Five representative H&E sections from each lung 
were analyzed. The percentage of mice that scored positively for metastatic 
lesions for each Irs genotype is shown and the number of mice analyzed is 
indicated. Statistical significance was determined using the chi square test. A 
p-value of ≤0.05 was considered statistically significant. 
 
 
Adapted from:  
Gibson, S.L., Z. Ma, and L.M. Shaw, Divergent roles for IRS-1 and IRS-2 in breast 
cancer metastasis. Cell Cycle, 2007. 6(6): p. 631-7. 
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MCF-10A leads to anchorage-independent growth in a soft-agar assay similar to 
IRS1 and IRS2 [118]. In addition to proliferation effects, IRS4 has been linked to 
resistance to breast cancer therapies. Expression of IRS4 in the Her2+ breast 
cancer cells SKBR3 and BT474 leads to resistance to Trastuzumab or Lapatinib 
[118].    
 
The IRS proteins also have very distinct roles in normal physiology as 
observed from studies of knockout mice.  Irs1-/- mice are deficient in body growth, 
while Irs2-/- mice have defects in brain development and pancreatic beta-cell 
survival [119-122].  Loss of either Irs1 or Irs2 in mice leads to the development of 
insulin resistance, but only the loss of Irs2 causes diabetes [121, 123]. This 
difference is due to the loss of beta cells and insulin production in the pancreas in 
Irs2-/- mice, as Irs2 has been shown to regulate the survival of beta cells [123].  
Irs1-/- mice develop pancreatic β-cell hyperplasia as they can only signal through 
Irs2 [120].  On the other hand, Irs4 knockout mice have only mild defects in growth, 
glucose homeostasis and reproduction [124].  Male Irs4-/- null mice are 10% 
smaller than their wild type counterparts while female Irs4-/- mice have no defects 
in growth.  Also, Irs4-null mice exhibit lower levels of blood glucose in the fed and 
fasted states but have no alterations in insulin levels [124].   
 
As demonstrated by the Irs1-, Irs2 and Irs4-null mice, the IRS proteins play 
an important role in normal metabolism.  The IRS proteins also have additional 
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roles in murine physiology. In the mouse heart, myocardium specific loss of Irs1 
and Irs2 leads to heart failure [125].  Irs2-/- deficient cells in the kidney tubules 
leads to a decrease in bicarbonate reabsorption, suggesting a role of the Insulin-
Irs2 axis in renal regulation of bicarbonate [126].  In the mouse eye, Irs2 deletion 
triggers a decrease in signaling downstream of Irs2 and higher induction of cell 
death, a phenotype that cannot be compensated for by the expression of Irs1 [127].  
These studies provide further proof of the differential roles the IRS proteins play in 
normal physiology and highlight the importance of understanding the regulation of 
IRS protein signaling.   
 
The IRS proteins belong to a class of proteins known as the intrinsically 
disordered proteins (IDPs).  These proteins are characterized by a low sequence 
complexity and a lack of a well-defined tertiary structure ([128]).  A characteristic 
of such proteins is the high content of hydrophilic charged amino acids and low 
proportion of hydrophobic bulky amino acids ([128]).  IDPs are completely 
functional but lack the ability to fold into stable globular three-dimensional 
structures and continually transition through multiple conformations that facilitate 
protein interactions and signaling [129].  Some IDPs are completely disordered 
while others contain combinations of structured globular domains and intrinsically 
disordered regions (IDRs).  IDPs have the ability of functioning as central 
regulators in protein interaction networks and are involved in the regulation of 
complex signaling pathways [130]. The nature of these proteins allows them to 
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interact with other proteins with high specificity and modest affinity, allowing for the 
fast activation and termination of signaling events [131].   
 
The IRS proteins contain two structured domains in their N-termini, the pleckstrin 
homology (PH) and phospho-tyrosine binding (PTB) domains, while their C-termini 
are comprised of the disordered sequence [132-135] (Figure1.2A).  IRS2 also 
contains the KRLB region, which was identified from a peptide screen as a region 
that binds the IR and plays a role in the downregulation of insulin signaling [136].  
This region has no confirmed tertiary structure. The PH domain contributes to the 
localization of the IRS proteins to activated receptors at the cell membrane by 
facilitating protein-protein interactions and the interaction between the protein and 
phospholipids at the cell membrane [132, 135].  The PTB domain mediates the 
interaction between the IRS proteins and activated receptors that harbor the NPXY 
motif [133, 134].  Recruitment of the IRS proteins to the activated receptors leads 
to the phosphorylation of multiple tyrosine residues in their C-termini.  The IRS 
proteins do not exhibit intrinsic kinase activity but their phosphorylation leads to 
the recruitment and activation of downstream signaling effectors that include PI3K, 
Grb-2 and Shp-2 [137-140].   As we learn more about the role of these proteins in 
cancer, new evidence sheds light into their differential functions.  We are interested 
in understanding the mechanism of IRS protein function as these adaptor proteins 
have been extensively implicated in many aspects of cancer biology.  
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Signaling through the IRS proteins: Upstream receptors 
 
Irs1 was discovered in 1985 as a downstream substrate of the insulin 
receptor (IR) using a phosphotyrosine-specific antibody screen after insulin 
stimulation of hepatoma cells [119, 141]. Irs2 was discovered in 1990 as an 
alternative substrate of the IR in Irs1-/- mice in response to insulin stimulation [119, 
142]. Subsequent studies revealed a role for the IRS proteins as signaling 
intermediates of the close family member Insulin-like growth factor-1 receptor 
(IGF-1R), as well as a subset of integrin and cytokine receptors [143].  In ER+ 
breast carcinoma cell lines, IRS1 mediates signaling downstream of the IL-4 
cytokine receptor, but IRS2 does not interact with this receptor [144].  There is also 
limited evidence for the involvement of the IRS proteins downstream of the growth 
hormone (GH) receptor, VEGFR, EGFR, and the prolactin receptor [145]. In 
normal physiology, the IRS proteins have been most extensively characterized for 
their role in mediating IR regulation of glucose metabolism and IGF-1R mediated 
mitogenesis [146, 147]. 
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Figure 1.2 Summary of Insulin Receptor Substrate signaling.  (A) Schematic 
of IRS1 and IRS2 depicting PH and PTB structural domains in grey and 
phosphotyrosine sites that bind PI3K.  (B) Overview of the IR/IGF-1R/IRS signaling 
pathway.   
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IR and IGF-1R signaling play a role in the growth and development of many 
tissues. During fetal development, IGF-1 and IGF-1R mutations can lead to 
developmental delays and postnatally children with these mutations display a 
growth deficiency [148]. In the mammary gland, disruption of IGF-1R signaling 
causes reduced gland growth [149].  The IR/IGF-1R signaling network is 
comprised of the ligands insulin, IGF-1 and IGF-2, the cell surface receptors IR-A, 
IR-B, IGF-1R and IGF-2R, and the IGF-binding proteins [150].  IR-A and IR-B are 
splice variants that differ in the inclusion (IR-B) or exclusion (IR-A) of exon 11 
resulting in a 12 amino acid difference in the β-subunit.  The IR-A isoform is 
expressed prenatally and is also expressed aberrantly in many cancers accounting 
for 60-100% of IR expression in tumor cells [151].  The IR-B isoform is the 
predominant receptor expressed in liver, muscle and adipocytes and is responsible 
for the metabolic effects of insulin [151].  The affinity of each receptor for ligands 
is different, with IR-A binding insulin, IGF-1 and IGF-2 and IR-B only binding insulin 
[152, 153].  The IR and IGF1R receptors can form homodimers as well as 
heterodimers in many tissues, including in cancer cells.    
 
Elevated levels of IGF ligands in the circulation are considered risk factors 
for the development of breast cancer [154, 155].  Low levels of IGF1-binding 
proteins (IGFBP) are also considered risk factors for cancer.  The IGFBPs bind 
free IGF-1 ligand in the circulation and decrease the level of bioavailable IGF-1. 
Upon a decrease in IGFBP expression, the level of free IGF ligands in the serum 
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rises, enhancing IGF-1 signaling in peripheral tissues and affecting cancers that 
depend on this signaling pathway. The IGF ligands at high concentration are not 
only risk factors for breast cancer but also risk factors for prostate and colon cancer 
[156].  Additionally, elevated insulin levels in breast cancer patients correlate with 
more aggressive disease and poor outcomes [157].  
 
The IGF-1R has been implicated in both tumor initiation and progression in 
breast cancer.  Expression of constitutively active IGF-1R in breast epithelial MCF-
10A cells increases growth in soft agar and promotes tumor formation in nude mice 
[158].  Transgenic overexpression of the IGF-1R also results in the induction of 
mammary tumors in vivo [159].  IGF-1R receptor signaling is crucial for tumor 
growth by mediating mitogenesis, maintaining the transformed phenotype and 
protecting tumor cells from apoptosis [160].  The IGF-1R pathway has also been 
implicated in progression of tumors from localized to metastatic disease.  In a 
murine metastatic model [161], inhibition of the IGF-1R did not inhibit primary 
tumor growth, but caused significant inhibition of metastasis in vivo.  Expression 
of dominant negative IGF-1R in human breast carcinoma cells decreased invasion 
and anchorage independent growth, and upon injection into mice, inhibited 
metastasis  [161, 162]. Also, in a bone metastatic clone of MDA-MB-231 cells, IGF-
1 blockade leads to a decrease in tumor cell motility and inhibits tumor metastasis 
in vivo [163]. In breast cancer patients, IGF-1R signaling, as determined by 
phosphorylation of IGF-1R at Tyr 1135/1136, is associated with metastasis of 
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breast and lung cancers to the brain [164, 165]. Moreover, upregulation of IGF-1R 
in breast cancer patients after neoadjuvant therapy predicts poor outcome [166], 
further supporting a role for the IGF-1R in breast cancer progression.   
 
In MCF-10A cells, overexpression of the IGF-1R leads to tumor growth in 
nude mice by the induction of EMT via the upregulation of Snail and inhibition of 
E-cadherin expression [158].   Several studies have shown that the expression of 
the IGF-1R receptor is elevated in TICs in comparison to the bulk population of 
tumor cells [167, 168].  Also, IGF-1 signaling has been shown in MDA-MB-231 
cells to be a positive regulator of the EMT transcription factor ZEB1, causing the 
induction of invasion and metastasis in these cells [167].  The involvement of IGF-
1R signaling in resistance to tumor therapy, EMT and TICs suggests that the IGF-
1R plays an important role in tumor progression by regulating both tumor initiation 
and invasion.  This evidence makes the IGF-1R signaling pathway an important 
target in breast cancer.   
  
 Inhibition of IGF-1R signaling in cancer cells in vitro and in mouse mammary 
tumor models has demonstrated the benefits of inhibiting this pathway in cancer. 
Several inhibitors are under clinical development to target this signaling pathway 
in patients.  However, targeting of the IGF-1R in clinical trials has demonstrated to 
be a complex task. Inhibitors against this pathway did not show the predicted 
outcomes based on their preliminary preclinical studies.  Failure was in part due to 
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upregulation of the Insulin receptor (IR-A), downregulation of the IGF-1R and 
upregulation of other tyrosine kinase receptors in the tumor cells [169].  Also, the 
constitutive activation of signaling molecules downstream of the receptor can limit 
the efficacy of this approach [170].  The dismal performance of these inhibitors 
does not take away from the importance of IGF-1R signaling in cancer.  Poor 
clinical trial design could have contributed to the lack of response in phase III trials 
as none of the patients participating in the trials were screened for IGF-1R 
expression in their tumors.  In the case of Ewing sarcoma, a cancer with high levels 
of IGF-1R expression, complete responses were observed upon inhibition of IGF-
1R signaling [169].   These results suggest that further understanding of this 
pathway, specifically understanding the IRS proteins as mediators of IR/IGF-1R 
signaling, can aide in the design of improved clinical trials that target key aspects 
of IR/IGF-1R signaling in a more efficient way.     
 
Signaling through the IRS proteins: Downstream effectors 
 
The IR and IGF-1R are composed of two extracellular alpha subunits and 
two transmembrane and intracellular beta subunits, which are joined by disulfide 
bonds [171].  Binding of the ligands IGF-1, IGF-2 or insulin to the extracellular 
subunits of the receptors causes activation of the kinase domains and 
autophosphorylation of the intracellular subunits. These phosphorylation events 
create docking sites for the IRS proteins [172]. Phosphorylation of the IRS proteins 
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by the receptor kinases leads to the recruitment of SH2 domain containing proteins 
like GRB2/SOS and phosphatidyl inositol 3’-kinase (PI3K) resulting in activation of 
the mitogen-activated protein kinase (MAPK) and PI3K pathways, respectively, 
that are important mediators of the IGF-1/insulin bioactivities [173-175].  Both of 
these signaling pathways have been implicated in cancer extensively, but their 
activation downstream of the IR or the IGF-1R can have very different outcomes.  
One possible mechanism for their differential outcomes is the recruitment of unique 
effectors by either IRS1 or IRS2 to activate different downstream signaling 
pathways.  Additionally, as mentioned previously the differential cellular 
localization of the adaptors may contribute to their divergent outcomes [111].   
 
A very important signaling molecule that is activated downstream of the IRS 
proteins is PI3K. PI3K is one of the major pathways activated by receptor tyrosine 
kinases and is extensively implicated in cancer.  Upon activation, PI3K generates 
phosphatidylinositol 3,4,5-triphosphate (PIP3) at the cell membrane leading to the 
recruitment of effectors and amplification of intracellular signaling [176, 177].  
There are three different classes of PI3K (Class I-III) with distinct lipid substrates 
and effectors.  Class I PI3K generates PIP3 and includes two subclasses: Class IA 
is activated in response to receptor tyrosine kinases like the IGF-1R and Class IB 
is activated by G-protein coupled receptors (GPCRs) [177].  As this work focuses 
on the IR/IGF-1R/IRS mediated regulation of cancer progression, further 
discussion of Class IA PI3K is required.   
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Class IA PI3K is formed by a heterodimer consisting of a regulatory subunit 
and a catalytic subunit [178]. There are 5 isoforms of the regulatory subunit (p85α, 
p55α, p50α, p85β and p55γ) and three isoforms of the catalytic subunit (p110α, 
p110β, and p110δ) [177].  In basal conditions the association of p85 with p110 
leads to inhibition of the lipid kinase activity of the catalytic subunit [179]. Upon 
receptor tyrosine kinase phosphorylation, the p85 subunit binds to phosphorylated 
tyrosine residues on the receptor or adaptor proteins, releasing the inhibition of the 
p110 catalytic subunit and rendering the kinase active [179].  Ligand stimulation of 
the IR or IGF-1R by insulin/IGF1 leads to receptor mediated phosphorylation of the 
IRS proteins and activation of PI3K.  Loss of IRS expression abrogates the 
activation of PI3K following stimulation of these receptors, indicating that these 
adaptors are required to activate the PI3K signaling pathway [180, 181].  The 
generation of PIP3 by PI3K activation leads to the recruitment of AKT to the cell 
membrane through its PH domain [182].  This event regulates processes like cell 
survival, growth, proliferation, transcription, glucose metabolism, cell motility and 
protein translation [183].  In addition, PIP3 can activate the RAC signaling pathway 
and regulate cell-to-cell contact, actin cytoskeleton rearrangements, cell adhesion, 
transcription, translation, cell survival and cell cycle [184].  Activation of AKT and 
RAC signaling by PI3K leads to the regulation of a variety of cellular processes 
that are essential for normal cell biology.  If these processes are dysregulated they 
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can also contribute to many aspects of tumorigenesis. Therefore, the dysregulation 
of PI3K signaling is a hallmark of many cancers.   
 
 In many cancers including colon, lung, gastric, breast and brain, PI3K is 
mutated [185, 186].  Activating mutations of the p110α catalytic subunit of PI3K 
(PI3KCA) take place in 25% of all breast cancers and the mutations occur mostly 
in exon 9 and exon 20, which encode the helical and catalytic domains of the 
protein [187].  These gain of function mutations cause increased PI3K activity and 
constitutive activation of downstream targets such as AKT, ribosomal protein S6 
kinase (S6K) and inactivation of glycogen synthase kinase-3 (GSK-3) [188].  The 
PI3K pathway can also be regulated by dephosphorylation of PIP3 by the 
phosphatase PTEN [189].  Loss of the tumor suppressor PTEN leads to 
deregulation of the PI3K pathway in cancer.  Germline mutations in the PTEN gene 
result in Cowden’s Syndrome and predispose patients to a number of different 
cancers, including breast cancer [189, 190].  Beyond mutations in PTEN, PI3K can 
be dysregulated through constitutively active signaling from upstream tyrosine 
kinase receptors.  In breast cancers and Ewing sarcomas, the IGF-1R pathway is 
commonly amplified causing the activation of PI3K signaling [169]. The 
requirement of the IRS proteins for activating PI3K in response to IR/IGF-1R 
signaling is an additional justification to support understanding the function of these 
adaptor proteins.   
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Regulation of IRS expression 
 
The regulation of IRS protein expression likely contributes to the differential 
impact of IRS-1 and IRS-2 in breast cancer.  The IRS genes are hormone 
responsive, with IRS1 regulated by the estrogen receptor (ER) and IRS2 regulated 
by the progesterone receptor (PR) [191, 192].  This differential regulation plays a 
role in response to therapy.  In the context of the ER antagonist tamoxifen that is 
used for treatment of ER+ breast tumors, inhibition of IRS1 contributes to a 
favorable response to this inhibitor [171]. IRS1 knockdown in MCF-7 cells 
enhances tamoxifen mediated cell death supporting the role of IRS1 expression in 
ER+ tumors [193].   Treatment of PR+ breast cancer cells with progestin increases 
the expression and phosphorylation of IRS2 [192, 194, 195].  Moreover, other 
growth factor receptors have been shown to regulate IRS protein expression 
including the EGFR and FGFR [196].  These receptors have also been implicated 
in breast cancer, suggesting a collaboration between the EGFR, FGFR and 
IGF1R/IR pathways in cancer.   
 
 The tumor microenvironment can contribute to the regulation of IRS protein 
expression.  As previously discussed, hypoxia plays an important role both in 
promoting tumor cell invasion and increasing tumor-initiating cells.  Hypoxia is also 
a regulator of IRS2 expression in breast carcinoma cells.  Exposure of breast 
carcinoma cells to hypoxia increases IRS2 expression at the mRNA and protein 
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level, while IRS1 protein expression decreases in hypoxic conditions.  The 
expression of siRNA against HIF1α and HIF2α represses IRS2 expression in 
hypoxic conditions [197].  The induction of IRS2 during hypoxia promotes 
enhanced tumor cell survival and invasion.  These findings provide evidence for a 
mechanism by which IRS2 and hypoxia can contribute to cancer metastasis.   
 
Another mechanism for regulating IRS expression is the post-transcriptional 
targeting of IRS mRNA by microRNAs (miRNAs).  miRNAs, small (18-24 
nucleotides) single-stranded non-coding RNAs, bind the 3’UTR region of mRNAs 
and target them for degradation or inhibit their translation [17].  miRNAs have been 
implicated in many biological processes such as cell proliferation, cell cycle, 
apoptosis, migration, invasion and differentiation.  In lung cancer two miRNAs, 
miR146a and miR338-3p, have been demonstrated to inhibit non-small cell lung 
cancer metastasis by targeting IRS2 expression [198, 199].  In the lung cancer cell 
lines H460 and H1299, miR146a repression of IRS2 inhibited migration and 
invasion of these cells, which was further validated with siRNA against IRS2 [199]. 
In A549 lung carcinoma cells, miRNA-338-3p decreases the expression of IRS2 
and inhibits tumor cell invasion. Overexpression of IRS2 using a 3’UTR deficient 
mRNA restored invasion in these cells  [198].  miR-141 also plays a role in the 
inhibition of tumor cell invasion in vitro in thyroid carcinoma cell lines and inhibits 
primary tumor growth in vivo by downregulating IRS2 expression [200].  All of these 
studies support the importance of IRS protein regulation for tumor progression.   
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In addition to transcriptional and post-transcriptional regulation, IRS protein 
levels can also be regulated through post-translational modifications.  Several 
studies have demonstrated that the IRS proteins are ubiquitinated by several 
ubiquitin ligases and targeted for degradation by the 26S proteasome [201].  The 
IRS proteins can also associate with the deubiquitinating enzyme ubiquitin specific 
protease 7 (USP7) [202]. This interaction plays a role in the stabilization of the IRS 
proteins and in turn the maintenance of IGF1R/IR signaling.  Ligand stimulation, 
IGF-1 for IRS2 and insulin for IRS1, leads to the dissociation of USP7 from the IRS 
proteins and their subsequent degradation.  Stimulation of these pathways in a 
ligand dependent manner can have differential regulation of expression at the IRS 
protein level and produce different responses in cells depending on which IRS 
protein remains expressed.   
 
The prolonged stimulation of signaling downstream of the IR/IGF-1R can 
activate a negative feedback loop that is dependent upon the mechanistic target 
of rapamycin (mTOR) ([203, 204].  Downstream of mTOR, S6 kinase 
phosphorylates the IRS proteins on serine/threonine residues and targets them for 
ubiquitination and degradation by the ubiquitin proteasome system (UPS) [109, 
201].  In addition, the phosphorylation of serine residues near the PI3K binding 
motifs can lead to a decrease in the association of p85 with the adaptor proteins 
and inhibition of signaling downstream of PI3K [205].  Most of the negative 
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feedback regulatory events for the IRS proteins have been studied in IRS1.  In the 
breast carcinoma cell line MDA-MB-468, the use of inhibitors against the PI3K 
pathway caused an increase in the expression of IRS2, but also resulted in 
increased association with the regulatory subunit of PI3K and allowed the further 
activation of PI3K signaling [206].  These results suggest that upon the activation 
of IR/IGF-1R signaling, one mechanism that cells can employ to turn off this 
pathway is degradation of the IRS proteins.   
 
 In addition to stimulating protein degradation, phosphorylation of serine 
residues in the IRS proteins can contribute to inhibition of insulin mediated IRS 
protein signaling.  Increased serine phosphorylation of IRS1 is a common finding 
during insulin resistance and diabetes [204, 207].  Insulin resistance and diabetes 
are known for the induction of inflammation.  In inflammatory states, the 
proinflammatory cytokine TNFα is secreted by macrophages and other immune 
cells.  TNFα causes activation of the c-Jun NH2-terminal kinase (JNK) and the 
phosphorylation of IRS1 at Ser307 [207].    This residue is located near the PTB 
domain and inhibits the interaction between the IR catalytic domain and the PTB 
domain causing inhibition of IR/IRS1 signaling [207].   The tumor microenvironment 
is rich in inflammatory cells that could contribute to the negative regulation of IRS1 
activity in tumors.  In support of this possibility, IRS1 serine phosphorylation is 
elevated in metastatic mammary tumors and this correlates with reduced activity 
as meaured by tyrosine phosphorylation [116]. 
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The microtubule cytoskeleton 
 
The microtubule cytoskeleton is composed of heterodimers of α- and β-
tubulin that polymerize in a head-to-tail array to form protofilaments [208]. These 
protofilaments have polarity with two distinct ends, a plus end and a minus end.  
The polarity is important in the trafficking of motor proteins along the microtubules 
[209].  13 protofilaments come together to give rise to the hollow cylindrical tubes 
that we know as microtubules.  Beyond their role in mitosis, microtubules are 
important players in intracellular trafficking, cell size and shape, protein signaling, 
cell division and cell migration and motility [210-212].    Microtubules are very 
dynamic structures with constant polymerization and depolymerization taking 
place simultaneously.  The regulation of polymerization and depolymerization 
rates in the cells determine the net growth of microtubules and plays a role in 
mitosis and cell motility and migration [213].   Independent of their role in mitosis 
the ability of microtubules to regulate cellular trafficking, motility and invasion can 
contribute to their role in tumor progression. 
 
One of the hallmarks of cancer is uncontrolled cell proliferation and the 
microtubules are very important in this process due to their role in cellular division.  
Due to this central role in mitosis, disruption of microtubules has been an exciting 
target in cancer therapeutics.  Two major approaches to targeting the microtubules 
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exist, the vinca alkaloid therapy that leads to the disruption of microtubules and the 
taxanes that cause the stability of the microtubules [214, 215].  The vinca alkaloids, 
which include the agents vinblastine, vincristine and vinorelbine, cause the 
disruption of the microtubule cytoskeleton [214].  On the contrary, taxane drugs 
like paclitaxel and docetaxel stabilize the microtubules and prevent the progression 
of the cell cycle [215].  The disruption or the stabilization of microtubules in cancer 
cells causes cell death and is one of the reasons these drugs are widely used in 
cancer therapy.    
 
In order to understand more about the role of microtubules in the cell it is 
necessary to understand their interacting proteins.  An important group of proteins 
that interact with microtubules are the motor proteins, which are essential in the 
trafficking of vesicles and organelles along the microtubules.  One of the motor 
proteins, Dyenin, allows retrograde movement towards the minus ends of 
microtubules, while kinesin motor proteins can facilitate anterograde movement 
towards the positive ends of the microtubules [216].  Kinesins are a family of 
microtubule motor proteins that mediate a diverse set of functions within the cell 
that include the transport of vesicles, organelles, chromosomes, protein 
complexes and even move microtubules [216, 217].  These enzymes are 
characterized by having a motor domain that contains the ATP binding site, a stalk 
and a tail.  The stalk and the tail are important for dimerization of the kinesins and 
confers specificity of the cargo binding.  There are 45 kinesins identified in humans 
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and 12 have been shown to be implicated in many aspects of mitosis including the 
segregation of the chromosomes, formation of the mitotic spindle, kinetochore-
microtubule dynamics, and cytokinesis [217, 218].   
 
The role of microtubule motor proteins in mitosis has made them an 
attractive target in cancer therapy.  The use of taxanes and vinca alkaloids for 
cancer treatment has severe neurotoxicity as a side effect due to the importance 
of microtubules in the trafficking of neurotransmitter vesicles along tubulin in axons 
and dendrites [210].  If mitotic kinesins are targeted instead, the broad side effects 
from microtubule disruption can be avoided.  A kinesin that has been extensively 
studied in cancer is KIF11 (also known as Eg5 or kinesin-5) and inhibitors against 
this motor protein have already progressed to clinical trials [219].  In pancreatic 
cancer cells, overexpression of KIF11 is associated with tumor cell invasion [219].  
Other kinesins involved in tumor cell invasion are KIF20 in pancreatic cancer and 
KIF2A in human glioma cells [220, 221].  Elevated levels of KIF20 has also been 
identified in cancers of the breast, lung and bladder [222].    
 
 Treatment of cancer cells with microtubule disrupting agents has been a 
well exploited therapeutic intervention in cancers, but not a perfect treatment.  In 
breast cancers, taxanes are one of the first line therapies used in the clinic and 
among the mechanisms of taxane resistance, the kinesin motors seem to play an 
important role. In breast cancer, the overexpression of KIFC3, KIF1C and KIF5A 
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caused resistance of breast cancer cells to docetaxel by opposing the stabilizing 
effects of the drug [223].  The effects of kinesin overexpression during vinca 
alkaloid treatment has yet to be determined.  Moreover, limitations to the inhibition 
of kinesins in the treatment of cancers have already appeared. In clinical trials 
KIF11 failed to work against slow or non-proliferating tumor cells [224].  As the 
understanding of microtubules improves, better approaches to cancer therapy 
continue to be developed.   
 
Cell Death: Apoptosis 
 
 The main goal of cancer therapies is the elimination of cancer cells through 
the induction of cell death.  In mammals, the predominant mechanism of cell death 
throughout development and tissue homeostasis is apoptosis.  In the case of 
cancer, cells have an acquired ability to evade apoptotic cell death [225].  The 
ability of cancer cells to escape apoptosis provides cells with an advantage to 
continue uncontrolled cell proliferation and also provides cells with the capability 
of resisting therapeutic interventions [226].  Apoptotic cell death is regulated by 
two pathways: one determined by intrinsic death stimuli and the other by extrinsic 
death stimuli.  Intrinsic stimuli include excessive oncogene activation, DNA 
damage or the unfolded protein response (UPR). Extrinsic stimuli involve the 
activation of the Fas or TNFα receptors on the cell surface [227]. These pathways 
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converge at the mitochondrial outer membrane (MOM) with the Bcl-2 proteins 
regulating the fate of apoptosis.   
 
 The Bcl-2 family of proteins consists of pro-apoptotic and anti-apoptotic 
proteins and it is divided into three classes based on the presence of the conserved 
Bcl-2 homology (BH) regions 1-4.  The anti-apoptotic proteins Bcl-2, Bcl-XL, Bcl-
W, Mcl-1 and A1 have the four BH regions.  Pro-apoptotic proteins are divided into 
the multi region BH proteins, Bax, Bak Bok and the BH-3 only proteins, Bad, Bim, 
Bid, Noxa, Puma, Bik/Blk, Bmf, Hrk/DP5, Beclin-1 and Mule [226].  BH-3 only 
proteins are essential initiators of the intrinsic apoptotic pathway and are important 
for the integration of many cellular processes into the regulation of apoptosis.  One 
of the BH-3 only proteins Bim associates with the microtubule motor protein dynein 
and localizes to the microtubules in healthy cells [228]. Upon apoptotic stimuli, 
release of Bim from microtubules leads to the binding of Bim to Bax and Bak, 
followed by the permeabilization of the mitochondrial membrane, release of 
cytochrome C and cell death.   
 
The multiplicity of apoptotic regulatory proteins that are present in 
mammalian systems allows for a fine-tuned control of the process and the 
integration of multiple signals into this pathway. Some of the BH-3 only proteins 
are regulated by growth factor receptor signaling.  Bim and Bad are 
transcriptionally upregulated by growth factor receptor signaling deprivation [229, 
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230].  Alterations in the regulation of the Bcl-2 family proteins have been 
demonstrated in multiple cancers.  Upregulation of anti-apoptotic proteins like 
BCL2 causes inhibition of BH-3 only pro-apoptotic proteins as seen in Chronic 
lymphocytic leukemia with BCL2-mediated sequestration of BIM and inhibition of 
apoptosis [226].    
 
Other important proteins in the apoptotic process are the cysteine-aspartic 
proteases (Caspases).  These are the proteins responsible for dismantling cells 
and causing changes in cell morphology and composition such as chromatin 
condensation and DNA fragmentation, loss of cell adhesion, cell shrinkage, 
membrane blebbing and the formation of apoptotic bodies [231].  Caspases are 
expressed in the cell as inactive zymogens, the procaspases, and their cleavage 
is necessary for their full activation.  There are two groups of caspases, the initiator 
caspases and the effector caspases.  The initiator caspases include Caspase-9, 
Caspase-8, Caspase-10 and Caspase 2 and the effectors consist of Caspase-3, 
Caspase-6 and Caspase 7.  Alterations in the expression of caspases have been 
reported in many cancers including breast cancer. A study looking at surgically 
resected breast tumors demonstrated a 75% decrease in Caspase-3 transcript and 
protein levels [232].  The reduction in Caspase-3 suggests that deregulation of 
apoptosis contributes to breast cancer.  In colon cancer, somatic mutations that 
cause a decrease in expression of Capase-3 have also been identified [233].  As 
deregulation of apoptosis plays a key role in cancer development and 
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maintenance, there are continuing efforts to understand how to target this pathway 
to enhance the induction of cell death.   
 
Rationale for Thesis Work 
 
  Understanding cellular processes that contribute to the progression of 
tumors from localized disease to metastasis is required for the development of 
better therapeutic approaches to target or prevent metastatic disease.  In the last 
decade, very little progress has been made when it comes to targeting disease 
that progresses beyond the primary tumor site.  The Insulin/IGF-1 pathway plays 
a role in development, metabolism and tumorigenesis.  The IRS proteins are key 
signaling intermediates downstream of these growth factor receptors.  Previous 
studies of the IRS proteins have demonstrated that IRS2, but not IRS1, plays a 
role in breast cancer metastasis. Despite evidence for the divergent roles of IRS1 
and IRS2 in breast cancer, a mechanistic explanation of how they function 
differentially is still lacking.  Additional studies in multiple human malignancies 
have demonstrated a correlation between IRS2 expression and function and 
metastatic disease.  In vitro work has revealed that IRS2 plays a role in regulating 
cellular functions such as invasion, cell survival and glycolysis, all processes that 
contribute to tumor progression and metastasis. For such an important player in 
tumor progression, the intricate biological details of its mechanism of action 
continue to be unknown.   
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The goal of my thesis research has been to develop a more detailed 
understanding of how IRS2 mediates its important functions to promote breast 
cancer metastasis. I set out to understand structural and functional differences 
between IRS1 and IRS2 that would explain how these two similar adaptor proteins 
have markedly different roles in cancer progression.  My long-term goal of 
elucidating the unique mechanisms of IRS2 function is to aide in the rational design 
of novel therapeutic approaches for targeting IRS2 in cancer.   
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ABSTRACT 
 
 The insulin receptor substrate (IRS) proteins serve as essential signaling 
intermediates for the activation of PI3K by both the insulin-like growth factor-1 
receptor (IGF-1R) and its close family member the insulin receptor (IR).   Although 
IRS-1 and IRS-2 share significant homology, they regulate distinct cellular 
responses downstream of these receptors and play divergent roles in breast 
cancer. To investigate the mechanism by which signaling through IRS-1 and IRS-
2 results in differential outcomes, we assessed the involvement of the microtubule 
cytoskeleton in IRS-dependent signaling.  Treatment with drugs that either stabilize 
or disrupt microtubules reveal that an intact microtubule cytoskeleton contributes 
to IRS-2, but not IRS-1, mediated activation of AKT by IGF-1.  Proximal IGF-1R 
signaling events including IRS tyrosine phosphorylation and recruitment of PI3K 
are not inhibited by microtubule disruption, indicating that IRS-2 requires the 
microtubule cytoskeleton at the level of downstream effector activation. IRS-2 
colocalization with tubulin is enhanced upon Taxol-mediated microtubule 
stabilization, which together with the signaling data suggests that the microtubule 
cytoskeleton may facilitate access of IRS-2 to downstream effectors such as AKT.  
Of clinical relevance, our data reveal that expression of IRS-2 sensitizes breast 
carcinoma cells to apoptosis in response to treatment with microtubule disrupting 
drugs, identifying IRS-2 as a potential biomarker for the response of breast cancer 
patients to vinca alkaloid drug treatment.  
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INTRODUCTION 
 
 Insulin receptor substrate-1 (IRS-1) and IRS-2 are cytoplasmic adaptors for 
the insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF-1R), and 
they play a major role in determining the cellular response to stimulation by these 
ligands [108]. Notably, the IRS proteins are required for the activation of PI3K 
downstream of the IR and IGF-1R, which activate AKT and mTOR to promote 
proliferation, survival, motility, protein synthesis, and glucose metabolism [180, 
234-236].  IRS-1 and -2 are expressed ubiquitously in humans, including the 
normal and malignant mammary epithelium [108].  Despite their considerable 
sequence homology however, IRS-1 and IRS-2 play divergent roles in breast 
cancer.  In vitro, studies to assess IGF-1-dependent signaling through the IRS 
proteins in breast carcinoma cells have revealed that IRS-1 primarily regulates 
proliferation and survival, whereas IRS-2 regulates motility, invasion, and 
glycolysis [115, 117, 237-239]. In vivo, overexpression of either IRS-1 or IRS-2 in 
the mouse mammary gland promotes mammary tumorigenesis [113].  However, 
metastasis is diminished in the absence of Irs-2 expression and increased in the 
absence of Irs-1 expression [115, 116].   
 
 Differential localization patterns of IRS-1 and -2 in human breast tumors 
suggest one explanation for their divergent functions in breast cancer [111].  In 
normal breast tissue, ductal carcinoma in situ (DCIS), and invasive breast tumors, 
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IRS-1 is primarily localized in the nucleus, and also diffusely in the cytoplasm, 
frequently correlating with nuclear expression of estrogen receptor (ER) [193, 240, 
241].  Nuclear expression of IRS-1 also correlates with response to tamoxifen in 
breast cancer patients [112].  IRS-1 has been implicated in the regulation of 
estrogen response genes through its interaction with the ER at estrogen response 
elements (ERE) in gene promoters [193].  The interaction of IRS-1 with -catenin 
and its regulation of genes such as c-Myc and Cyclin D1 likely contribute to its role 
in stimulating proliferation [242, 243].  In contrast to IRS-1, IRS-2 is absent from 
the nucleus in normal breast and breast tumors, and is expressed either in the 
cytoplasm or at the cell membrane [111].  Diffuse cytoplasmic IRS-2 staining is 
associated with better overall survival of breast cancer patients, whereas 
membrane localization of IRS-2 in breast tumors is associated with decreased 
overall survival, particularly in patients with progesterone receptor negative tumors 
[111].   
 
 The localization pattern of IRS-1 and IRS-2 in human tumors suggests that 
their trafficking to distinct subcellular compartments contributes to their ability to 
elicit unique signaling responses.  However, the mechanism by which the 
intracellular localization of IRS-1 and IRS-2 is determined is not known. The 
microtubule cytoskeleton, which plays an important role in intracellular trafficking, 
has been implicated in insulin-dependent regulation of glucose uptake, and this 
role for microtubules occurs distal to IRS phosphorylation [210, 212, 244].  These 
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observations support a role for microtubules in IRS-mediated downstream 
signaling, potentially through targeting of these adaptor proteins to unique 
subcellular compartments.  We examined the role of the microtubule cytoskeleton 
in determining differential signaling and functional outcomes for IRS-1 and IRS-2.     
The data we obtained in the current study reveal that IRS-2 co-localizes with 
microtubules and that the microtubule cytoskeleton contributes to IRS-2, but not 
IRS-1, dependent signaling to AKT.  The differential involvement of the microtubule 
cytoskeleton in IRS-1 and IRS-2-mediated AKT signaling influences the apoptotic 
sensitivity of breast carcinoma cells to microtubule disrupting drugs. 
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EXPERIMENTAL PROCEDURES 
Cell lines, shRNA and transfection.  The MDA-MB-231 cell line was obtained 
from the ATCC Cell Biology Collection.  SUM-159 cells were a kind gift from Art 
Mercurio (UMass Medical School, Worcester, MA).  Wildtype (WT), Irs-1-/-, and Irs-
2-/- mammary tumor cell lines were established from MMTV-PyV-MT-derived 
tumors as previously described [115]. Irs-1fl/fl and Irs-2fl/fl mammary tumor cells 
were isolated from female FVB MMTV-PyMT::Irs-1fl/fl and MMTV-PyMT::Irs-2fl/fl 
mice, respectively, and Irs-/- cells were generated by infection with adenoviral Cre-
recombinase as described previously [180].  Lentiviral vectors containing small 
hairpin RNAs (shRNAs) targeting GFP and human IRS-2 were obtained from Open 
Biosystems (Hunstville, AL).  MDA-MB-231 cells were infected with virus, and 
stably expressing cells were selected by the addition of 2g/ml puromycin.  IRS 
expression was restored in the Irs-/- mammary tumor cells by transfection with HA-
tagged human IRS-1 or IRS-2 (kindly provided by Adrian Lee; University of 
Pittsburgh, Pittsburgh, PA) and selection in G418 (0.5mg/ml) [113]. 
 
Immunoblotting and immunoprecipitation.  Cells were either serum starved 
overnight (MDA-MB-231) or for 4 hours (PyMT cells) in serum-free medium.  Drugs 
were added to the medium prior to stimulation with IGF-1.  MDA-MB-231 cells were 
treated with nocodazole or vinblastine for 30 minutes and Taxol for 2 hours.  The 
mouse tumor cell lines were treated with nocodazole, vinblastine or vinorelbine for 
1 hour.  The concentrations (see Figure Legends) and time periods of incubation 
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were determined to stabilize or disrupt the microtubule cytoskeleton as assessed 
by immunofluorescence staining for tubulin.  For microtubule altering drugs, 
Paclitaxel (#T7402) was obtained from Sigma-Aldrich (St. Louis, MO), and 
Nocodazole (#S2775), Vinblastine (#S1248) and Vinorelbine (#S4269) were 
obtained from Selleckchem (Houston, TX). MK2206 (#S1078) was obtained from 
Selleckchem. Cells were stimulated for 5-30 minutes with human recombinant IGF-
1 (R&D Systems, Minneapolis, MN) prior to extraction.   
 For total cell extract immunoblots, cells were solubilized at 4oC in RIPA lysis 
buffer (25 mM Tris, pH 8.0, 0.1% sodium dodecyl sulfate, 1% sodium 
deoxycholate, 1% Nonidet P-40, 150 mM sodium chloride, 10 mM sodium fluoride, 
1 mM sodium orthovanadate) containing protease inhibitors (Roche, Basel, 
Switzerland). Cell extracts containing equivalent amounts of protein were resolved 
by SDS-PAGE and transferred to nitrocellulose membranes. The membranes 
were blocked for 1 h with a 50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl, 
0.05% Tween 20, and 5% (wt/vol) dry milk or 5% bovine serum albumin (BSA), 
incubated overnight at 4oC in the same buffer containing primary antibodies and 
then incubated for 1 h in 5% blocking buffer with milk containing peroxidase-
conjugated secondary antibodies. Proteins were detected by enhanced 
chemiluminescence (Biorad, Hercules, CA) using a ChemiDoc XRS+ (Bio-Rad) 
with Image lab software. Only signals within a linear range were used for 
quantitation and signals were normalized to total protein and/or housekeeping 
genes.  The following antibodies were used for immunoblotting: IRS-1 (human: 
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#C20, Santa Cruz Biotechnology, Santa Cruz, CA; mouse: Bethyl Custom 
Immunochemistry Services), IRS-2 (#4502, Cell Signaling, Danvers, MA), p85 
(#05-212, Millipore, Billerica, MA), IGF-1R (#3025, Cell Signaling), phospho-AKT 
S473 (#9271 and #4060, Cell Signaling), phospho-AKT T308 (#2965, Cell 
Signaling), AKT (#sc-8312, Santa Cruz; #9272, Cell Signaling), -tubulin (#T5168, 
Sigma-Aldrich), phospho-ERK (#9106, Cell Signaling), ERK (#9102, Cell 
Signaling), GAPDH (#A300-642A, Bethyl), Cleaved Caspase-3 (#9664, Cell 
Signaling), BIM (#2933, Cell Signaling), peroxidase-conjugated goat anti-rabbit 
IgG (#111-035-144, Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA), and peroxidase-conjugated goat anti-mouse IgG (#711-035-151, Jackson 
ImmunoResearch Laboratories, Inc). 
 For immunoprecipitations, cells were extracted using a 20 mM Tris, pH 7.4 
buffer containing 1% Nonidet P-40, 0.137 M NaCl, 10% glycerol, 10 mM sodium 
fluoride, 1 mM sodium orthovanadate and protease inhibitors (Roche).  Aliquots of 
cell extracts containing equivalent amounts of protein were pre-cleared for 30 min 
with protein A sepharose beads and then incubated overnight at 4°C with 
antibodies and protein A sepharose beads (Amersham Biosciences, Piscataway, 
NJ) with constant agitation.  The beads were washed three times in extraction 
buffer.  Laemmli sample buffer was added to the samples and immune complexes 
were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and 
immunoblotted as described above.  The following antibodies were used for 
immunoprecipitation: IRS-1 (#C20, Santa Cruz), IRS-2 (Bethyl Custom 
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Immunochemistry Services), IGF-1R (#3025, Cell Signaling), rabbit IgG (#sc-2027, 
Santa Cruz) and mouse IgG2b (#ab18421, Abcam).   
 
Immunofluorescence microscopy.  Subconfluent, adherent cells plated on glass 
coverslips were treated with nocodazole (1M) for 1 hour or Taxol (20 M) for 2 
hours.  Cells were washed three times with Dulbecco’s PBS and fixed in 3.8% 
paraformaldehye in Dulbecco’s PBS with 0.5% Tween (PBST) for 1 hr.  
Permeabilized cells were blocked for 1 hr using 3% BSA in PBST.  Primary 
antibodies diluted in blocking buffer were added to cells and incubated at room 
temperature for 1 hr.  Secondary antibodes were diluted in the same buffer and 
cells were incubated at room temperature for an additional 30 minutes.  Cells were 
washed three times with PBST after each antibody incubation. Coverslips were 
then mounted on glass slides using Prolong Gold containing DAPI (Cell signaling) 
and the slides were viewed by confocal microscopy (Ziess LSM700; 63X oil 
immersion objective).  All images were adjusted equally for brightness/contrast 
using ImageJ software.  Antibodies used for immunofluorescence include IRS-1 
(#H165, Santa Cruz, Santa Cruz, CA), IRS-2 (#NB110-57138, Novus, Littleton, 
CO), -tubulin (#T5168, Sigma-Aldrich, St. Louis, MO), Alexafluor-488 Donkey 
anti-rabbit IgG (#A-21206; ThermoFisher Scientific, Waltham, MA) and Alexafluor-
568 Donkey anti-mouse IgG (#A10037; ThermoFisher Scientific).  The specificity 
of the IRS-1 and IRS-2 antibody staining was validated by staining PyMT:Irs1-/-
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,Irs2-/- double null cells that were transfected with either empty vector, IRS-1 or 
IRS-2 (Supplemental Fig. 1). 
 
Cell cycle analysis.  MDA-MB-231 cells were treated with nocodazole (1M), 
vinblastine (20nM), vinorelbine (20nM), Taxol (10μM) or MK2206 (250nM) for 48 
hours.    The mouse PyMT mammary tumor cell lines were treated with nocodazole 
(1M) or Taxol (1 or 10M) for 48 hours. Adherent cells were collected by 
trypsinization after treatment and combined with non-adherent cells from the 
culture medium for cell cycle analysis.  After centrifugation, the cell pellet was 
washed once in cold PBS, and the cells were then fixed in 70% methanol and 
stored overnight at -20oC.  The fixed cells were washed once in PBS and then 
resuspended in PBS containing 0.1% Triton-X-100, 0.1 mM EDTA, 0.05 mg/ml 
RNAse A (50 U/mg) and 50 g/ml propidium iodide.  The cells were analyzed by 
flow cytometry using a Becton Dickinson (Franklin Lakes, NJ) FACSCalibur after 
a 1 hour incubation at room temperature. 
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RESULTS 
IGF-1R signaling is dependent upon the microtubule cytoskeleton. 
To investigate the role of the microtubule cytoskeleton in IRS-dependent 
IGF-1R signaling, MDA-MB-231 cells were stimulated with IGF-1 after short-term 
(30 min - 1hr) treatment with Paclitaxel (Taxol) or nocodazole.  Taxol, a taxane 
drug commonly used in cancer treatment, stabilizes microtubules, whereas 
nocodazole causes depolymerization of the tubulin cytoskeleton [208, 211, 215].  
IRS signaling was measured by assessing the phosphorylation status of AKT, a 
downstream signaling effector of PI3K, because the IRS proteins are required for 
the recruitment and activation of PI3K by the IGF-1R [180, 236, 245]. Although 
microtubule stabilization by Taxol treatment did not alter the level of AKT activation 
(Fig. 2.1A), disruption of the microtubule cytoskeleton in response to nocodazole 
treatment significantly reduced phosphorylation of AKT at both threonine 308 
(T308) and serine 473 (S473) (Fig. 2.1B).  By contrast, the activation of ERK1/2 
by IGF-1, which can occur independently of the IRS proteins [180], was not 
decreased by nocodazole treatment (Fig. 2.1B).  IGF-1-dependent AKT activation 
was also reduced when cells were treated with the vinca alkaloid drug vinblastine, 
which also disrupts microtubules and is used clinically in chemotherapy regimens 
(Fig. 2.1C) [215].  Taken together, these results indicate that an intact microtubule 
cytoskeleton contributes to IRS-dependent activation of AKT by the IGF-1R.  
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Figure 2.1. Involvement of the microtubule cytoskeleton in IGF-1 stimulated 
AKT activation. MDA-MB-231 cells were treated with DMSO, Taxol (20 uM), 
nocodazole (1 uM) or vinblastine (20 nM) for 30 minutes and then stimulated with 
IGF-1 (20ng/ml) for 5 min.  (A-C) Aliquots of cell extracts containing equivalent 
amounts of total protein were immunoblotted with antibodies specific for phospho-
S473AKT (pAKT S473), phospho-T308AKT (pAKT T308) or phospho-
Thr202/Tyr204ERK (pERK). The immunoblots were subsequently stripped and 
reprobed with total AKT and ERK-specific antibodies. (D) Aliquots of cell extracts 
containing equivalent amounts of total protein were immunoprecipitated with 
antibodies specific for IRS1, IRS2 or IGF-1R subunit and immunoblotted with 
antibodies specific for phosphotyrosine (pTyr) and the p85 subunit of PI3K (p85). 
The pTyr immunoblots were subsequently stripped and reprobed with IRS1, IRS2 
or IGF-1R-specific antibodies. Total cell extracts were also immunoblotted with 
antibodies specific for phospho-S473AKT and total AKT (WCL, bottom panels).  
The immunoblots shown for all panels are representative of three independent 
experiments. 
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To investigate the mechanism by which nocodazole inhibits AKT activation, 
phosphorylation of the IGF-1R and IRS proteins, and IRS/PI3K association were 
examined.  Treatment with nocodazole did not decrease IRS-1 or -2 tyrosine 
phosphorylation or association with the p85 regulatory subunit of PI3K in response 
to IGF-1 stimulation, indicating that activation of PI3K upstream of AKT was not 
inhibited by microtubule disruption (Fig. 2.1D).  Of note, expression of the IGF-1R 
-subunit and its IGF-1-dependent tyrosine phosphorylation were increased 
following nocodazole treatment (Fig. 2.1D).  We attribute this increase to the 
accumulation of the activated receptor at the cell surface or in early endosomes, 
resulting in sustained expression and activation [246].  
 
IRS-2, but not IRS-1, requires the microtubule cytoskeleton to activate AKT 
To determine if there is a selective role for the microtubule cytoskeleton in 
IRS-1 or IRS-2 mediated signaling, mammary tumor cells derived from PyMT:WT, 
PyMT:Irs-1-/- or PyMT:Irs-2-/- tumors were treated with nocodazole and stimulated 
with IGF-1 (Fig. 2A).  WT cells that express both Irs-1 and Irs-2 demonstrated a 
40% reduction in Akt activation after treatment with nocodazole.   PyMT:Irs-1-/- 
cells, which signal exclusively through Irs-2, exhibited a further reduction in IGF-1-
dependent Akt activation (~50%) following treatment with nocodazole.   In contrast, 
Akt activation was equivalent in PyMT:Irs-2-/- cells, which signal exclusively 
through Irs-1, in response to IGF-1 stimulation following DMSO or nocodazole 
treatment.  
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Figure 2.2. Selective requirement of the microtubule cytoskeleton for IRS-2 
mediated signaling.  (A) PyMT:WT, PyMT:Irs-1-/-, and PyMT:Irs-2-/- cells were 
treated with DMSO or 20 uM nocodazole for 1 hour and then stimulated with IGF-
1 (10ng/ml) for 5 min. (B) PyMT:Irs-2-/- cells transfected with empty vector (Irs2-/-) 
or IRS2 (Irs2-/-:IRS2) were treated with DMSO, 1 uM nocodazole, 20nM 
vinblastine or 20nM vinorelbine for 1 hour and then stimulated with IGF-1 (10ng/ml) 
for 15 min. (C) PyMT:Irs-1-/- cells transfected with empty vector (Irs1-/-) or IRS1 
(Irs1-/-:IRS1) were treated with DMSO, 1 uM nocodazole or 10 uM Taxol for 1 hour 
and then stimulated with IGF-1 (10ng/ml) for 5 min. (D) MDA-MB-231 cells 
expressing either an shRNA targeting GFP (shGFP) or IRS2 (shIRS2) were treated 
with DMSO, 1 uM nocodazole or 20nM vinblastine for 30 min and then stimulated 
with IGF-1 (10ng/ml) for 30 min.  (E) MDA-MB-231 cells expressing either an 
shRNA targeting GFP (shGFP) or IRS2 (shIRS2) were treated with DMSO or 1 uM 
nocodazole for 30 min and then stimulated with IGF-1 (10ng/ml) for the time 
periods indicated.  The data in the graph represent the fold change in phospho-
AKT between DMSO and Nocodazole treated cells for each cell type.   Aliquots of 
cell extracts containing equivalent amounts of total protein were immunoblotted 
with antibodies specific for IRS1, IRS2, phospho-S473AKT, total AKT, tubulin or 
GAPDH. The data shown in the graphs for each immunoblot represent the mean 
of three (±SEM) independent experiments. *p≤0.05 relative to shGFP; **p≤0.01 
relative to shGFP.  
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The role of IRS-2 in the sensitivity of cells to microtubule disruption was 
explored further using PyMT:Irs-1-/- and PyMT:Irs-2-/- cells that were derived from 
PyMT:Irs-1fl/fl and PyMT:Irs-2fl/fl cell lines, respectively, after acute adenoviral-Cre 
infection.  PyMT:Irs-2fl/fl cells with or without restored IRS-2 expression were 
stimulated with IGF-1 after treatment with nocodazole and vinblastine.  An 
additional vinca alkaloid drug vinorelbine, which is used to treat breast cancer 
patients [215, 247], was also assayed [248].  As observed previously (Fig. 2.2A), 
disruption of microtubules did not decrease Akt activation in cells lacking Irs-2 
expression (Irs2-/-), whereas the increase in Akt activation that was observed upon 
restoration of IRS-2 expression was eliminated by microtubule disruption (Irs2-/-
:IRS2) (Fig. 2.2B).  In contrast, the fold-change reduction in Akt activation observed 
in Irs1-/- cells after nocodazole treatment (50%) was diminished (30%) upon 
restoration of IRS-1 expression (Irs-/-:IRS1) (Fig. 2.2C).  Taxol treatment did not 
inhibit Akt activation in the mouse mammary tumor cells (Fig. 2.2C) as was 
observed for the MDA-MB-231 cells (Fig. 2.1A).  
 
To assess the role of microtubules in IRS-2-mediated signaling in human 
breast carcinoma cells, IRS2 expression was suppressed by shRNA-targeting in 
MDA-MB-231 cells (Fig. 2.2D).  Total AKT activation in response to IGF-1 
stimulation was reduced in shIRS-2 cells compared to shGFP cells (lanes 2 and 
6).  Treatment of shGFP cells with either nocodazole or vinblastine significantly 
reduced AKT activation (lanes 3 and 4) (Fig. 2.2D), as was observed for the 
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parental cells (Fig. 2.1C).  In contrast, no significant reduction in AKT 
phosphorylation occurred in the shIRS2 cells, which signal predominantly through 
IRS-1, upon treatment with either nocodazole or vinblastine (lanes 7-8) (Fig. 2.2D). 
The fold difference in AKT activation observed in the shGFP and shIRS2 cells upon 
microtubule disruption increased with time of stimulation indicating that 
microtubules are required to sustain IRS2-dependent signaling (Fig. 2.2E). Taken 
together with the mouse cell line data, these results support that an intact 
microtubule cytoskeleton contributes to IGF-1 signaling through IRS-2, but not 
IRS-1,  
 
The dependency of IRS2 signaling to Akt on an intact microtubule 
cytoskeleton indicates a potential interaction of IRS-2 with microtubules.  To 
investigate this possibility, the localization of IRS-1, IRS-2 and tubulin was 
examined by immunofluorescent staining and confocal imaging.   For these 
experiments, SUM-159 breast carcinoma cells were used because they express 
both IRS-1 and IRS-2, spread well on coverslips and retain their spread 
morphology upon treatment with Taxol and nocodazole, which facilitates detection 
of co-localization. Both IRS-1 and IRS-2 were expressed in a punctate manner 
throughout the cytoplasm, with a modest enhancement in the perinuclear region 
(Fig. 2.3; left panels).  Although no specific pattern of staining was observed for 
IRS-1, the punctate staining for IRS-2 was more organized, with some apparent  
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Figure 2.3. Intracellular localization of IRS proteins and co-localization with 
microtubules.  SUM159 cells were treated with either DMSO, 20 M Taxol or 1 
uM nocodazole for 1-2 hours before fixation.  Fixed cells were co-stained for IRS-
1 or IRS-2 (green) and tubulin (red).  Individual images for IRS-1/IRS-2 and 
merged IRS/tubulin images are shown (magnification 63x).  Bar = 20μM 
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alignment along microtubules.  To assess further the association of IRS-2 with 
microtubules, cells were stained after a short-term incubation with either Taxol or  
nocodazole to evaluate their impact on IRS localization.  The organized, linear 
pattern of IRS-2 staining was more apparent upon Taxol stabilization of the 
microtubules, and a subset of IRS-2 puncta co-localized with tubulin under these 
conditions (Fig. 2.3B; middle panels).   IRS-2 was dispersed throughout the 
cytoplasm with no tubulin co-localization upon disruption of microtubules by 
nocodazole (Fig. 2.3B; right panels). In contrast, IRS-1 staining was not modified 
in response to Taxol or nocodazole treatment (Fig. 2.3A). 
 
IRS-2 determines cellular responses to microtubule disruption  
Drugs that target the microtubule cytoskeleton are used clinically for the 
treatment of cancer [215].  To investigate how IRS-2 may impact the response of 
tumors to microtubule stabilizing or disrupting drugs, MDA-MB-231 cells were 
treated for 48hours with either nocodazole or Taxol and then analyzed for viability 
by propidium iodide staining and flow cytometry analysis.   A significant increase 
in the sub-G1 population occurred in response to both nocodazole and Taxol 
treatment in the shGFP control cells (Fig. 2.4A), consistent with an induction of cell 
death.  When compared with the shGFP cells, cell death was significantly 
diminished in the shIRS-2 cells in response to nocodazole treatment (Fig. 2.4A). 
In contrast, when cells were treated with Taxol, which does not inhibit IRS2-
mediated AKT signaling (Figs. 2.1A and 2.2C), cell death levels were similar for  
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 Figure 2.4.  Role of IRS-2 in the cellular response to microtubule disruption.  
MDA-MB-231 cells were treated with DMSO or the indicated drugs for 48 hrs.   The 
cells were stained with propidium iodide and analyzed by flow cytometry.  Shown 
are the % of cells in the sub-G1 peak (A, B) or cell cycle stages (C,D). The data 
shown represent the mean of representative experiments performed three (±SEM) 
(nocodazole, vinblastine and vinorelbine) or two (±SD) (Taxol) independent times.  
*p≤0.05 relative to shGFP; **p≤0.01 relative to shGFP. 
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the shGFP and shIRS2 cells.   To investigate further the clinical relevance of the 
IRS2-dependent sensitivity of breast carcinoma cells to microtubule disruption, 
MDA-MB-231 cells were treated with vinblastine or vinorelbine, both of which are 
used in the treatment of solid tumors, including breast cancer [215].  As was 
observed for nocodazole treatment, cell death was significantly diminished in the 
shIRS2 cells treated with either vinblastine or vinorelbine when compared with the 
shGFP treated cells (Fig. 2.4B).   
 
A similar resistance to cell death upon treatment with nocodazole was 
observed for PyMT:Irs2-/- cells when compared with parental cells (PyMT:Irs2fl/fl), 
or Irs2-/- cells in which WT Irs-2 expression was restored (Irs2-/-:IRS2) (Fig. 5A).  
In contrast, restoration of IRS1 expression to PyMT:Irs1-/- cells reduced cell death 
in response to nocodazole treatment (Fig. 2.5B).   Similar to the MDA-MB-231 
cells, cell death in response to Taxol treatment was not dependent upon Irs 
expression in the PyMT mammary tumor cells (Fig. 2.5A and 2.5B).  
 
As has been reported previously, cells undergo a G2/M arrest in response 
to microtubule disruption or stabilization [249].   Cell cycle profiles of the cells 
treated with nocodazole or Taxol were analyzed to determine if IRS2 expression 
influences the cell cycle response to microtubule-targeting drugs. MDA-MB-
231:shGFP cells exhibited an increase in G2/M arrest when treated with 
nocodazole (Fig. 2.4C). In contrast, a significantly higher percentage of MDA-MB-  
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Figure 2.5.  Differential impact of Irs1 and Irs2 on the cellular response to 
microtubule disruption. PyMT cells were treated with DMSO or the indicated 
drugs for 48 hrs.   The cells were stained with propidium iodide and analyzed by 
flow cytometry.  Shown are the % of cells in the sub-G1 peak (A, B) or cell cycle 
stages (C-G). The data shown represent the mean (±SEM) of representative 
experiments performed three or two (Taxol;Irs2 cells) independent times.  2fl/fl, 
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PyMT:Irs2fl/fl cells; 2-/-, PyMT;Irs2-/- cells; 2-/-:IRS2, PyMT:Irs2-/-:IRS2 cells. 1-/-
, PyMT;Irs1-/- cells; 1-/-:IRS1, PyMT:Irs1-/-:IRS1 cells. *p≤0.05 relative to Irsfl/fl; 
**p≤0.001 relative to Irsfl/fl.   
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231:shIRS2 cells remained in G1/G0 upon disruption of microtubules (Fig. 2.4D).   
This increase in G1/G0 cells was also observed in PyMT:Irs2-/- cells (Fig. 2.5D), 
and  
rescue of IRS-2 expression restored the G2/M arrest profile to that of the parental 
PyMT:Irs2fl/fl cells (Fig. 2.5C,E).  In contrast, PyMT:Irs1-/- exhibited a G2/M arrest, 
and restoration of IRS-1 expression promoted in an increase in G1/G0 cells (Fig. 
2.5F,G), similar to the profile of the IRS2 deficient cells that signal only through 
IRS1.  All cells treated with Taxol exhibited a similar G2/M arrest profile (Fig. 2.4 
and 2.5).  These data indicate that breast carcinoma cells that express and signal 
through IRS-2 are more sensitive to drugs that depolymerize microtubules and 
respond by undergoing cell cycle arrest and increased cell death, whereas Taxol 
response is not determined by IRS-2 expression.  
 
Given that AKT signaling is selectively resistant to microtubule disruption in 
cells deficient for IRS2 expression, we hypothesized that the resistance of these 
cells to nocodazole-mediated cell death was the result of sustained AKT signaling 
in these cells.   To test this hypothesis, cells were treated with nocodazole for 48hrs 
in the presence or absence of an AKT-specific inhibitor, MK2206.  Treatment of 
MDA-MB-231 shGFP and shIRS2 cells with MK2206 alone did not alter the % of 
sub-G1 cells (Fig. 2.6A) or cell cycle profile (Fig. 2.6B,C), as has been reported 
previously for parental MDA-MB-231 cells at the concentration of inhibitor used in 
these assays [247].  This concentration of MK2206 was, however, sufficient to 
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Figure 2.6.  Role of AKT in the IRS-2-dependent response to microtubule 
disruption.  MDA-MB-231 cells were treated with DMSO or the indicated drugs 
for 48 hrs. (A-C) Cells were stained with propidium iodide and analyzed by flow 
cytometry.  Shown are the % of cells in the sub-G1 peak (A) or cell cycle stages 
(B,C). The data shown represent the mean (±SEM) of representative experiments 
performed three independent times. *p≤0.05 relative to shGFP (D) Aliquots of cell 
extracts containing equivalent amounts of total protein were immunoblotted with 
antibodies specific for IRS1, IRS2, phospho-S473AKT, total AKT or Tubulin. The 
data shown in the graph below represent the mean (±SEM) of three independent 
experiments.  *p≤0.05 relative to DMSO; **p≤0.001 relative to DMSO. 
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inhibit AKT activation (Fig. 2.6D).   Combined treatment of the MDA-MB-
231:shGFP cells with MK2206 and nocodazole did not increase cell death (Fig. 
6A) or alter cell cycle progression (Fig. 2.6B).  In contrast, addition of MK2206 to 
the nocodazole treated MDA-MB-231:shIRS2 cells increased the % of sub-G1 
cells to that observed for the shGFP cells treated with nocodazole alone (Fig. 
2.66A).   Combined treatment with MK2206 and nocodazole also promoted a G2/M 
arrest in these cells, restoring the cell cycle profile to that of the nocodazole-treated 
IRS2-expressing cells (Fig. 2.6C).    
 
To investigate the mechanism of cell death in response to microtubule 
disruption, cell extracts from MDA-MB-231 cells treated with nocodazole for 48hrs 
in the presence or absence of MK2206 were immunoblotted for cleaved-caspase 
3. Caspase 3 cleavage increased significantly upon treatment of shGFP cells with 
nocodazole, confirming that these cells undergo an apoptotic cell death (Fig. 2.7A) 
[225].  Cleaved caspase 3 levels were significantly lower in the shIRS2 
nocodazole-treated cells. However, combined treatment of shIRS2 cells with both 
nocodazole and MK2206 increased caspase 3 cleavage, supporting a role for AKT 
signaling in the enhanced viability of these cells.  Analysis of upstream apoptotic 
effectors identified the BCL2 homology 3 (BH3)-only protein BIM as a potential 
regulator of caspase 3 activation in response to microtubule disruption [225].  
Specifically, the BIM-EL and BIM-L isoforms of BIM were expressed at elevated 
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levels in shGFP cells when compared with shIRS2 cells, and expression increased 
upon co-treatment with MK2206 in shIRS2 cells (Fig. 2.7B).     
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Figure 2.7. Involvement of the apoptotic effector BIM in the response to 
microtubule disruption.  MDA-MB-231 cells were treated with DMSO or the 
indicated drugs for 48 hrs. Aliquots of cell extracts containing equivalent amounts 
of total protein were immunoblotted with antibodies specific for Cleaved Caspase-
3 (A) or BIM (B) and Tubulin. The data shown in the graphs below each panel of 
immunoblots represent the mean (±SEM) of three independent experiments.  
*p≤0.05 relative to DMSO; **p≤0.01 relative to DMSO; #p≤0.05 relative to shGFP-
Nocodazole; ## p≤0.01 relative to shGFP-Nocodazole. 
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DISCUSSION 
 We demonstrate in the current study a differential involvement of the 
microtubule cytoskeleton in IRS-dependent activation of AKT.  AKT activation in 
response to IGF-1 stimulation is maintained when the microtubule cytoskeleton is 
disrupted in cells that signal only through IRS-1.  In contrast, microtubule disruption 
significantly diminishes AKT activation when the IGF-1R signals through IRS-2.   
Proximal IGF-1R signaling events including receptor tyrosine phosphorylation, IRS 
tyrosine phosphorylation and recruitment of PI3K are not inhibited by microtubule 
disruption, indicating that IRS-2 requires the microtubule cytoskeleton at the level 
of downstream effector activation.  The co-localization of IRS-2, but not IRS-1, with 
tubulin is enhanced upon Taxol-mediated microtubule stabilization, which in 
concert with the signaling data suggests an interaction of IRS-2 with the 
microtubule cytoskeleton that may facilitate its access to effectors such as AKT.  
Functionally, IRS-2 sensitizes breast carcinoma cells to apoptotic cell death in 
response to treatment with microtubule disrupting drugs through a mechanism 
involving the inhibition of AKT signaling and regulation of the BH3-only apoptotic 
activator BIM.   Our data identify IRS-2 as a potential biomarker for the response 
of breast cancer patients to vinca alkaloid drug treatment.  
 
The IRS proteins function as signaling intermediates for both the IGF-1R 
and IR.  Previous studies have investigated the importance of the microtubule 
cytoskeleton in signaling through the IR in insulin-responsive cell types such as 
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adipocytes and muscle [212, 244].   Similar to our findings with IGF-1R signaling, 
proximal IR signaling events are not impacted by microtubule disruption, while 
distal events such as GLUT4 translocation to the plasma membrane are inhibited 
[244].  The impact of microtubule disruption on AKT activation in response to 
insulin stimulation is cell type dependent. Insulin-induced AKT activation was 
modestly reduced in 3T3-L1 adipocytes, maintained in CHO cells that express IR 
and IRS-1 (CHO.IR.IRS-1), and inhibited in skeletal muscle cells upon treatment 
with microtubule disrupting drugs [212, 250]. Importantly, the involvement of either 
IRS-1 or IRS-2 was not investigated in these different cell models.  The differential 
expression and activation of IRS-1 and IRS-2 in each cell type may explain the 
differential responses of these cells to microtubule disruption. 
 
Our demonstration that IRS-1 and IRS-2 differ in their dependence upon an 
intact microtubule cytoskeleton for their downstream signaling adds to the 
mechanistic understanding of how signaling by these homologous proteins 
regulates distinct functional outcomes.  IRS-1 and IRS-2 are both capable of 
recruiting PI3K and activating AKT, yet the functional response to this activation is 
quite different for each adaptor protein [108].  Stimulation of cells with insulin or 
IGF-1 promotes proliferation when IRS-1 is the dominant signaling adaptor [239, 
251].  Although a direct role for AKT in this response has not been demonstrated, 
it is dependent upon activation of PI3K [251].   In contrast, stimulation of breast 
carcinoma cells that express IRS-2 as the dominant signaling adaptor respond by 
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increasing migration/invasion and glycolytic metabolism [115, 117, 238, 239]. IRS-
2-dependent activation of PI3K is also required for these cellular responses [180].  
With regard to metabolism, the ability of IRS-2 to selectively regulate distinct 
downstream AKT effectors contributes to this differential outcome. IRS-2-
dependent activation of AKT results in the phosphorylation and inactivation of 
GSK3 and this inactivation is required for IRS-2-mediated regulation of glucose 
uptake [180].   In the current study, expression of the apoptotic activator BIM 
increased in response to disruption of IRS-2-dependent AKT activation, a 
mechanism that may involve the selective regulation of another AKT effector 
pathway.  Specifically, BIM expression is positively regulated by FOXO 
transcription factors, which are inactivated by AKT phosphorylation [252-254].  
IRS-2 has been previously shown to mediate insulin regulation of Foxo1 activity 
and Bim expression in neonatal mouse hepatocytes [255].     
 
Our current data support the hypothesis that the ability of IRS-2 to interact 
with and potentially traffic along microtubules may determine its access to distinct 
subsets of effectors to elicit unique functional responses.    Of note, a selective 
role for IRS-1 and IRS-2 dependent signaling in skeletal muscle has been reported 
that involves differential AKT isoform activation.   Insulin stimulated myoblast 
differentiation and glucose metabolism are regulated by IRS-1/AKT2 signaling, 
whereas signaling through IRS-2/AKT1 controls lipid metabolism [256].   The 
possibility that AKT isoforms are selectively sensitive to microtubule disruption 
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could contribute to the differential sensitivity of IRS-1 and IRS-2 to microtubule 
loss.   
 
 The results of our study are consistent with the work of other groups that 
suggest a central role for AKT in the tumor cell response to microtubule-disrupting 
drugs [257-259]. Specifically, AKT promotes the phosphorylation of microtubule 
binding proteins that stabilize microtubules, and in doing so increases the 
resistance of tumor cells to drugs that function by disrupting the microtubule 
cytoskeleton.   Our data now reveal that the mechanism by which tumor cells 
regulate AKT activity will also influence response to these drugs.  Our results have 
implications for the use of microtubule-disrupting drugs, such as vinblastine and 
vinorelbine, for the treatment of breast cancer. The differential responses of IRS-1 
and IRS-2-dependent signaling to these chemotherapeutic drugs raise the 
possibility that IRS-2 may influence how breast tumors respond to vinca alkaloid 
drug treatment.  We reported previously that expression of IRS-2 at the cell 
membrane is associated with a statistically significant decrease in overall survival 
in breast cancer patients [111].  We hypothesize that IRS-2 at the cell membrane 
is indicative of active signaling, and patients that have tumors with this staining 
pattern may be more sensitive to microtubule-disrupting drugs than patients 
without active IRS-2 signaling.  Moreover, breast tumors with low IRS2 
expression/function could be responsive to combination therapies that pair an AKT 
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inhibitor with a vinca alkaloid drug.  Therefore, IRS-2 could be used as a biomarker 
to identify patients for targeted treatment with these drugs.   
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Abstract  
 
The insulin receptor substrate (IRS) proteins IRS1 and IRS2 play divergent roles 
in breast cancer.  Although IRS1 and IRS2 share considerable homology and 
activate PI3K signaling downstream of the insulin receptor (IR) and the insulin-like 
growth factor 1 receptor (IGF-1R), they mediate very different outcomes. IRS2, but 
not IRS1, is a positive regulator of mammary tumor metastasis and IRS2 loss 
decreases mammary carcinoma cell invasion, survival and glycolysis.  To 
investigate the mechanism by which IRS2 regulates tumor metastasis, we took a 
mutagenesis approach to identify structural features of IRS2 that are required for 
regulating invasion and self-renewal, two essential functions for cancer 
progression.  Our studies reveal that the ability of IRS2 to promote invasion is 
dependent upon upstream IGF-1R/IR activation and the recruitment and activation 
of PI3K.  Additional sequences within the C-terminus of IRS2 are also required for 
IRS2 -mediated tumor cell invasion, and these sequences are sufficient to confer 
invasion-promoting ability when swapped into IRS1.  We demonstrate for the first 
time that IRS2, but not IRS1, regulates tumor-initiating cell (TIC) self-renewal of 
breast carcinoma cells, and the ability of IRS2 to activate PI3K, as well as the IRS2 
C-terminus, are also required for this function.  Additional deletion analysis of the 
IRS2 C-terminus identified two distinct regions that regulate tumor cell invasion 
and self-renewal, respectively.  Further analysis of the invasion region revealed an 
interaction with bone morphogenic protein-2 inducible kinase (BMP2K), a serine 
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threonine kinase of the numb associated kinase (NAK) family. Suppression of 
BMP2K expression decreases IRS2-dependent invasion.  Taken together, our 
data contribute to the mechanistic understanding of how IRS2 regulates breast 
carcinoma cell invasion and self-renewal, two important processes for metastasis.   
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Introduction  
 
  The insulin receptor substrate (IRS) proteins IRS1 and IRS2 are 
cytoplasmic adaptor proteins that contribute to the growth and progression of 
breast cancer [108].  Although they share significant homology and the ability to 
activate similar signaling pathways, these adaptor proteins play distinct functional 
roles in breast cancer.  IRS1 is an estrogen receptor (ER) regulated gene and it is 
expressed at high levels in the ER+, luminal subtype of breast cancer [260].  IRS1 
interacts with the ER to positively regulate its transcriptional activity at estrogen 
response genes [112].   In this regard, tamoxifen response in breast cancer 
patients positively correlates with nuclear IRS1 expression [112].  In vitro studies 
implicate a role for IRS1 in the regulation of proliferation and survival in luminal 
breast carcinoma cells [110].  IRS1 expression decreases as ER expression or 
function is lost in more poorly differentiated, invasive breast tumors [110].   In 
contrast, IRS2 is expressed at higher levels in ER- breast carcinoma cells of the 
basal-like/triple negative breast cancer (TNBC) subtypes and it regulates tumor 
cell invasion and glycolytic metabolism [117, 197].   The differential functions of 
IRS1 and IRS2 in breast cancer are further evidenced by the fact that mouse 
mammary tumors that lack IRS2 are significantly diminished in their ability to 
metastasize to the lungs, whereas tumors lacking IRS1, but expressing elevated 
IRS2, have enhanced metastatic potential [114].  IRS2 expression at the cell 
membrane in human breast tumors correlates with decreased overall survival, a 
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finding that further supports a role for IRS2 in more aggressive tumor behavior 
[111].    
 
The IRS proteins are recruited to cell surface receptors through N-terminal 
PH and PTB domains where they are phosphorylated on multiple tyrosine residues 
within their C-termini, either directly by receptor tyrosine kinases or by associated 
non-receptor kinases [261-263].  These phosphorylation events generate binding 
sites for the recruitment and activation of signaling effectors to amplify signaling 
downstream of the receptors and modify cell behavior.  The IRS proteins were first 
characterized as regulators of signaling downstream of the insulin receptor (IR) 
and the insulin-like growth factor receptor (IGF-1R), but they can also serve as 
signaling intermediates of additional growth factor, cytokine and integrin receptors 
[145, 262, 264].  Many of these receptors have been implicated in tumor 
development, growth and metastasis, highlighting the importance of understanding 
the mechanism by which the IRS proteins mediate their distinct downstream 
signaling outcomes [145, 265, 266].   
 
The IRS proteins are “intrinsically disordered” proteins (IDP) that contain 
structured N-terminal PH and PTB domains followed by a predominantly 
disordered C-terminal extension, which likely contributes to the divergent function 
of these proteins.  The lack of structure within the C-terminal region of these 
adaptor proteins is thought to allow for flexibility in coordinating multiple 
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interactions in response to upstream signals through the formation of “loops” that 
interact with distinct binding partners to stimulate different downstream outcomes 
[130]. Both IRS1 and IRS2 recruit and activate the PI3K/AKT pathway in vitro and 
in vivo.  Additional common binding proteins include growth factor receptor-bound 
protein 2 (GRB-2) and SHP2 [137, 138].  To date, unique binding partners have 
not been identified for IRS1 and IRS2 to explain their functional differences.  
Although both IRS1 and IRS2 are capable of activating the PI3K pathway, they 
have different mechanisms of AKT activation downstream of PI3K, with IRS2 
requiring an intact microtubule cytoskeleton for full AKT activation and IRS1 
activating AKT independently of microtubules [267].  Selective regulation of 
downstream AKT effectors by IRS1 and IRS2, such as GSK-3 Beta, has also been 
demonstrated [180].  The differential sensitivity to microtubule disruption for 
signaling suggests trafficking and intracellular localization of the IRS proteins 
contributes to their distinct functional outcomes. 
 
Metastasis is the leading cause of mortality in breast cancer patients. 
Although there have been significant advances made in the treatment of primary 
breast tumors, there remains a relative lack of effective therapeutic approaches for 
metastatic disease [11, 12].  Metastasis is a complex, multi-step process.  The 
ability to invade from the primary tumor through the underlying basement 
membrane into the surrounding stromal microenvironment and to access the 
vasculature is an early pre-requisite of metastatic cells [268, 269]. Dissemination 
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through the blood or lymphatic vessels, extravasation and colonization of 
secondary organ sites is also required.  The cancer stem cell properties of self-
renewal and pluripotency, as well as their ability to differentiate and repopulate the 
heterogeneity of a tumor, facilitate the metastatic colonization of distant organs 
[89, 270]. The prevention of tumor cell invasion and secondary tumor formation 
are major goals of therapy aimed at treating metastatic disease.   In the current 
study, we sought to investigate the mechanism by which IRS2 selectively regulates 
mammary tumor metastasis. Our structural dissection of IRS2 reveals discrete 
regions within the C-terminus that are required for the ability of IRS2 to regulate 
both invasion and self-renewal.   
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EXPERIMENTAL PROCEDURES 
 
Cells, shRNA, transfection and infection. MDA-MB-231 cells were obtained 
from the ATCC Cell Biology Collection.  SUM-159 cells were a kind gift from Art 
Mercurio (UMass Medical School, Worcester, MA). Mammary tumor cells were 
isolated from female FVB MMTV-PyMT:Irs1f/f/Irs2f/f mice and Irs1-/-,Irs2-/-:PyMT 
cells were generated by infection with adenoviral Cre-recombinase and subcloning 
to isolate cells with complete knockout of both Irs1 and Irs2 as described previously 
[180].  IRS1/IRS2 double null SUM-159 cells were generated by CRISPR/Cas9-
mediated gene editing. gRNAs were designed using MIT CRISPR DESIGN 
(http://crispr.mit.edu/) to target an early 5’ exon region for either IRS1 (sequence 
of gRNA: GCATGCTCTTGGGTTTGCGCAGG) or IRS2 (sequence of gRNA: 
AACCACAGCGTGCGCAAGTGCGG). The gRNAs were subcloned into the 
pSpCas9(BB)-2A-GFP plasmid (Addgene #48138). Cells were transfected with the 
CRISPR plasmid containing the IRS1-gRNA using lipofectamine 2000 (Invitrogen) 
and sorted by flow cytometry for the GFP-high population to obtain IRS1-/- cells. 
IRS1-/- cells were transfected with the CRISPR plasmid containing the IRS2-
specific gRNA and sorted for GFP high cells to generate SUM-159:IRS1-/- ,IRS2-
/- cells. Lentiviral vectors containing shRNAs targeting GFP, IRS2 and mouse 
BMP2K were obtained from the UMass RNAi core (Worcester, MA).  Cells were 
infected viruses and stable cell lines were generated by selection in 100 ug/ml 
puromycin.  PyMT cells were transfected with Lipofectamine 2000 (Invitrogen) 
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according to manufacturer’s protocol. For stable selection, cells were grown in 
G418 (0.5mg/ml) or puromycin (100 ug/ml).    
 
Mutagenesis and Cloning.  Primers for human IRS2 were purchased from 
Integrated DNA technologies (IRS1Δ942, fwd 5’ TACCCCTACGACGTCCC 3’ and 
rev 5’ CTGAGCAGCTGTGTCCAC 3’; IRS2Δ917, fwd 5’ 
TACCCCTACGACGTCCC 3’ and rev 5’ AGGCACTACAGGGTGAGG 3’; 
IRS2Δ1014, 5’ TACCCCTACGACGTCCC 3’ and rev 5’ 
ATACGGGGAGGAGGCCT 3’; IRS2Δ1188, fwd 5’ TACCCCTACGACGTCCC 3’ 
and rev 5’ GCCCTCGCTGCTTTTCCT 3’; IRS2ΔSR, 5’ CCGCCGTTGCCCCCG 
3’ and rev 5’ GGGCTCGCCAAAGTCGATG 3’; IRS2ΔINV, fwd 5’ 
GGCGTGGGTGTCGGC 3’ and rev 5’ ATACGGGGAGGAGGCCT 3’).  IRS 
mutants were generated from pCDNA-IRS2-HA and pCDNA-IRS1-HA by PCR 
amplification with Q5 Hot Start High-Fidelity DNA Polymerase (#M0493S, New 
England Biolabs) and PCR products were ligated using the Quick Ligation Kit 
(#M2200S, New England Biolabs).  IRS protein chimeras were generated using 
PCR (IRS1/S2 chimera, IRS2 C-terminus insert fwd 5’ GACCAGTACGTGCTCAT 
GAGCT 3’ and rev 5’ 
CACAGTCGAGGCTGATCAGCTCAGCTGGCGTAGTCGGG 3’; IRS1 vector fwd 
5’ GCTGATCAGCCTCGACTGTG 3’ and rev 5’ AGCTCATGAGCACGTA 
CTGGTCGTATCCCCCACCCAGGCT 3’; IRS2/S1 chimera, IRS1 C-terminus 
insert fwd 5’ TGCGGGGCTAGGCTGGAG 3’  and rev 5’ 
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GCACAGTCGAGGCTGATCAGCCTAGCTGGCGTAGTCGGGGAC 3’, IRS2 
vector fwd 5’ GCTGATCAGCCTCGACTGTGC 3’ and rev 5’ CTCCAGCC 
TAGCCCCGCAGCTGTCCCCGCCACAGGT 3’).   C-terminal inserts and IRS1 
and IRS2 N-termini with vector were generated by PCR using High-Fidelity 
Phusion DNA Polymerase (#M0530S, New England Biolabs). IRS1 and IRS2 C-
termini were transferred to IRS2 and IRS1 vectors respectively using Phusion 
PCR.   
Individual IRS2 regions were generated by PCR amplification from pCDNA-
IRS2-HA (CONT region, fwd 5’ CTCAAGCT TGGCGTGGGTGTCGGC 3’ and rev 
5’ ACCGTCGACCCACCGCCTCCGGACTCTTTCACGATGGTGGC CT 3’; SR 
region, fwd 5’ CTCAAGCTTGGGGCCCGCCTGTCG 3’ and rev 5’ 
ACCGTCGACCCACCGCCTCCGGAATACGGGGAGGAGGCCTC 3’; INV region, 
fwd 5’ CTCAAGCTTCCGCCGTTGCCCCCG 3’ and rev 5’ 
ACCGTCGACCCACCGCCTCCGGAGCCCTCGCTGCTTTTCCT 3’; INV region 
for pulldown, fwd 5’ CTCTCTAGAATGCCGCCGTTGCCCCCG 3’ and rev 5’ 
CTAGGAATTCGCCCTCGCTGCTTTTCCT 3’).  After amplification, regions were 
subcloned into the pCDH-mVenus vector.  The INV region was also subcloned into 
a tandem affinity purification vector pCDNA-3xFLAG-6His (INV fwd 5’ 
CTCTCTAGAATGCCGCCGTTGCCCCCG 3’ and rev 5’ CTAGGAATTCG 
CCCTCGCTGCTTTTCCT 3’)  
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Immunoblotting and immunoprecipitation.  Cells were serum starved for 4 
hours (PyMT cells) in serum-free medium before stimulation with IGF-1 for 10 
minutes.  Cells were pretreated with the IR/IGF1R inhibitor BMS754807 (#S1124, 
Selleckchem) for 4 hours before serum starvation (4 hours) and stimulation with 
IGF-1.    For total cell extract immunoblots, cells were solubilized at 4oC in RIPA 
lysis buffer (25 mM Tris, pH 8.0, 0.1% sodium dodecyl sulfate, 1% sodium 
deoxycholate, 1% Nonidet P-40, 150 mM sodium chloride, 10 mM sodium fluoride, 
1 mM sodium orthovanadate) containing protease inhibitors (Roche, Basel, 
Switzerland). Cell extracts containing equivalent amounts of protein were resolved 
by SDS-PAGE and transferred to nitrocellulose membranes. The membranes 
were blocked for 1 h with a 50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl, 
0.05% Tween 20, and 5% (wt/vol) dry milk or 5% bovine serum albumin (BSA), 
incubated overnight at 4oC in the same buffer containing primary antibodies and 
then incubated for 1 h in 5% blocking buffer with milk containing peroxidase-
conjugated secondary antibodies. Proteins were detected by enhanced 
chemiluminescence (Biorad, Hercules, CA) using BIORAD ChemiDoc XRS+ with 
Image Lab Software.  The following antibodies were used for immunoblotting: HA 
(#11867423001, Roche), IRS-2 (#4502, Cell Signaling, Danvers, MA), p85 (#05-212, 
Millipore, Billerica, MA), IGF-1R (#3025, Cell Signaling), pIGF-1R Y1135/1136 
(#3024, Cell Signaling), phospho-AKT S473 (#9271 and #4060, Cell Signaling), 
phospho-AKT T308 (#2965, Cell Signaling), AKT (#9272, Cell Signaling), -tubulin 
(#T5168, Sigma-Aldrich), peroxidase-conjugated goat anti-rabbit IgG (#111-035-
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144, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA), and 
peroxidase-conjugated goat anti-mouse IgG (#711-035-151, Jackson 
ImmunoResearch Laboratories, Inc). 
 For immunoprecipitations, cells were extracted using a 20 mM Tris, pH 7.4 
buffer containing 1% Nonidet P-40, 0.137 M NaCl, 10% glycerol, 10 mM sodium 
fluoride, 1 mM sodium orthovanadate and protease inhibitors (Roche).  Aliquots of 
cell extracts containing equivalent amounts of protein were pre-cleared for 1hr with 
protein A sepharose beads and then incubated overnight at 4°C with antibodies 
and protein A sepharose beads (Amersham Biosciences, Piscataway, NJ) with 
constant agitation.  The beads were washed three times in extraction buffer.  
Laemmli sample buffer was added to the samples and immune complexes were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes, and 
immunoblotted as described above.  An HA-specific Ab 9#, Roche) was used for 
immunoprecipitation.   
 
Lactate and Glucose Uptake assays. Cells were grown in 12-well plates to near 
confluence, washed with PBS, and then incubated in 0.1% BSA/DMEM (1g/liter 
glucose) for 24 hours.  Lactate levels in the conditioned media were measured 
using a lactate assay kit (Trinity Biotech), and glucose levels were measured using 
a glucose assay kit (Sigma), according to the instructions of the manufacturer.  Cell 
density per well was determined using a crystal violet staining, and lactate 
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production and glucose uptake were expressed as a rate measurement 
(millimolar/milligram/hour) normalized to cell density.   
 
Transwell Invasion assay.  Matrigel (5ug; Corning) was diluted in sterile water 
and dried overnight onto the upper side of Transwell chambers (6.5-mm diameter, 
8-um pore size; Corning).   One hour before the assay, Matrigel was rehydrated 
with Dulbecco’s modified Eagle’s medium (DMEM; 1g/liter glucose) containing 
0.1% Bovine serum albumin (BSA).  Cells (104) were placed into the top chamber 
and conditioned media from NIH-3T3 cells was placed in the bottom chamber.  
After 4 hours, non-invading cells in the top chamber were removed using a cotton 
swab, and cells on the bottom surface of the filter were fixed with methanol and 
allowed to dry overnight at room temperature.  Nuclei were stained with DAPI 
quantified using ImageJ. 
 
3D Matrigel-Collagen I assay.  Growth factor reduced Matrigel (#354230, 
Corning) and rat tail collagen I (#354236, Corning) were mixed to a final 
concentration of 2mg/ml and 1mg/ml, respectively, and 150 ul was added to each 
chamber of an 8 chamber slide to form an underlayer (#354118, Corning).  For the 
cell suspension, Matrigel was mixed with Collagen I to a final concentration of 
2.17mg/ml Matrigel and 1.09mg/ml collagen I and 230ul of the Matrigel/Collagen I 
was mixed with 20 ul of a cell suspension containing 3000 cells.  250ul of the 
Matrigel/Collagen I/cell suspension, with a final concentration of Matrigel (2mg/ml) 
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and Collagen I (1mg/mg), was added to the chambers. After a 3 hour incubation 
at 37ºC, 300ul of 10%FBS-DMEM media was added to the chambers.  The media 
was changed every 2-3 days for a total of 8 days.  The number of invasive and 
non-invasive colonies was scored.    
 
Mammosphere serial passage assay.  Single cells in suspension were plated in 
ultralow attachment plates (#Corning) at a density of 25,000 viable cells/ml.  Cells 
were grown in serum-free HAM-F12 media (#Corning) supplemented with B27 
(Invitrogen), 20 ng/ml EGF, 20 ng/ml bFGF (BD Biosciences) and 50ng/ml insulin 
(Sigma). After 4 days, the number of mammospheres 50 um or larger were scored.  
For serial passage, mammospheres were collected by centrifugation (1,500rpm) 
and dissociated enzymatically for 15 min in 0.05% trypsin, 0.53 mM EDTA 
(Invitrogen).  Trypsin was inhibited by adding a 1:1 volume of 1X Soybean Trypsin 
inhibitor (Sigma), after which cells were centrifuged and washed once in 1X PBS.  
Cells were resuspended in mammosphere media and 25,000 cells were plated into 
new ultralow attachment plates.  The collection and dissociation of 
mammospheres was performed for 3 passages.   
 
Microscopy. SUM-159 cells were infected with lentiviruses containing pCDH-
vector, pCDH-SR-mVenus, pCDH-INV-mVenus or pCDH-CONT-mVenus.  Cells 
were plated in 60mm cell culture dishes at a subconfluent density.  Fluorescent 
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and phase contrast images were taken using a Olympus IX71 microscope. All 
images were adjusted equally for brightness and contrast using ImageJ.   
 
Tandem affinity purification and mass spectrometry. Six 15cm plates of SUM-
159 cells were lysed after transient transfection of pCDNA-INV-3XFlag-6His, 
washed twice in PBS and lysed by scrapping cells in lysis buffer (50mM Tris, [pH 
7.4], 250mM NaCl, 0.1% Tx-100, plus 10 mM sodium fluoride, 1 mM sodium 
orthovanadate) containing protease inhibitors (Roche, Basel, Switzerland).  The 
lysate was incubated on ice for 20 minutes, clarified twice by centrifugation and 
incubated for 3 hours in 200ul of a FLAG M2 Agarose bead slurry (Sigma) that had 
been previously equilibrated in lysis buffer.  Beads were washed five times and 
then the INV region was eluted five times with 0.5mg/ml 3x FLAG peptide (Sigma) 
in lysis buffer, with 15 minutes of incubation prior to recovery of each elution.  
Pooled FLAG elutions were incubated with 100ul of pre-equilibrated TALON 
(Millipore) agarose beads for 2 hours, washed five times in lysis buffer, and eluted 
five times with lysis buffer plus 250mM imidazole (15 minutes incubation per 
elution).   
Pooled elutions from the TALON beads were Trichloroacetic acid 
precipitated by adding 0.11 volumes of ice cold 100% TCA and incubation on ice 
for 10 minutes before adding an additional 500 ul of cold 10% TCA and incubation 
on ice for another 20 minutes.  Samples were centrifuged for 30 minutes at 14,000 
rpm, after which the supernatant was removed, the pellet was washed with 500ul 
97 
 
cold acetone, centrifuged at 14,000 rpm for 10 minutes and then the pellet was 
dried in a vacuum evaporator for 5 minutes.  The protein pellet was reconstituted 
in 1x Laemmli sample buffer and resolved on an SDS-PAGE 2 cm short gel.  Gels 
were stained with Comassie blue and then destained. The samples were cut out 
of the gel and sent for mass spectrometry analysis at the UMASS Proteomics Core 
(Shrewsbury, Massachusetts).   
 
Quantitative RT-PCR.  Total RNA was isolated using the Qiagen RNeasy Plus 
Mini kit. Reverse transcription was performed with the qScript cDNA Supermix kit 
(Quantabio) using 1 ug RNA. RT-qPCR was performed in a 20 uL reaction with 
primers designed from the Harvard PrimerBank.  Mouse Actin primers (control) 
and BMP2K primers (fwd 5’ GCTTCCGTCCCTTTCATTTCT 3’Rev 
5’AGCCTCCATTTTTGGTAAGGTTT 3’) were used. RT-qPCR was performed with 
the Applied Biosystems QuantStudio 6 Flex apparatus. The RT-qPCR program 
consisted of an initial step of 20 seconds at 95°C followed by 40 cycles of 95°C for 
1 second with 60°C at 20 seconds. The delta –delta Ct method was used to 
determine relative mRNA expression.  Actin was used as a control for 
normalization.   
 
Statistics.  For the densitometry analysis of immunoblots, the results were 
compared using the Student t-test and the values were represented as means ± 
standard errors (SEM) for each group.  Student t-test was also used for analysis 
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of the invasion and mammosphere serial passage assay data.  In all analyses, a 
P value of 0.05 was considered statistically significant.  Corresponding significance 
levels are indicated in the Figure Legends.   
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RESULTS 
 
The IGF1R/PI3K axis contributes to IRS2-mediated tumor cell invasion.   
 
We have previously demonstrated that mammary tumor cells lacking Irs2 
expression are deficient in their ability to invade [115].  To further our 
understanding of how IRS2 regulates tumor cell invasion, we used double Irs1/Irs2 
null (PyMT:Irs1-/-/Irs2-/-) mouse mammary tumor cells to assess Irs2 function in 
the absence of Irs1 expression.  As shown in Figure 3.1A, restoration of Irs2 
expression in the double null cells significantly increases invasion.  The IRS 
proteins are regulated by tyrosine phosphorylation in response to upstream 
receptor activation.  To determine if the IGF-1R or IR regulate IRS2-dependent 
invasion, assays were performed in the presence of the dual IGF1R/IR small 
molecule inhibitor BMS-754807 [271-273]. Cells were pretreated for 4 hours and 
then incubated with inhibitor throughout the Transwell Matrigel invasion assay.  
Inhibition of IR/IGF1R did not alter the invasion of Irs1-/-Irs2-/- cells expressing 
empty vector.  In contrast, the enhanced IRS2-dependent tumor cell invasion was 
inhibited in a dose dependent manner (Fig. 3.2A).    Cells treated in parallel with 
BMS-754807 and then acutely stimulated with IGF-1 were assayed for IGF-1R/IR 
phosphorylation and downstream activation of AKT, as a measure of PI3K activity, 
to confirm inhibition of the pathway. BMS-754807 efficiently blocked both IGF-
1R/IR and AKT phosphorylation (Fig. 3.1B).   
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Figure 3.1. The IR/IGF-1R contributes to IRS2-mediated tumor cell invasion.  
PyMT:Irs1-/-/Irs2-/- cells expressing EV or IRS2 were treated with DMSO or 
BMS754807 at the concentrations indicated for 4 hours.  (A) Matrigel Transwell 
invasion assays performed for 5 hours.  The data shown represent the mean ± 
S.E.M of three experiments.  ns, no significant difference; **, p<0.01 relative to EV-
DMSO; ##, p<0.01 relative to IRS2-DMSO. (B) Cells were stimulated with IGF-1 
(50 ng/ml) for 10 minutes in the presence or absence of BMS7548047. Aliquots of 
cell extracts containing equivalent amount of proteins were immunoblotted with 
antibodies specific for IRS2, p-IGF1R (Y1135/1136), IGF1R, pAKT (S473), AKT, 
or tubulin.   
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Both IRS1 and IRS2 can recruit and activate PI3K, but only IRS2 promotes 
invasion.  We next wanted to examine if the ability of IRS2 to activate PI3K 
signaling is required for IRS2-mediated tumor cell invasion. Previous work from 
our group identified four essential tyrosines in IRS2 (Y649, Y671, Y734, Y814) that 
are required for the recruitment of PI3K and activation of the downstream 
PI3K/AKT pathway in response to IGF-1 and insulin stimulation [180]. PyMT:Irs1-
/-/Irs2-/- cells expressing equivalent levels of Irs2 or Irs2-Y5F, an IRS2 mutant in 
which the essential tyrosines have been mutated to phenylalanine (Irs2-Y5F) to 
prevent PI3K recruitment (Fig. 3.2B), were examined for their invasive potential in 
a Transwell Matrigel invasion assay.    As observed previously, expression of Irs2 
resulted in a 2-fold increase in tumor cell invasion. Cells expressing Irs2-Y5F 
showed a modest increase in invasion, but they were significantly less invasive 
than cells expressing Irs2 (Fig. 3.2C).  To confirm the results of the 2D Matrigel 
Transwell assay, cells were grown within a Matrigel/Collagen I matrix to assess 
invasive potential in a 3D environment that mimics the tumor matrix 
microenvironment in vivo [36].  Poorly/less invasive cells grow as spherical 
colonies in this 3D-matrix, whereas invasive cells invade into the matrix and form 
branched colonies (Fig. 3.2E).  Although Irs2 and Irs2-Y5F expressing cells formed 
similar numbers of colonies, cells expressing Irs2 were significantly more invasive 
than cells expressing Irs2-Y5F (Fig. 3.2D).  The partial reduction of tumor cell 
invasion in the Irs2-Y5F mutant raises the possibility that in addition to the ability 
of Irs2 to   
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Figure 3.2. IRS2 activation of PI3K contributes to IRS2-mediated tumor cell 
invasion. (A) Schematic of Irs2 and Irs2-Y5F proteins.  (B) Aliquots of cell extracts 
from PyMT:Irs1-/-/Irs2-/- cells expressing EV, Irs2 or Irs2-Y5F were immunoblotted 
with antibodies specific for IRS2 and Tubulin. (C) Matrigel Transwell invasion 
assays. The data shown represents the mean ± S.E.M of three experiments. **, 
p<0.01 relative to EV; ##, p<0.01 relative to IRS2. (D,E) Matrigel-Collagen I 3D 
invasion assay.  Representative images of colonies formed in EV, Irs2 and Irs2-
Y5F expressing cells are shown below (magnification X10).  The data shown 
represent the mean ± S.E.M of a representative experiment performed three times 
independently.  **, p<0.01 relative to EV; ##, p<0.01 relative to IRS2.  
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activate the PI3K pathway, additional mechanisms contribute to IRS2 regulation of 
tumor cell invasion.   
 
The IRS2 C-terminus regulates tumor cell invasion 
 
  The IRS proteins are intrinsically disordered proteins that lack defined 
domain structure with the exception of N-terminal PH and PTB domains that 
mediate recruitment to upstream receptors. To dissect additional structural 
requirements of IRS2 involved in promoting tumor invasion, we sought to identify 
regions of the protein that are required for this functional outcome while preserving 
the ability of IRS2 to be recruited to upstream receptors and activate the PI3K/AKT 
pathway.  To do so, we generated an IRS2 truncation mutant lacking the C-
terminal portion of the protein 3’ to the PI3K binding sites (IRS2∆917) (Fig 3.3A). 
A corresponding truncation mutant was also generated for IRS1 (IRS1∆942) (Fig 
3.3A).  Wild type and mutant proteins were expressed in the double-null cells and 
their phosphorylation and ability to interact with the PI3K regulatory subunit p85 in 
response to IGF-1 stimulation was examined. Both truncation mutants maintained 
their ability to be phosphorylated and recruit PI3K in response to IGF-1 stimulation 
(Fig 3.3B).   To examine further the role of the C-terminus in the function of the 
IRS proteins, IRS1/S2 and IRS2/S1 chimeras were generated by swapping the C-
termini of each adapter protein (Fig 3.3A).  The chimeric IRS proteins were 
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phosphorylated and interacted with PI3K to a similar level as the WT proteins.  The 
IRS proteins are required for IGF-1R-dependent stimulation of PI3K activation as  
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Figure 3.3. The IRS2 C-terminus regulates tumor cell invasion. (A) Schematic 
depicting WT IRS1, WT IRS2 and the IRS mutant proteins.  (B) PyMT:Irs1-/-/Irs2-
/- cells were serum starved for 4 hours and stimulated with IGF-1 (50 ng/ml) for 10 
minutes. Aliquots of cell extracts containing equivalent amounts of total protein 
were immunoprecipitated (IP) with an HA-specific antibody and immunoblotted 
with antibodies specific for HA or the p85 subunit of PI3K (p85).  Total cells extracts 
were also immunoblotted with antibodies specific for HA, pAKT (S473), pAKT 
(T308), AKT and Tubulin. (C) Matrigel Transwell invasion assays. The data shown 
represent the mean ± S.E.M of three experiments. **, p<0.01 relative to EV; ##, 
p<0.01 relative to IRS2. (D) Matrigel-Collagen I 3D invasion assays. (F) 
Representative images of colonies formed are shown below (magnification10X).  
The data shown represent the mean ± S.E. of a representative experiment 
performed three times independently. **, p<0.01 relative to EV; ##, p<0.01 relative 
to IRS2.  (E) Matrigel Transwell invasion assay with SUM-159 cells expressing EV, 
WT IRS1, IRS1Δ942, WT IRS2 and IRS2Δ917. The data shown represent the 
mean ± S.E.M of three experiments. *, p<0.05 relative to EV; **, p<0.01 relative to 
EV; ##, p<0.01 relative to IRS2. 
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evidenced by the lack of AKT activation in the double IRS1/IRS2 null cells in 
response to IGF-1 stimulation (EV; Fig 3.3B).  Expression of either IRS1 or IRS2 
restores the ability of IGF-1 to stimulate AKT phosphorylation at both Thr308 and 
Ser473 sites.  Truncation or swapping of the IRS C-termini resulted in a similar 
level of AKT activation (Fig 3.3B).  These results demonstrate that the C-terminal 
regions of IRS1 and IRS2 are not required for the IGF-1-dependent activation of 
the PI3K/AKT pathway.  
 
Previous studies have implicated IRS2, but not IRS1, in the promotion of 
tumor cell invasion.  Consistent with these previous findings, the invasion of cells 
expressing IRS1 or the IRS1 truncation mutant (IRS1942) was equivalent to the 
invasion observed for cells expressing empty vector (pCDNA) (Fig 3.3C).  
Truncation of the IRS2 C-terminus prevented the IRS2-dependent increase in 
invasion (Fig 3.3C), indicating that sequences contained within this region are 
important for IRS2-dependent promotion of invasion.  To examine the sufficiency 
of the IRS2 C-terminus to promote invasion, cells expressing the IRS1/S2 chimera, 
which contains the N-terminal portion of IRS1 and the C-terminal portion of IRS2, 
were assayed for their invasive potential.  Cells expressing the IRS1/S2 chimera 
exhibited a similar increase in invasion that was observed for cells expressing WT 
IRS2.  In contrast, cells expressing the IRS2/S1 chimera, which contains the N-
terminal portion of IRS2 and the C-terminal portion of IRS1, failed to increase 
invasion above vector control cells (Fig 3.3C). Cells expressing either WT IRS2 or 
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the IRS1/S2 chimera also grew in a highly invasive manner within the 
Matrigel/Collagen I matrix (Fig3.C-F).  In contrast, cells expressing the IRS2 
truncation mutant or the IRS2/S1 chimera exhibited little to no invasion and the 
colonies formed were similar to cells expressing empty vector or IRS1.   Similar 
invasion results were obtained when the WT-IRS proteins and their truncation 
mutants were expressed in an IRS1/IRS2 double null SUM-159 human breast 
carcinoma cell line that was generated by CRISPR/Cas9 knockout (Fig 3.3E). 
Taken together, these data demonstrate that the C-terminus of IRS2 is both 
necessary and sufficient for IRS-mediated tumor cell invasion.   
 
The IRS2 C-terminus plays a role in the regulation of tumor-initiating cell 
self-renewal.   
 Once a tumor cell invades from the primary tumor and spreads to distant 
organs it must establish a secondary tumor in these foreign microenvironments.  
Tumor cells that have the ability to form successful metastatic lesions are thought 
to possess the properties of cancer stem cells (CSC), also referred to as tumor 
initiating cells (TIC) [270, 274].  One important property of TICs is their ability to 
self-renew, which sustains the stem cell population ([85]).   To determine if IRS2 
regulates TIC self-renewal, serial passage mammosphere assays were performed 
[103].  PyMT:Irs1-/-/Irs2-/- cells expressing either empty vector, IRS1 or IRS2 were 
plated in non-adherent conditions and grown for 4 days, at which time the 
mammospheres were counted and then dissociated to re-plate for additional 
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passages.   A similar number of mammospheres were observed for cells 
expressing either empty vector, IRS1 or IRS2 in the first plating.  Upon serial 
passage, cells that express IRS2 maintained higher mammosphere numbers than 
cells expressing either empty vector or IRS1 (Fig 3.4A).   
To determine if the ability of IRS2 to activate PI3K signaling is required for 
TIC self-renewal, cells expressing the Irs2-Y5F PI3K-binding mutant were 
evaluated for mammosphere formation.  The number of mammospheres formed 
by cells expressing Irs2-Y5F at each passage was similar to empty vector 
expressing cells.  These data support that activation of PI3K signaling by IRS2 
plays a role in the regulation of self-renewal.  IRS1/IRS2 null PyMT cells 
expressing IRS truncations and chimeras were also evaluated by mammosphere 
serial passage to determine if the IRS2 C-terminus contributes to the regulation of 
TIC self-renewal.  The number of mammospheres formed by cells expressing 
IRS2Δ917 and IRS2/S1 at each passage was similar to cells expressing empty 
vector and IRS1 (Fig 3.3C).  In contrast, cells expressing both WT-IRS2 and 
IRS1/S2 sustained an enhanced ability to form mammospheres over several 
passages, supporting a positive role for the IRS2 C-terminus in the regulation of 
self-renewal (Fig 3.3C).  
 
Identification of distinct regions within the IRS2 C-terminus that regulate 
tumor cell invasion or TIC self-renewal.   
  
110 
 
 
Figure 3.4. The IRS2 C-terminus regulates tumor-initiating cell self-renewal.  
(A-C) PyMT:Irs1-/-/Irs2-/- expressing the indicated IRS proteins were assayed for 
their ability to form mammospheres over three serial passages.  The data shown 
represent the mean ± S.E.M of representative experiments performed three times 
independently.  **, p<0.01 relative to EV; ##, p<0.01 relative to IRS2.   
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 The IRS2∆917 truncation mutant lacks the final 421 amino acids of the IRS2 
protein.  To dissect further how this region contributes to the regulation of tumor 
cell invasion and self-renewal, smaller truncation mutants were generated that lack 
either 324 amino acids (IRS2Δ1014) or 150 amino acids (IRS2Δ1188) (Fig 3.5A).  
The mutants were expressed in the IRS1/IRS2 null PyMT cells and assayed for 
their response to IGF-1 stimulation.  As was observed for the larger truncation 
mutant (IRS2Δ917), deletion of smaller regions of the IRS2 C-terminus did not 
impair tyrosine phosphorylation, PI3K recruitment or downstream AKT signaling 
(Fig. 3.5B).   
 
 Cells expressing the IRS2Δ1014 and IRSΔ1188 IRS2 truncation mutants 
were assayed for their invasive and self-renewal potential.  Deletion of the C-
terminal 150 amino acids (IRS2Δ1188) did not inhibit the ability of IRS2 to promote 
either invasion (Fig. 3.5C) or self-renewal (Fig. 3.5D) when compared with full 
length IRS2 (Fig. 3.5C-D).  The IRS2Δ1014 mutant was deficient in promoting 
tumor cell invasion (Fig. 3.5C), but retained the ability to regulate self-renewal (Fig 
3.5D).  Taken together, these data identify discrete regions within the IRS2 C-
terminus that are important for its functional outcomes.  A 174 amino acid region 
(1014-1188) is required for the ability of IRS2 to enhance tumor cell invasion, 
whereas a 97 amino acid region (917-1014) is essential for the ability of IRS2 to 
regulate of self-renewal (Fig. 3.5A).  
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Figure 3.5. Identification of distinct regions that regulate tumor cell invasion 
and tumor-initiating cell self-renewal.  (A) Schematic depicting WT IRS1, WT 
IRS2 and the IRS mutant proteins.  (B) PyMT:Irs1-/-/Irs2-/- cells expressing the 
indicated IRS2 proteins were serum starved for 4 hours and stimulated with IGF-1 
(50 ng/ml) for 10 minutes. Aliquots of cell extracts containing equivalent amounts 
of total protein were immunoprecipitated (IP) with an HA-specific antibody and 
immunoblotted with antibodies specific for HA or the p85 subunit of PI3K (p85).  
Total cells extracts were also immunoblotted with antibodies specific for HA, pAKT 
(S473), pAKT (T308), AKT and Tubulin. (C) Matrigel Transwell invasion assays. 
The data shown represent the mean ± S.E.M of three experiments. **, p<0.01 
relative to EV; ##, p<0.01 relative to IRS2. (D) Mammosphere serial passage assay.  
The data shown represent the mean ± S.E.M of a representative experiment 
performed three times independently.  **, p<0.01 relative to EV; ##, p<0.01 relative 
to IRS2.   
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 To confirm the contribution of these independent regions to the regulation 
of tumor cell invasion and self-renewal by IRS2, internal deletion mutants were 
generated in which either the 174 amino acids between residues 1014 and 1188 
(IRS2∆INV) or the 97 amino acids between residues 917 and 1014 (IRS2∆SR)  
were deleted (Fig. 3.6A).  Both internal deletion mutants maintained their ability to 
associate with PI3K and activate the AKT pathway in response to IGF-1 stimulation 
(Fig. 3.6B).  Consistent with the results obtained with the IRS2 truncation mutants, 
deletion of the 174 amino acid region alone rendered IRS2 incapable of promoting 
tumor cell invasion as measured by both Matrigel Transwell (Fig. 3.6C) and 3D 
Matrigel-Collagen I (Fig. 3.6D) assays. Deletion of the 97 amino acid region alone 
inhibited serial passage mammosphere formation (Fig. 3.6E).  Importantly, 
IRS2∆INV retained the ability to regulate self-renewal and IRS2∆SR retained the 
ability to promote tumor cell invasion (Fig. 3.6C-E).  
In previous work, we identified a role for IRS2 in the regulation of aerobic 
glycolysis that is dependent upon the recruitment and activation of PI3K [180].  To 
determine if the IRS2 C-terminus also contributes to the regulation of aerobic 
glycolysis, PyMT:Irs1-/-/Irs2-/- cells expressing WT-IRS2, IRS2Δ917, IRS2ΔSR 
and IRSΔINV were assayed for their level of glycolytic metabolism.  As 
demonstrated previously, expression of WT-IRS2 significantly increased glucose 
uptake and lactate production in comparison to empty vector control cells.  All of 
the IRS2 deletion mutants supported equivalent glucose uptake and lactate 
production as WT-IRS2, demonstrating that the C-terminus of IRS2 is not required  
114 
 
 
115 
 
Figure 3.6. Internal deletion of the SR and INV regions impairs their 
respective functions.  (A) Schematic depicting IRS2ΔSR and IRS2ΔINV mutants.  
(B) PyMT:Irs1-/-/Irs2-/- cells expressing the indicated IRS2 proteins were serum 
starved for 4 hours and stimulated with IGF-1 (50 ng/ml) for 10 minutes. Aliquots 
of cell extracts containing equivalent amounts of total protein were 
immunoprecipitated (IP) with an HA-specific antibody and immunoblotted with 
antibodies specific for HA or the p85 subunit of PI3K (p85).  Total cells extracts 
were also immunoblotted with antibodies specific for pAKT (S473), AKT and 
Tubulin. The data shown in the graph below shows quantification of p85 
association with the IRS proteins and represents the mean ± S.E.M. of three 
independent experiments. No statistical significance was observed among the 
groups.  (C) Matrigel Transwell invasion assays. The data shown represent the 
mean ± S.E.M. of three experiments. **, p<0.01 relative to EV; ##, p<0.01 relative 
to IRS2. (D) Matrigel-Collagen I 3D invasion assay. (E) Representative images of 
colonies formed are shown below (magnification10X). The data shown represent 
the mean ± S.E.M. of a representative experiment performed three times 
independently.  **, p<0.01 relative to EV; ##, p<0.01 relative to IRS2. (F) Cells were 
assayed for their ability to form mammospheres over three serial passages.The 
data shown represent the mean ± S.E.M of a representative experiment performed 
three times independently.  **, p<0.01 relative to EV; ##, p<0.01 relative to IRS2.     
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Figure 3.7. The SR and INV regions are not required for the IRS2-dependent 
regulation of aerobic glycolysis.  PyMT:Irs1-/-/Irs2-/- cells expressing EV, WT 
IRS2, IRS2Δ917, IRS2ΔSR and IRS2ΔINV were grown in 0.1%BSA/DMEM for 
24 hours.  (A) Glucose uptake and (B) lactate production were measured and 
normalized to cell density.  The data shown represent the mean ± S.E.M. of three 
independent experiments.  *, p<0.05 relative to EV.   
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for the regulation of glycolysis.   Therefore, the inhibition of tumor cell invasion and 
self-renewal observed for the IRS2ΔINV and IRSΔSR mutants does not result from 
defects in aerobic glycolysis in these cells.     
 
The invasion region (INV) of IRS2 inhibits IRS2-mediated cell invasion. 
  
 IRS2 is an adaptor protein with no intrinsic kinase activity that is responsible 
for coordinating signaling downstream of the IR/IGF-1R.  We hypothesized that the 
INV and SR regions in the IRS2 C-terminus contribute to IRS2 function through 
specific inter- or intramolecular interactions that alter IRS2 downstream signaling.  
To investigate these potential interactions, we generated green fluorescent protein 
(GFP)-tagged constructs containing the 97 aa self-renewal region (SR), the 174 
aa invasion region (INV) or the final 150 aa of the IRS2 C-terminus (CONT) that 
we demonstrated was not required for either invasion or self-renewal (Fig. 3.8A).   
These domains were expressed at equivalent levels after lentiviral infection and 
stable selection of SUM-159 breast carcinoma cells (Fig. 3.8B). Expression of the 
SR, INV and CONT domains did not inhibit the expression of endogenous IRS2 or 
interfere with IGF-1R-dependent PI3K/AKT activation (Fig. 3.8C).  Cells 
expressing the C-terminal domain constructs were assayed for their ability to 
invade in a Matrigel Transwell assay.  Expression of the INV region decreased 
invasion significantly, while expression of the SR or CONT regions had no impact 
upon invasion (Fig. 3.8D).  Similar results were obtained when the IRS2-INV, SR  
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Figure 3.8. The IRS2 INV region behaves in a dominant negative manner. (A) 
Schematic depicting the SR, INV and CONT regions tagged with mVenus.  SUM-
159 cells expressing EV, CONT, SR or INV regions of IRS2 were imaged. (B) 
Fluorescence and phase contrast images of SUM-159 cells expressing the 
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individual domains (Magnification X10). (C) Total cell extracts were immunoblotted 
with antibodies specific for GFP and Tubulin. SUM-159 expressing IRS2 CONT, 
SR and INV were serum starved for 4 hours and stimulated with IGF-1 (50 ng/ml) 
for 10 minutes. Aliquots of cell extracts containing equivalent amounts of total 
protein were immunoblotted with antibodies specific for IRS2, pIGF-1R 
(Y1135/1136), IGF-1R, pAKT (T308), pAKT (S473), AKT and tubulin.  (D) SUM-
159 cells and (E) MDA-MB-231 cells expressing CONT, SR and INV regions were 
evaluated for invasion in Matrigel Transwell invasion assays. The data shown 
represent the mean ± S.E.M. of three experiments. **, p<0.01 relative to EV.  *, 
p<0.01 relative to EV.  
  
120 
 
and CONT constructs were expressed in human triple negative MDA-MB-231 
breast carcinoma cels (Fig. 3.8E).  The ability of the INV region to act in a dominant 
negative manner and inhibit invasion suggests that there are interactions in this 
region of IRS2 that are important for the regulation of cell invasion.     
 
 To identify proteins that interact with the INV region, tandem affinity 
purification followed by mass spectrometry was performed.  To do so, the INV 
region was tagged with a flexible triple-Flag-His tag (INV-3XFLAG-His) and 
transiently transfected into SUM-159 cells.  Mass spectrometry analysis identified 
bone morphogenetic protein-2-inducible kinase (BMP2K) as an interacting protein 
for the INV region (Fig. 3.9A). BMP2K is a member of the numb associated kinase 
(NAK) family of serine-threonine kinases and it has been implicated in osteoblast 
activation during bone formation [275].  To investigate the role of BMP2K in IRS2-
dependent cell invasion, BMP2K expression was suppressed by shRNA targeting 
in IRS1/2-null PyMT cells expressing WT-IRS2. Knockdown of BMP2K resulted in 
a significant decrease in BMP2K mRNA (Fig. 3.9B).  As a positive control, an 
shRNA targeting IRS2 was also expressed in these cells (Fig. 3.9C).  Suppression 
of either IRS2 or BMP2K expression decreased tumor cell invasion (Fig. 3.9C). 
Taken together these data suggest that the interaction of BMP2K with the invasion 
region plays a role in the regulation of tumor cell invasion by IRS2.   
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Figure 3.9. BMP2K contributes to IRS2-mediated tumor cell invasion.  (A) 
Schematic of BMP2K binding.   (B) Two shRNAs targeting BMP2K (shBMP2K#1 
and shBMP2K#2) were expressed in PyMT:Irs1-/-/Irs2-/- cells expressing IRS2. 
and BMP2K expression was assessed by quantitative PCR.  The data shown are 
expressed as BMP2K mRNA expression relative to control EV control cells 
expressing shIRS2 and represent the mean ± S.E.M of one experiment.  ##, p<0.05 
relative to EV.  (C) PyMT:Irs1-/-/Irs2-/- cells expressing EV or IRS2 were infected 
with lentiviruses expressing shRNA targeting shGFP, shIRS2, shBMP2K#1 or 
shBMP2K#2 and Matrigel Transwell invasion assays were performed. The data 
shown represent the mean ± S.E.M of three experiments. **, p<0.01 relative to EV; 
##, p<0.01 relative to IRS2. 
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Figure 3.10. Model of Insulin Receptor Substrate-2 signaling.  Overview of 
IRS2 signaling and its contributions to metastasis.     
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Discussion 
 
 In this study, we investigated mechanisms by which IRS2 regulates breast 
carcinoma cell functions that are important for metastasis. Our mutagenesis 
analysis identified structural features of IRS2 that are required for regulating 
invasion and self-renewal, two essential functions of metastatic tumor cells.  
Although it was previously established that IRS2 regulates invasion, we 
demonstrate for the first time that IRS2, but not IRS1, regulates TIC self-renewal.  
Our studies reveal that the ability of IRS2 to promote invasion is dependent upon 
upstream IGF-1R/IR activation and the recruitment and activation of PI3K.  
Additional sequences within the C-terminus of IRS2 are also required for IRS2-
mediated tumor cell invasion, and these sequences are sufficient to confer 
invasion-promoting ability when swapped into IRS1. The ability of IRS2 to activate 
PI3K and the IRS2 C-terminus are also required for the regulation of self-renewal.  
Importantly, we identified two independent regions within the IRS2 C-terminus that 
regulate either tumor cell invasion or self-renewal, respectively, supporting that 
IRS2 regulates these functions through distinct signaling mechanisms.  We 
demonstrate that the C-terminal region required for invasion inhibits invasion when 
expressed exogenously, indicating that essential binding interactions occur within 
this region. Tandem affinity purification and mass spectrometric analysis of this 
invasion region revealed an interaction with BMP2K, and suppression of BMP2K 
decreases IRS2 dependent invasion.  Our study demonstrates that the C-terminus 
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of IRS2 plays an important role in determining the functional outcomes of IRS2 
signaling.  
 
 Our structure/function analysis of IRS2 reveals important mechanistic 
information regarding the differential functions of IRS1 and IRS2.  An open 
question about IRS1 and IRS2 has been how these adaptor proteins can each 
activate PI3K and downstream AKT signaling in response to common upstream 
receptor stimuli but regulate diverse cellular outcomes.  The intrinsically disordered 
nature of these proteins has made it difficult to compare their sequences to identify 
unique domains that would explain these differences. IDPs tend to be highly 
dynamic and their function is dependent on their ability to acquire specific protein 
conformations during intramolecular and intermolecular interactions [276], 
suggesting that specific binding interactions are likely to occur with the IRS 
proteins.  Our structure/function analysis demonstrated that sequences within the 
IRS2 C-terminus are both necessary and sufficient for the ability of the IRS proteins 
to regulate tumor invasion and self-renewal.  It will be informative in future studies 
to determine if sequences in the IRS1 C-terminus also contribute to the ability of 
this adaptor protein to uniquely regulate breast carcinoma cell proliferation.   The 
ability to activate PI3K is important for the function of both IRS1 and IRS2 and their 
C-termini are not required for the recruitment or activation of this signaling 
pathway.  These findings suggest that intramolecular interactions or intermolecular 
interactions with unique binding partners that occur within the C-terminus are likely 
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to modify the outcomes of or cooperate with PI3K to regulate downstream 
signaling.  The differential requirement for an intact microtubule cytoskeleton in the 
IRS-dependent activation of AKT suggests an additional mechanism by which 
selective interactions within the C-termini could alter signaling outcomes through 
the regulation of the intracellular localization of these adapter proteins.   
 
Our study is the first to demonstrate a role for IRS2 in the regulation of tumor 
initiating cell function.  The TIC properties of self-renewal and pluripotency, the 
ability to differentiate and repopulate the heterogeneity of a tumor, are thought to 
facilitate the metastatic colonization of distant organs.   In support of this role for 
TICs in metastasis, a single cell analysis of metastatic breast cells revealed that 
early stage metastatic cells have a stem-like gene expression signature, whereas 
late stage metastatic cells (high tumor burden) are more heterogeneous and 
similar to the primary tumor in their gene expression, likely reflecting the division 
of the early arriving stem cells to generate more differentiated, proliferative 
progeny.  IRS2 promotes the formation of mammospheres upon serial passage, 
supporting that it regulates self-renewal to sustain the tumor initiating cell 
population.  This ability of IRS2 to regulate self-renewal would support metastatic 
colonization of distant organs.  IRS2 promotion of both tumor cell invasion and self-
renewal is reminiscent of the epithelial to mesenchymal transition (EMT).  EMT is 
a developmental program whereupon epithelial cells lose their cell-adhesion and 
polarity and become mesenchymal in morphology.  Cells that have undergone an 
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EMT lose expression of epithelial genes such as E-cadherin and gain 
mesenchymal genes such as vimentin and fibronectin.  In cancer, cells that have 
undergone an EMT acquire both invasive and self-renewal capabilities.  To date, 
there are limited reports on IRS function in EMT.  In H1299 lung cancer cells, IRS2 
expression decreases the epithelial marker E-cadherin and enhances the 
mesenchymal marker vimentin [199].   The regulation of EMT by IRS2 in this model 
leads to increased cell invasion.  Loss of IRS2 expression in a model of renal 
tubular fibrosis increases E-cadherin expression.  In the same model, IRS1 inhibits 
TGFβ induction of EMT [277].   The inverse impact of IRS1 and IRS2 on the EMT 
is consistent with the differential regulation of invasion, self-renewal and 
metastasis by the IRS proteins in breast cancer [114-116].  
 
The dominant negative behavior of the INV region suggests that important 
binding interactions occur within this region that contribute to IRS2-mediated 
invasion.  Deletion of this region could impact IRS2 function by preventing IRS2 
from acquiring specific protein conformations required for the regulation of tumor 
cell invasion or by affecting the interaction of IRS2 with key proteins that facilitate 
invasion.   Our identification of BMP2K as a novel IRS2-interacting protein supports 
the latter mechanism, although it doesn’t negate the possibility that additional 
intramolecular interactions are also important.   BMP2K is a relatively unstudied 
serine threonine kinase that has been implicated in osteoblast activation and 
differentiation during osteogenesis [275].  In this regard, BMP2K plays a role in 
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TGF-β/BMP signaling downstream of BMP-2 [278].  Additionally, BMP2K is part of 
the NUMB endocytic adaptor protein complex [279].  The NUMB complex plays a 
role in the endocytic trafficking of the transmembrane receptors Notch, E-cadherin 
and β1-integrin [280-282].   Of interest, NUMB has been implicated in TGF-β 
signaling in renal fibrosis [283], the same model system in which IRS2 regulates 
E-cadherin expression. The common involvement of NUMB and IRS2 in fibrosis 
implicates IRS2-BMP2K in the regulation of EMT that promotes tumor cell 
invasion.   Future studies are necessary to elucidate the mechanistic role of 
BMP2K in the IRS2 regulation of tumor invasion.     
 
 A key outcome from our study is the elucidation of the role of the IRS2 C-
terminus in regulating each of the metastasis promoting functions of IRS2.   The 
ability to invade, self-renew, and support glycolytic metabolism are important 
properties of metastatic tumor cells.  All three functions share a common 
requirement for IRS2-dependent PI3K activation, as demonstrated by the inability 
of cells expressing the IRS2-Y5F mutant that is deficient in PI3K recruitment to 
invade, form mammospheres after serial passage or enhance glucose uptake and 
lactate production.  However, the contribution of the IRS2 C-terminus to each of 
these important functions is distinct. The C-terminus is not required for regulating 
glycolysis and mutually exclusive sequences contribute to the promotion of 
invasion and self-renewal.  These findings reveal that IRS2 regulates each of these 
functions through distinct mechanisms.  Importantly, these mechanistic differences 
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can be exploited to dissect the importance of individual IRS2 functions for breast 
cancer metastasis.   
 
The IGF-1R pathway has been implicated in many aspects of tumorigenesis 
and continues to be a studied target for cancer therapy.   Our data demonstrate 
that IRS2 is the mediator of IGF-1R signaling in tumor cell invasion and may also 
regulate self-renewal.  Targeting the IGF-1R receptor has proved unsuccessful 
clinically as multiple specific inhibitors have failed to inhibit tumor growth [169].  
One reason for the failure of IGF-1R inhibitors is the upregulation of the insulin 
receptor to compensate for the loss of IGF-1R signaling [170].  A concern with 
targeting both receptors is the disruption of normal metabolic homeostasis.  Our 
results provide a rationale for considering IRS2 and IRS2-interacting proteins as a 
viable alternative approach for the inhibition of the IGF-1R/IR pathway in cancer.  
We have identified regions that isolate the regulation of invasion and self-renewal 
from the regulation of glycolysis. The identification of the INV and SR regions 
opens the door to possible therapeutic approaches that can allow the exclusive 
targeting of IRS2-mediated tumor cell processes that contribute to cancer 
metastasis without affecting IRS2-mediated metabolic processes in normal 
tissues.  
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Summary of Findings 
 
 IRS1 and IRS2 are adaptor proteins downstream of the insulin and the IGF-
1 receptors.  The expression of these proteins in cancer has been investigated and 
their role in cancer is well known.  These proteins play very distinct roles in cancer 
and there is a need to understand how they differentially regulate essential tumor 
processes such as aerobic glycolysis, cell survival and cellular invasion.  Since the 
IRS proteins share considerable sequence homology and regulate the activation 
of similar pathways, I sought to identify possible differential signaling mechanisms 
of IRS1 and IRS2.  I determined through manipulation of the microtubule 
cytoskeleton that IRS-2 requires the microtubule cytoskeleton to fully activate the 
PI3K/AKT pathway.  In contrast, cells that signal through IRS1 are able to maintain 
PI3K/AKT signaling upon disruption of microtubules.  More important, I determined 
that IRS-2-dependent cells are more sensitive to microtubule disruption induced 
cell death while cells that express IRS-1 are more resistant to the disruption of the 
microtubules.  We analyzed the mechanism of IRS2-dependent microtubule 
disruption induced apoptosis and determined that the disruption of microtubules 
decreases AKT activation causing the upregulation of the BH3-only proapoptotic 
protein BIM. The differential regulation of AKT activation by the IRS proteins and 
the ability of IRS2 to regulate BIM levels in cancer cells is one mechanism that 
contributes to IRS2 regulation of cell survival.   
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 Our structural/functional studies of IRS2 significantly further our 
understanding of IRS2 in cancer.  To investigate the mechanism by which IRS-2 
regulates tumor metastasis, I took a mutagenesis approach to identify structural 
features of IRS-2 that are required for functions that contribute to cancer 
progression.  My studies reveal that the ability of IRS-2 to promote invasion is 
dependent upon upstream IGF-1R/IR activation and the recruitment and activation 
of PI3K.   I demonstrate for the first time that IRS2, but not IRS1, regulates tumor-
initiating cell (TIC) self-renewal of breast carcinoma cells, and the ability of IRS-2 
to activate PI3K, as well as the IRS-2 C-terminus, are required for both invasion 
and self-renewal.  One of my most significant discoveries was the identification of 
two distinct regions within the IRS2 C-terminus that regulate tumor cell invasion or 
self-renewal.  Further analysis of the invasion region revealed an interaction with 
bone morphogenic protein-2 inducible kinase (BMP2K), a serine threonine kinase 
of the numb associated kinase (NAK) family. I also determined that suppression of 
BMP2K expression decreases IRS-2 dependent invasion.   
 
Implications of the differential signaling downstream of the IRS proteins 
 
One of the roles of IRS2 in cancer cells is the regulation of cell survival. In 
Chapter 2, we determine that signaling downstream of IRS2 requires the 
microtubule cytoskeleton and that disruption of the ability of IRS2 to signal upon 
disruption of the microtubule cytoskeleton causes apoptosis by increased 
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expression of the pro-apoptotic protein BIM. Further inhibition of AKT 
phosphorylation by treatment with a pan-AKT inhibitor (MK2206) does not enhance 
cell death.  These data suggest to us that there is a pool of AKT inhibited by 
disruption of the microtubule cytoskeleton that is responsible for the death 
phenotype that I observe.  AKT has three isoforms, AKT1, AKT2 and AKT3, and 
these isoforms are known to play distinct roles in cancer.  Selective roles for IRS1 
and IRS2 signaling downstream of the IR in skeletal muscle cells have been shown 
to require the specific regulation of AKT isoforms by the IRS proteins.  Insulin 
mediated myoblast differentiation and glucose metabolism are mediated by 
IRS1/AKT2 signaling, whereas signaling through IRS2/AKT1 regulates lipid 
metabolism [256].  In the mammary epithelial cell line MCF-10A, differential roles 
for AKT1 and AKT2 isoforms have been identified.  AKT1 expression represses 
cell migration and invasion, while AKT2 increases cell survival and increases EMT 
through the downregulation of E-cadherin [284].   In the breast cancer cell line 
MDA-MB-435, AKT2 plays a role in tumor cell invasion and metastasis upon 
injection of these cells into mice [285].  These data suggest the possibility that in 
mammary carcinoma cells the IRS protein can selectively regulate different AKT 
isoforms for the regulation of cell survival, invasion and metabolism.  I hypothesize, 
that the selective effect of microtubule disruption in IRS2-expressing cells could be 
due to the differential requirement of AKT isoforms on an intact microtubule 
cytoskeleton.  Given the known function of AKT2, I propose that for IRS2 regulation 
of AKT2 is important for cell survival.   
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To further identify a mechanism responsible for the differential effects of 
microtubule disruption in IRS1- and IRS2-expressing cells, determining if IRS2 
requires the microtubule cytoskeleton to access a specific AKT isoform would be 
important.   Previous work suggesting that IRS1 and IRS2 differentially regulate 
the AKT isoforms for the regulation of aerobic glycolysis, makes me believe that 
the effects of microtubule disruption induced cell death in IRS2-dependent cells 
can be a product of IRS2 requiring microtubules for activation of a specific AKT 
isoform.  In order to determine the impact of microtubule disruption in IRS2-
dependent AKT isoform activation, PyMT:WT, PyMT:Irs1-/- and PyMT:IRS2-/- 
cells could be treated with either DMSO or Nocodazole. These samples would be 
used for immunoprecipitation (IP) of AKT1, AKT2 and AKT3 to assess the 
phosphorylation of individual AKT isoforms after microtubule disruption. 
 
The ability of IRS to regulate specific AKT isoforms can be implicated in the 
ability of IRS2 to selectively regulate distinct AKT effectors.  IRS2 dependent 
activation of AKT results in the phosphorylation and inactivation of GSK3 and this 
inactivation is required for IRS2-mediated regulation of glucose uptake [180].  In 
my current study, IRS2 activation of AKT resulted in the regulation of the pro-
apoptotic protein BIM.  The expression of BIM is regulated by the FOXO 
transcription factors, which are inactivated by AKT phosphorylation [253].  IRS2 
has been previously shown to regulate Foxo1 activity and Bim expression in 
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mouse hepatocytes [255].  I hypothesize in breast carcinoma cells that IRS2 is 
dependent on the microtubule cytoskeleton to activate AKT2, and inhibit the FOXO 
transcription factors resulting in inhibition of BIM expression.  Upon disruption of 
the microtubule cytoskeleton IRS2 is unable to activate AKT2 releasing inhibition 
in FOXO transcription factors leading to increase expression of BIM and apoptosis 
[252, 255].  
 
Based on our work in IRS protein signaling and the IRS2 dependency on 
microtubules to activate the PI3K/AKT pathway, the next step would be to 
determine the role of IRS1 and IRS2 in response to microtubule disruption in vivo.  
To do so, PyMT:IRS1-/- cells that signal through Irs2 and PyMT:Irs2-/- cells that 
signal through Irs1 would be injected into the mammary fat pads of female 
NOD/SCID mice.  Upon tumor formation mice will be treated with vehicle or 
Vinorelbine.  This study would help address the impact of microtubule disruption 
in primary tumor growth and metastasis of tumors that signal through Irs1 or Irs2.  
 
The requirement of an intact microtubule cytoskeleton for IRS2 activation of 
AKT in breast carcinoma cell suggests that there is an interaction between IRS2 
and microtubules.  The IRS proteins do not contain any known microtubule binding 
sequences.  The only reported interaction between the IRS proteins and the 
microtubule cytoskeleton is the interaction between IRS proteins and the C-
terminus NH2-terminal kinase (JNK) interacting protein 1 (JIP1) [286].  JIP1 
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interacts with the kinesin light chain (KLC) of kinesin-1 for trafficking along the 
microtubules [287].  This is evidence of IRS interaction with microtubules.  
However, both IRS proteins can interact with JIP1/kinesin-1 which would suggest 
a sensitivity of both adaptor proteins to disruption of microtubules.  Other potential 
mediators of IRS protein interactions with microtubules are the 14-3-3 proteins.  
14-3-3 protein interact with kinesin-1 to regulate trafficking in neuronal cell axons 
[288].   There is evidence of 14-3-3 proteins regulating IRS1/PI3K signaling [289].  
The interaction between IRS1 and 14-3-3 proteins requires IRS1 phosphorylation 
at Ser-270, Ser374 and Ser641 [290].  This interaction inhibits IRS1 signaling upon 
insulin stimulation in skeletal muscle [290].  The interaction between IRS2 and 14-
3-3 proteins was determined in the same study but the role of this interaction was 
not elucidated.  There is a possibility that the interaction of IRS2 with the 
microtubule cytoskeleton mediates the trafficking along the microtubule 
cytoskeleton for the localization of IRS2/PI3K/AKT signaling complex.   A 
differential role of IRS2 and IRS1 interaction with 14-3-3 protein could explain the 
selective inhibition of IRS2 signaling upon the disruption of the microtubule 
cytoskeleton.   
 
I have developed a set of tools in my IRS2 structural/functional analysis that 
I can employ to further identify a mechanism of IRS2-microtubule dependent 
signaling. First, PyMT:IRS2-/- cells expressing EV, WT IRS1, IRS1Δ942, WT IRS2 
and IRS2Δ917 could be used to determine the response of these mutants to 
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microtubule disruption upon IGF-1 stimulation and if the IRS2 C-terminus is 
required for IRS2 dependency on the microtubule cytoskeleton for signaling.  Also, 
IRS1/S2 and IRS2/S1 chimeras can be used to determine if transferring the IRS2 
C-terminus to IRS1 can sensitize IRS1 expressing cells to microtubule disruption.  
We can use other mutants like the IRS2ΔSR and IRS2ΔINV to determine if the 
effects we are seeing in tumor cell invasion and TIC self-renewal can be due to a 
loss in IRS2-microtubule interaction.   
 
To further understand the differential requirement of the IRS proteins for the 
microtubule cytoskeleton to activate the PI3K/AKT pathway I need to determine 
the mediators of the interaction between IRS proteins and microtubules, I want to 
determine if the interaction is direct, mediated by microtubule associated proteins 
(MAPS) or other unidentified proteins. Using either purified recombinant IRS2 and 
IRS1 (My BioSource) or cytosolic extracts from MDA-231 cells (high IRS2 
expression), I will perform an in vitro binding assay incubating the cytosolic extract 
and the recombinant IRS proteins with MAPS containing tubulin (Cytoskeleton) or 
MAPS free tubulin as described in [291]. These mixtures will allow me to determine 
if the interaction between IRS and microtubules is direct, in the absence of MAPS 
and other cytosolic proteins, or mediated by a third protein that might be part of the 
MAPS or present in the cytosolic extract.  IRS2-null cells extracts, purified JNK-
interacting protein 1 (JIP1) (EzBiolab) a well-known protein that does not interact 
directly with microtubules), will be used as negative control [286, 287].  Purified 
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recombinant RBl2p/cofactor A (EzBiolab) a well-known direct microtubule binding 
protein will serve as a positive control, JIP1 can serve as a positive control of 
indirect microtubule interaction because it binds microtubules in a MAPS-
dependent manner.  Binding to tubulin will be examined by microtubule co-
sedimentation assays follow by western blot analysis for the detection of IRS 
proteins or other proteins binding tubulin.  The identification of the proteins that 
mediate the interaction between IRS proteins and microtubules can advance our 
understanding of IRS1 and IRS2 signaling.  The mediators of the IRS-microtubule 
interaction can be important regulators of IRS protein signaling and help 
understand the differential roles IRS1 and IRS2 have in cancer.   
 
In addition to the differential requirement of the microtubule cytoskeleton for 
IRS1 and IRS2 to signal to the AKT pathway, there are other possible mediators 
of IRS2 and IRS1 that required closed attention. There are three PI3K p110 
catalytic subunits and these are frequently mutated in cancer [177, 185, 186].  
More work needs to be performed to elucidate the interactions between IRS1 and 
IRS2 with the different PI3K catalytic subunits and if differential interaction between 
the adaptors with different mutant p110 mutants accounts for the differential effects 
in IRS proteins functions. Moreover, the activation of PI3K by the IRS proteins not 
only activates the PI3K/AKT pathway but can also contribute to the activation of 
the RAC signaling pathway.  This pathway regulates cell-to-cell contact and actin 
cytoskeleton rearrangements [184].  The RAC pathway is implicated in tumor cell 
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invasion and there is a need to address if the differential activation of RAC 
downstream of IRS proteins contributes to the ability of IRS2 to regulate tumor cell 
invasion.  Additionally, I have shown that mutations in the IRS2 C-terminus does 
not impair the ability of this adaptor to activate the PI3K pathway. I need to 
investigate if our mutants IRS2Δ917 and IRS2ΔINV do not have an effect in the 
activation of RAC signaling.  The inability of these mutants to activate RAC 
signaling can contribute to the effects of these mutants in tumor cell invasion.   
 
New discoveries: IRS2-dependent regulation of tumor cell invasion and 
TICs self-renewal 
 
IRS2 significantly contributes to the metastatic process by the regulation of 
tumor cell invasion and we recently identified additional contributions of IRS2 to 
the regulation of breast carcinoma TIC self-renewal.  Data from previous studies 
suggest that IGF-1R activation of AKT is required for the regulation of tumor cell 
invasion.  In glioma cells, miRNA-383 downregulates IGF-1R and decreases AKT 
activation and causes a decrease in tumor cell invasion [292].  Prostate cancer 
cells DUI45 increase IGF-1R activity upon stimulation increases AKT activity and 
causes an increase in tumor cell invasion [293].  Inhibition of IGF-1R signaling by 
monoclonal antibody EM146 against the IGF-1R receptor in MDA-MB-435 cells 
inhibits tumor cell invasion. My data provides evidence that the ability of IGF-1R to 
recruit IRS2 and activate the PI3K pathway contributes to the regulation of tumor 
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cell invasion.  In human mammary epithelial cells MCF-10A ablation of AKT1 
enhances tumor cell invasion and metastasis in vivo.  Loss of AKT1 decreases 
miRNA-200 expression and these miRNAs are responsible for the regulation of the 
E-cadherin transcription repressors ZEB1 and ZEB2 [294, 295].  The knockdown 
of AKT1 and TGFβ stimulation of these cells enhances mammosphere formation 
[296].  These data suggest that AKT2 signaling contribute to the regulation of EMT 
in MCF-10A cells and increases invasion in this cell line.   In a glioblastoma cell 
line CD133+ cells require AKT activation for mammosphere formation and 
inhibition of AKT ablates the ability of these cells to form mammospheres.   We 
have seen that inhibition of AKT activation by the Irs2-Y5F mutant shows a defect 
in TIC self-renewal, suggesting that AKT activation downstream of IRS2/PI3K may 
be required for both invasion and self-renewal. The ability of IRS2 to activate 
specific AKT isoforms may also contribute to its ability to regulate tumor cell 
invasion and TIC self-renewal.    
 
In addition to the requirement of IRS2/PI3K/AKT signaling for tumor cell 
invasion and self-renewal, I identified two distinct regions in the IRS2 C-terminus 
that play a role in the regulation of self-renewal (SR) and invasion (INV). Deletions 
of each of these regions renders IRS2 unable to regulate their respective functions 
while maintaining the ability of the protein to activate PI3K/AKT signaling. These 
results suggest that additional requirements in IRS2 protein are needed to regulate 
these processes.  The IRS2 is an adaptor protein with no intrinsic kinase activity 
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and understanding protein interactions with these regions can help elucidate 
mechanistic regulation of tumor cell invasion and TICs self-renewal by IRS2.  I 
used tandem affinity purification and mass spectrometry to identify interactions of 
the INV-region with protein that could be responsible for the role of this region in 
tumor cell invasion.  Our protein purification approach contained nuclear and 
cytosolic fractions, the presence of the nuclear fraction results in the presence of 
many nuclear proteins in our mass spectrometry.  I believe that these are artifacts 
as we know that IRS2 is not a nuclear protein.  Future experiments would require 
an isolation of the cytosolic fraction to diminish the number of non-specific binding 
detected in the whole cell extract.      
 
Among the interactors identified in this approach were, intersectin, 
desmoplakin and BMP2K.  Intersectin and desmoplakin have previously been 
implicated in tumor cells invasion and metastasis.  These proteins remain 
important targets to investigate as we continue to determine the regulation of tumor 
cell invasion by IRS2 and the role of the INV region.   The association of IRS2 with 
BMP2K is a novel finding that reveals potential mechanistic information regarding 
IRS2 regulation of invasion.  Although there is relatively little information about 
BMP2K function in cancer, according to the human protein atlas, BMP2K is 
overexpressed in lymphoma, breast, pancreatic, prostate and skin cancers.  
Potential contributions of BMP2K to IRS2 function in cancer can be postulated from 
its known function in normal cell biology.   
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BMP2K is part of the Numb endocytic adaptor protein complex [279].  The 
Numb complex plays a role in the endocytic trafficking of the transmembrane 
receptors Notch, E-cadherin and β1-integrin [280-282].  All these receptors play a 
role in cancer suggesting that BMP2K as a Numb associated kinase (NAK) could 
also play a role in tumorigenesis.  Structural analysis of NAKs revealed that 
BMP2K, along with other members of this kinase family, can bind with high affinity 
to inhibitors that were previously thought to be selective for their targets [297].  The 
JNK inhibitor SP600125, JAK inhibitors momelotinib and baricitinib, Aurora kinase 
A inhibitor AT9283 and a dual MAPK and TAK1 inhibitor have all been identified 
as strong inhibitors of BMP2K.  There is a need to be determine if the inhibition of 
BMP2K by these different drugs contributes to their effects in cancer.  Additionally, 
these data suggest that BMP2K can be a druggable target in cancer.   
 
The biology of BMP2K remains to be elucidated but the biology of its binding 
partner Numb is well studied.  There is evidence that implicates Numb independent 
of its role in endocytosis in the regulation of breast tumor cell invasion.  Expression 
of the Numb isoform Numb6 in D-17 breast carcinoma cell lines leads to the 
regulation of EMT factors Vimentin and Slug while suppressing the expression of 
E-cadherin [298].  Inhibition of the PI3K/AKT pathway in this model inhibits the 
regulation of EMT and tumor cell invasion by Numb6.  Based on the requirement 
of PI3K/AKT for Numb6-dependent regulation of tumor cell invasion we can 
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hypothesize that IRS2 activation of the PI3K pathway and its interaction with Numb 
can contribute to the regulation of tumor cell invasion.   Studies to determine the 
interaction between Numb, BMP2K and IRS2 need to be elucidated and this 
complex can play a role in the regulation of tumor cell invasion.   
 
The role Numb plays in endocytosis have been shown to have a role in the 
regulation of Notch signaling in Drosophila and mammalian models [280, 299].  In 
drosophila neural progenitor cells and colon cancer stem cells, Numb has been 
implicated in the differential regulation of Notch signaling and endosomal trafficking 
to regulate assymetric cell divison and maintenance of the stem cell population 
[300]. These suggest that in addition to a role in tumor cell invasion, the ability of 
Numb to regulate endocytosis can play an impact in breast cancer TICs.  The 
ability of IRS2 to interact with BMP2K a Numb-associated kinase can implicate that 
the interaction of IRS2 with BMP2K can play a role in the ability Numb stem cell 
biology.   
 
Of interest, Numb is also implicated in TGF-β signaling in renal fibrosis 
[283].  This implicates BMP2K in TGF-β signaling regulation during renal fibrosis 
as part of the Numb endocytic complex.  In the same model of renal fibrosis IRS2 
negatively regulates E-cadherin expression. There is a possibility that IRS2-
BMP2K interaction could be playing a role in the regulation of EMT in renal fibrosis, 
as well as in breast cancer tumor cell invasion.  I hypothesize that the disruption 
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of the IRS2 interaction with BMP2K in our IRS2ΔINV mutant renders IRS2 unable 
to regulate EMT, causing a defect in cellular invasion.   
 
The conditions we used in our pulldown experiment allowed us to identify 
BMP2K as an interactor with the IRS2 INV-region.  Given that the IRS proteins are 
intrinsically disordered, the interactions of the IRS proteins with binding partners 
are predicted to be weak, and transient interactions might not have been preserved 
during our pulldown.  Scansite analysis of the 174 amino acids in the INV region 
revealed possible interactions between this region and the protein Intersectin and 
Cortactin.  Both proteins have been extensively implicated in cancer cell migration, 
invasion and tumor metastasis due to their role in cytoskeletal remodeling [301, 
302].  Interestingly, Intersectin, Cortactin and the Numb complex are implicated in 
endocytosis of clathrin coated vesicles [282, 303, 304].   The role of these proteins 
in endocytosis and their interaction with the INV region of IRS2 point to a role of 
IRS2 as a regulator of endocytosis, and this role in endocytosis as part of its ability 
to regulate tumor cell invasion.  Additional studies to validate the interaction 
between IRS2 and BMP2K are warranted.  In order to do so, immunoprecipitation 
of WT IRS2, IRS2Δ917 and IRS2ΔINV should be performed to validate the 
interaction with the INV region. Immunoblotting for Intersectin and Cortactin in 
these experiments would also help uncover other novel IRS2-interacting proteins.   
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Beyond the validation of the IRS2 and BMP2K interaction we want to 
determine how the interaction of IRS2 and BMP2K is contributing to tumor-cell 
invasion.  BMP2K is a serine/threonine kinase and the targets of this proteins 
remain to be elucidated.  This proteins kinase domain is well identified and 
inhibitors against it are available.  Among our future studies we need to identify the 
targets of BMP2K as part of the mechanism of IRS2-BMP2K regulation of tumor 
cell invasion.  Additionally, we need to determine if IRS2 is phosphorylated by 
BMP2K and if this is of importance for the regulation of IRS2 biology.  Generation 
of BMP2K kinase mutant will help determine if the kinase activity of BMP2K is 
required for IRS2-mediated tumor cell invasion.  Also, this mutant and a phospho 
proteomics approach can help identify BMP2K targets. We identified BMP2K as 
an interactor with the INV region but mammosphere formation assays in BMP2K 
knockdown cells are needed to determine if this protein has an impact in IRS2-
mediated TIC-self-renewal.   
 
Additional studies of the SR region are required to fully understand how 
IRS2 regulates TIC self-renewal. Pulldown of the SR region and mass 
spectrometry, as done with the INV region, will help elucidate novel protein 
interactions in this region that could help determine the mechanism of IRS2 
regulation of TICs self-renewal.   Scansite analysis of the SR region predicts the 
AMP-activated protein kinase (AMPK) phosphorylation of IRS2 in this region.  
Activation of AMPK by the diabetic drug metformin in the fibrosarcoma cell line 
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FSaII has shown a decrease in the TICs fraction and a decrease in the ability of 
these cells to form mammospheres [305, 306].  Metformin also inhibits serial-
passage mamosphere formation in thyroid carcinoma cells lines suggesting that 
AMPK activation plays a role in regulation of self-renewal [307]. Further studies to 
determine if AMPK phosphorylation of the SR region in IRS2 and the effects of this 
phosphorylation on IRS2-mediated TIC self-renewal are warranted.   
 
To determine the role of the SR and the INV regions in tumor formation and 
metastasis in vivo, PYMT:IRS2-/- cells expressing EV, WT IRS2, IRS2ΔSR and 
IRS2ΔINV can be injected orthotopically into mice to determine their role in tumor 
formation.  These studies could also serve to identify which IRS2-regulated 
process, cellular invasion, TIC self-renewal or both are required for primary tumor 
growth or IRS2-mediated metastasis.  Also, limiting dilution assay and serial 
transplantation assays in vivo should be performed to determine the effects of WT 
IRS2, IRS2ΔSR and IRS2ΔINV on the frequency of tumor initiating cells and the 
regulation of self-renewal in vivo.   
 
As stated in the introduction, the immune system plays a very important role 
in the regulation of tumor metastasis. To elucidate the importance of IRS2 SR and 
INV regions in breast carcinoma metastasis I would like to have a mouse model 
with an intact immune system.  The generation of mammary gland conditional 
knock-in IRS2ΔSR and IRS2ΔINV mutants will facilitate determining the impact of 
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just the loss of IRS2’s ability to regulate self-renewal or tumor cell invasion without 
altering the rest of the tumor microenvironment.  We can also cross IRS2ΔSR and 
IRS2ΔINV mutant mice with MMTV-PyMT mice to determine the impact of these 
mutants on tumor formation and metastasis in a spontaneous tumor model.  The 
use of orthotpic models or immunocompromised models represented a limitation 
due to the artificial environment that is created during tumor cells injections and 
the lack of an intact immune system.   Generation of conditional knock-in under 
the endogenous promoter will mimic the condition that take place during the tumor 
formation.  If in the event of aberrant mammary gland development due to the 
expression of IRS2 mutant proteins we can generate and inducible system and 
induce our mutant proteins after the glad has developed.   
 
The conditional knock-in models can be utilized not only to study the impact 
of IRS2ΔSR and IRS2ΔINV in tumor formation and metastasis but also in cancer 
stem cells self-renewal. Using the mouse stem cell markers CD29+ and CD24+ we 
can isolate tumor initiating cells for serial transplantation to determine the effects 
of these mutants on TIC-self-renewal in vivo.  Based on our mammosphere 
formation assays in vitro, upon initial injection of isolated TICs we might not see a 
difference in tumor formation as this is equivalent to passage one in our in vitro 
assay and we do not see a difference in tumor formation.  Upon serial 
transplantation in vivo, we can be able to detect a difference in tumor formation 
consistent with depletion of stem cells.   
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 Additionally, IRS2 plays an important role in glucose metabolism, 
especially in the regulation of pancreatic β-cell functions, and glycolysis in 
peripheral tissues.   As we try to dissect IRS2-dependent regulation of cancer 
specific functions it will be important to determine if deletion of the SR and INV 
regions affects the role of IRS2 during development and metabolism. To elucidate 
the effect of IRS2ΔSR and IRS2ΔINV in development and metabolism in vivo, we 
require the generation of CRISPR/Cas9 mice with these regions deleted.  These 
animals will help investigate the effects of SR and INV region loss in development 
and in adult tissue physiology.  Is of vital importance that we determine the role of 
these regions in adult tissue physiology and we look to target them in cancer 
treatment.  Ideally, we can disrupt the SR and INV region functions in cancers 
without derailing the normal metabolic functions of IRS2.       
 
 One of the biggest limitations to our understanding of IRS protein biology is 
a lack of structural information.  The structure of proteins is very important when it 
comes to understanding function and the development of drugs to target them 
[130].  The intrinsically disordered nature of IRS1 and IRS2 gives the proteins a 
tremendous advantage as efficient signaling molecules, but limits our ability to 
study their structure.   Better understanding of IRS protein structure can help 
understand their role in multiple cellular processes that contribute to their biology 
in cancer.  My work and the works of others demonstrate the important role IRS2 
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plays in breast cancer metastasis.  To further elucidate the biology of this protein 
a better understanding of its structure can be of significance.  Based on structural 
models, protein-protein interactions can be discovered and this is a significant 
accomplishment in understanding how this protein works.  Additionally, future 
approaches to target IRS2 in cancer can benefit from the known structure of this 
protein for the development of agents that can inhibit its cancer related functions 
and not metabolic functions.   
 
The experimental approaches of X-ray and electron crystallography that are 
amenable to stably folded proteins do not work on IDPs. Nuclear magnetic 
resonance (NMR) has also been used to determine IDPs structural analysis with 
limited success due to the fast changes in conformation IDPs undergo and the 
limitation in detection of distance interactions among atoms [308].  This makes 
extensive computer modeling needed for the elucidation of average structural 
conformations.   Cryo-electron microscopy (Cryo-EM) can be used to look at the 
structure of proteins as single molecules or complexes in their natural environment 
with no need of crystal structures [309]. Also, this technique allows capturing 
multiple conformation of proteins and the flexibility in conformational changes that 
IDPs undergo do not represent a problem for structural determination [309].  
Currently, Cryo-EM is the best approach available to determine structure in IDPs.  
A combination of Cryo-EM and mass spectrometry can help determine the 
structures of protein complexes and determine the proteins involved in these 
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complexes.  We can use WT IRS2, IRS2ΔSR and IRS2ΔINV mutants and 
determine how loss of the SR or INV region affects the conformation and the 
interaction with other proteins using Cryo-EM.         
 
How to develop novel approaches for cancer treatment 
 
The IR/IGF-1R signaling pathway has been extensively implicated in many aspects 
of cancer.  Due to their contributions to tumorigenesis and progression, targeting 
these signaling molecules was hypothesized to represent a benefit for cancer.   
Due to the importance of insulin signaling in metabolism and glucose homeostasis, 
targeting the IGF-1R was the first approach taken.  Monoclonal antibodies that 
block receptor/ligand binding and small molecule inhibitors targeting the receptor’s 
active site showed promising results in vitro and in preclinical animal studies [310].   
On the contrary, the performance of these agents was disappointing in clinical 
trials.  Many of the studies performed did not achieve a clinical response with the 
exception of some complete responses in Ewing sarcomas [169, 311].  The biggest 
question that the scientific community needs to address is, why did these trials fail?   
 
 There is a lot to learn from this experience and with our current findings we 
hope to improve future trial design.   Poor clinical trial design contributed 
significantly to the poor performance of these trials.  For phase III clinical trials, 
patients were not screened for the expression of IGF-1R in their tumors.  If the 
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target of the drug is not present in the cancer, using the inhibitors in these patients 
is like treating them with a placebo.  In the case of HER2 positive tumors and the 
Herceptin trials, proper patient selection and screening for the target of interest 
ensured successful trials [312].  The best example of IGF-1R inhibition efficacy 
was in Ewing Sarcoma tumors that express high levels of the IGF-1R receptor and 
are very dependent on this pathway for tumor cell survival [311].    In addition to 
poor trial design, inhibition of the IGF-1R receptor resulted in downregulation of 
IGF-1R and upregulation of the IR-A isoform of the insulin receptor in tumors [170].  
The IGF-1R and IR-A can form heterodimers at the cell surface.  Many of the IGF-
1R inhibitors fail to block IGF-1R/IR-A heterodimers, also contributing to the failure 
of IGF-1R inhibition.  These data demonstrate that targeting IGF-1R alone is not 
sufficient for cancer treatment.   
 
In a mouse model of Her2-mediated breast cancer on a background of 
hyperinsulinemia (MTB/TAN/MKR+/+ mice), larger tumors developed and there 
was an increase in metastasis to the lungs in comparison to non-hyperinsulinemic 
mice. Tumors from this animal model have elevated phosphorylation of the 
IR/IGF1R, suggesting activation of these receptors during hyperinsulinemia. Also, 
tumors from these animals have elevated levels of vimentin (EMT marker) and are 
more aggressive with extensive pulmonary metastasis [313].   Additional in vivo 
studies looking at the impact of IR/IGF-1R signaling in breast cancer metastasis 
looked at TIC markers in Mvt-1 mouse mammary tumor cells [314].   In this model, 
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IR knockdown decreases the expression of CD24, a maker of tumor initiating cells 
in murine mammary malignancies.  Taken together, the studies from Ferguson and 
Rostoker implicate IR/IGF-1R signaling with tumor progression by the induction of 
EMT and regulation of tumor-initiating cells in hyperinsulinemia conditions.  
Downstream of IGF-1R or IR homodimers and IGF-1R/IR heterodimers the IRS 
proteins function as important signaling molecules.  Moreover, previous studies 
have not determined which IRS protein is mediating signaling downstream of the 
receptors.   Based on my studies, I hypothesize that IRS2 is contributing to the 
effects of IR/IGF-1R in cancer metastasis and is doing so by contributing to 
regulation of tumor cell invasion and TIC self-renewal. 
 
IGF-1R and IR play a critical role in metabolism and the IRS1 proteins are 
necessary mediators. Irs1-/- mice develop insulin resistance in peripheral tissues 
but fail to develop diabetes, while Irs2-/- mice develop diabetes due to failure of β-
cells in the pancreas [109, 123].  When targeting IRS2 to disrupt IR/IGF-1R 
signaling we must consider the fundamental role this pathway plays in metabolism 
and try to separate the role of IR/IGF-1R/IRS2 in metabolism and cancer.   My 
identification of two distinct regions in IRS2 that regulate tumor cell invasion and 
TIC self-renewal could facilitate targeting IRS2-specific cancer functions that 
contribute to metastasis.  I demonstrated that IRS2ΔSR and IRS2ΔINV maintain 
their ability to activate PI3K/Akt signaling and do not impair aerobic glycolysis in 
cancer cells.  Additional studies are required to investigate the role these IRS2 
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mutants will have in other tissues.  Disrupting cancer-specific functions of IRS2 
may lead to better disruption of the IR/IGF-1R pathway in cancer without causing 
tremendous side-effects.  
 
Today, this country is facing an epidemic of obesity. Obesity leads to insulin 
resistance in peripheral tissues like fat and muscle.  One of the responses to insulin 
resistance is the increased production of insulin by β-cells in the pancreas.  
Eventually the β-cells in the pancreas are depleted leading to the development of 
diabetes.  IRS2 plays a role in the activation of PI3K and AKT activation and 
promotes the regeneration of β-cells in the pancreas.  New approaches are being 
developed to induce the expression of IRS2 in pancreatic cells using agents like 
Trimeprazine [315].  Special consideration needs to be paid to this approach as it 
can lead to induction of IRS2 in tumor tissues and have a negative impact in 
tumorigenesis.   
 
Our data provides the rationale for IRS2 as a biomarker in breast cancer 
tumors for the design of new therapeutic approaches.  Based on our microtubule 
disruption data, disrupting the microtubule cytoskeleton can specifically target 
IRS2-expressing cells.  IRS2-expressing cells, based on our discoveries in this 
study and extensive work by our group have a more aggressive phenotype [114, 
198, 200].  Disruption of microtubules will ensure disruption of IRS2 signaling 
independent of the upstream activator of the protein.  Retrospective studies looking 
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at IRS2 expression in tumors from patients treated with vinca alkaloids and 
correlating clinical response with IRS2 expression would provide information 
towards the clinical benefits of this approach in cancer.   Vinca alkaloids, more 
specifically vinorelbine, are used in breast cancer for treatment of advanced 
disease with limited clinical benefits [248].  Our data supports the introduction of 
vinorelbine earlier in treatment for patients with tumors that express high levels of 
IRS2, as eliminating tumor cells that express IRS2 can provide more clinical 
benefits earlier in the course of disease.  
  
When designing clinical interventions for cancer therapeutics we need to 
always keep in mind the heterogeneous nature of tumors [316].  Targeting one 
specific pathway in cancer might not always be the best approach when it comes 
to this complex disease.  The design of combination therapies based on the 
dependence of tumors on multiple signaling pathways can improve the clinical 
benefit of these interventions.  The IR/IGF-1R signaling has been proven to cause 
resistance to Her2 inhibition in breast tumors and EGFR inhibition in lung tumors 
[317-319].  These results suggest that for those specific cases mentioned above, 
combination of Her2 or EGFR inhibitors with IR/IGF-1R/IRS2 targeted inhibitors 
could result in better clinical responses.   
 
Overall significance 
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IRS2 has gained notoriety as a regulator of metastasis in cancers of the 
breast, pancreas, lungs, liver, brain and thyroid.  This protein regulates metastasis 
by contributing to the regulation of TIC self-renewal, invasion, glycolysis and cell 
survival in tumor cells, all processes that are important in the metastatic cascade.  
The results of my study looking into the requirement of microtubules for IRS2 
activation of AKT provided us information to understand differential regulation of 
PI3K/AKT signaling by the IRS proteins in breast carcinoma cells.  In addition, 
these data provided us with the rationale for novel approaches to target IRS2 
signaling and IRS2-expressing cells in cancers.  We provide the rationale for the 
use of IRS2 as a biomarker for response to vinorelbine therapy in cancer.  
Vinorelbine is currently used for the treatment of advance disease, but could be 
repositioned as a first-line therapy in IRS2-dependent malignancies.  In this study, 
we also provide the rationale for IRS1 as a biomarker for response to combination 
therapy consisting of microtubule disruption and AKT inhibition.    
 
Finally, while the role of IRS2 in cancer continues to gain attention the need 
to further understand mechanistic inputs of IRS2 into processes that contribute to 
metastasis has become a priority.  My study dissecting IRS2 and determining the 
contribution from different protein regions to the regulation of tumor cell invasion 
and TIC self-renewal permitted the identification of two distinct regions that 
regulate each process without affecting the ability of IRS2 to regulate PI3K/AKT 
signaling or aerobic glycolysis.   I demonstrated that these regions are required for 
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IRS2 dependent regulation of TIC self-renewal and invasion in vitro.   We have 
also determined that the INV region requires the interaction with the Ser/threonine 
kinase BMP2K for the regulation of IRS2-dependent tumor cell invasion.  BMP2K 
has a potential to become a target for the inhibition of IRS2-dependent tumor cell 
invasion in cancer.   
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The Insulin receptor substrate-2 (IRS-2)                 
C-terminus regulates its subcellular localization  
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 Previous studies from the Shaw lab and other labs have demonstrated that 
the intracellular localization of the IRS proteins in human breast tumors plays a 
role in patient response to therapy (IRS1) and overall patient survival (IRS2).  IRS1 
is expressed predominantly in the nucleus or diffusely in the cytoplasm, and its 
nuclear expression correlates with positive response to tamoxifen treatment. IRS2 
is expressed either in the cytoplasm, diffusely or in a punctate pattern, or at the 
cell membrane.  The membrane staining of IRS2 correlates with a significant 
decrease in overall patient survival [111].  These correlations of response and 
survival with subcellular localization suggest that the localization of IRS1 and IRS2 
impacts their downstream signaling outcomes.  In support of this role for 
localization, in Chapter 2 of this thesis, I determined that the ability of IRS2, but not 
IRS1, to signal efficiently to AKT was dependent upon an intact microtubule 
cytoskeleton.   
 In Chapter 3, I developed a series of IRS1 and IRS2 deletion mutants and 
chimeras to investigate the contribution of the C-terminus of each protein to their 
function.  My studies demonstrated that the IRS2 C-terminus is necessary and 
sufficient for the regulation of tumor cell invasion and TIC self-renewal.  Moreover, 
I identified discrete regions within the IRS2 C-terminus that are required for either 
invasion or self-renewal.  As a next step in understanding how these C-terminal 
sequences contribute to IRS2 functions, I investigated their impact on the 
subcellular localization of IRS2.   
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To perform the localization experiments, I expressed the WT and 
mutant/chimeric proteins in IRS1/IRS2-null Sum159 cells (Fig. A1A).  These cells 
spread well in cell culture allowing for good visualization of the nuclear and 
cytoplasmic compartments.  Cells were plated on glass coverslips and fixed for 1 
hour in 4% formalin followed by permeabilization with 0.1% Triton-X.  Following 
permeabilization, cells were incubated in rabbit anti-HA antibody (CS#3724), 
washed 3 times in 1XDPBS with 0.1%Tween 80, and incubated with mouse anti-
Rabbit 488 conjugated secondary antibody. After washing, glass coverslips were 
mounted on glass slides in Prolong Gold mounting medium with DAPI for nuclear 
staining.  Images were taken using a (Zeiss LSM700).  The percentage of nuclear 
staining was determined using the imaging software ImageJ.   
I first examined the localization of WT-IRS1 and WT-IRS2.  Consistent with 
previous reports in human breast tumors, IRS1 is expressed in the cytoplasm and 
nucleus and IRS2 is only expressed in the cytoplasm in SUM-159 cells.  Truncation 
of the IRS1 C-terminus (IRS1Δ942) does not alter the localization of IRS1 when 
compared to the wild type protein (Fig. A.1B).  In contrast, truncation of the IRS2 
C-terminus (IRS2Δ917) resulted in the redistribution of IRS2 to both the nucleus 
and cytoplasm (Fig. A.1B) These data suggest that the C-termini of the IRS 
proteins are important for the regulation of protein localization, a finding that was 
confirmed by the fact that a chimeric IRS1 protein with the N-terminus of IRS1 and 
C-terminus of IRS2 (IRS1/S2) is restricted to the cytoplasm while an IRS2/S1 
chimera localizes to both compartments (Fig. A1B).  The percentage of IRS protein  
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Figure A.1. The IRS2 C-terminus is sufficient for the regulation of IRS2 
localization.  (A) Schematic depicting WT IRS1, IRS1Δ942, IRS1/S2, WT IRS2, 
IRS2Δ917 and IRS2/S1 proteins.  SUM-159 IRS1/IRS2-null cells expressing the 
proteins depicted in (A) were plated on glass coverslips. (B) Cells were stained for 
HA and mounted in Prolong Gold medium with DAPI.  Representative DAPI (blue), 
HA (green) and merged HA/DAPI images are shown (magnification X63). (C) The 
percentage of nuclear staining was quantified and the data shown represent the 
mean ± S.E.M of 10 cells. **, p<0.01 relative to IRS1; ##, p<0.01 relative to IRS2.    
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that is localized to the nucleus was quantified (Fig. A1C).  IRS1 contains two 
nuclear localization sequences that are not located within the C-terminal region 
that was deleted.  These data suggest that IRS2 can traffic to the nucleus, but the 
C-terminus is responsible for retaining IRS2 in the cytoplasm.  
 To further dissect the contribution of the IRS2 C-terminus to subcellular 
localization, I examined two additional IRS2 C-terminal deletion mutants in which 
324 amino acids (IRS2Δ1014) or 150 amino acids (IRS2Δ1188) were deleted (Fig 
A.2A).  The IRS2Δ1014 mutant localizes to the nucleus and cytoplasm, whereas 
the IRS2Δ1188 mutant remains cytoplasmic (Fig. A.2B-A.2C).   The final 150 
amino acids of IRS2 are not required for retaining IRS2 in the cytoplasm However, 
deletion of an additional 174 amino acids (IRS2Δ1014) or 271 amino acids 
(IRS2Δ917) causes a redistribution of IRS2 to the nucleus, suggesting that 
sequences within this 271 amino acid region control the cytoplasmic retention of 
IRS2.   
 In Chapter 3, I identified discrete regions within the IRS2 C-terminus that 
are required for either self-renewal (SR) or invasion (INV) (Fig. A.3A).  To 
determine if these regions regulate subcellular localization of IRS2 to contribute to 
their respective functions, the SR and INV deletion mutants, IRS2ΔSR and 
IRS2ΔINV, were expressed in Irs1/Irs2-null PyMT cells. In contrast to the full IRS2 
C-terminal deletion mutant (IRS2Δ917) which localizes to both the nucleus and 
cytoplasm, the internal SR and INV deletion mutants were expressed exclusively 
in the cytoplasm (Fig. A.3B-A.3C).  From these data, I conclude that the defects in  
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Figure A.2. Identification of a region within the IRS2 C-terminus that 
regulates IRS2 subcellular localization. (A) Schematic depicting WT IRS2, 
IRS2Δ917, IRS2Δ1014 and IRS2Δ1188.  SUM-159 IRS1/IRS2-null cells 
expressing the proteins depicted in (A) were plated on glass coverslips. (B) Cells 
were stained for HA and mounted in Prolong Gold medium with DAPI.  
Representative DAPI (blue), HA (green) and merged HA/DAPI images are shown 
(magnification X63). (C) The percentage of nuclear staining was quantified and the 
data shown represent the mean ± S.E.M. of 10 cells. **, p<0.01 relative to IRS2. 
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IRS2ΔSR self-renewal and IRS2ΔINV invasion are not related to aberrant protein 
subcellular localization as both deletion mutants localize to the cytoplasm similar 
to wild type IRS2.  
 IRS2 does not contain any canonical nuclear localization sequences, and 
yet it is able to traffic into the nucleus upon truncation of the C-terminus.  Of 
interest, the IRS1/S2 chimera is cytoplasmic even with the nuclear localization 
sequences in the IRS1 N-terminus. These data suggest that a role of the IRS2 C-
terminus is to maintain IRS2 in the cytoplasmic compartment.  To investigate 
further how the IRS2 C-terminus regulates the trafficking of IRS2, and restricts the 
protein from the nuclear compartment, I treated cells expressing WT-IRS2, 
IRS2Δ917, IRS2Δ1014 and IRS2Δ1188 with the nuclear export inhibitor 
Leptomycin B. WT-IRS2 and IRS2Δ1188, which are normally restricted to the 
cytoplasm, exhibited increased expression in the nucleus upon inhibition of nuclear 
export (Fig. A.4A).   In contrast, treatment of cells expressing IRS2Δ917 or 
IRS2Δ1014, which exhibit elevated nuclear expression in the absence of 
treatment, did not increase the percentage of nuclear IRS expression in response 
to leptomycin B (Fig. A.4B).  Taken together, these data suggest that IRS2 is 
capable of trafficking into the nuclear compartment, but it is rapidly exported out of 
the nucleus. 
      Taking into consideration my data from the internal deletion mutants and 
IRS2Δ1188, I conclude that the final 150 amino acids of IRS2 (1189-1338) are not 
required for cytoplasmic retention of the protein.  Neither the loss of this region in  
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Figure A.3. Internal deletion of the IRS2 SR and INV regions does not alter 
IRS2 subcellular localization. (A) Schematic depicting WT IRS2, IRS2Δ917, 
IRS2ΔSR and IRS2ΔINV.  PyMT:Irs1-/-/Irs2-/- cells expressing the proteins 
depicted in (A) were plated on glass coverslips. (B) Cells were stained for HA and 
mounted in Prolong Gold medium with DAPI.  Representative DAPI (blue), HA 
(green) and merged HA/DAPI images are shown (magnification X63). (C) The 
percentage of nuclear staining was quantified and the data shown represent the 
mean ± S.E.M. of 10 cells. **, p<0.01 relative to IRS2.   
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Figure A.4. The IRS2 C-terminus is required for the nuclear export of IRS2.  
SUM-159 IRS1/IRS2-null cells expressing WT IRS2, IRS2Δ917, IRS2Δ1014 and 
IRS2Δ1188 were plated on glass coverslips and treated with DMSO or Leptomycin 
B (10 ng/ml) for 24 hours. (A) Fxed cells were stained for HA and mounted in 
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Prolong Gold medium with DAPI.  Representative DAPI (blue), HA (green) and 
merged HA/DAPI images are shown (magnification X63). (B) The percentage of 
nuclear staining was quantified and the data shown represent the mean ± S.E.M 
of 10 cells. **, p<0.01 relative to IRS2. 
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IRS2Δ1188 nor its presence in IRS2ΔSR and IRS2ΔINV alters the subcellular 
localization of IRS2.  Internal deletion of the SR or INV regions alone also does not 
impair IRS2 localization.  However, in apparent conflict with the IRS2ΔINV mutant, 
IRS2Δ1014, which also lacks the INV domain, localizes to the nucleus.   I 
hypothesize that the combined loss of the INV region with the final 150 amino acids 
may alter intramolecular interactions and impair proper protein folding that could 
affect important protein interactions that regulate IRS2 localization within the 
cytoplasm.   This misfolding could interfere with interactions that restrict IRS2 to 
the cytoplasm or interactions that are required for interaction with exportin proteins 
that regulate nuclear export of IRS2.  
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